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Samenvatting 
Het opzet van dit werk bestond erin om, in twee specifieke therapeutische gebieden, nl. de 
behandeling van infectieziekten met antibiotica en een anti-tumorale behandeling met paclitaxel, de 
effectiviteit van de huidig gebruikte doseringsregimes te evalueren. Alhoewel beide therapeutische 
gebieden elk hun eigen specifieke noden en behoeftes kennen, is er ook een duidelijke 
overeenkomst. Zo zijn zowel voor de behandeling met antibiotica als de behandeling met anti-
tumorale middelen geen eenvoudig meetbare eindpunten beschikbaar die de behandelende arts 
toelaat om de therapie op te volgen / te optimaliseren.   
Daarenboven zijn geneesmiddelenfabrikanten niet verplicht om hun geneesmiddelen te evalueren in 
iedere specifieke patiëntenpopulatie waarvoor men het geneesmiddel, eens op de markt, zal 
gebruiken. Hierdoor is er voor sommige patiënten-groepen (zeer jonge kinderen, morbide obese 
patiënten, post-bariatrische chirugie patiënten, etc.) dus vaak onvoldoende informatie voorhanden 
ivm. de veiligheid en werkzaamheid van het gebruikte geneesmiddel. Daar komt nog bij dat in 
sommige patiëntenpopulaties, vaak bij gebrek aan goedgekeurde geneesmiddelenvormen voor een 
bepaalde indicatie, formulaties gebruikt worden die goedgekeurd werden voor een andere indicatie, 
doelgroep, toedieningsweg, etc.  
Om een optimalisatie van de farmacotherapie te bewerkstelligen hebben we in beide therapeutische 
gebieden (i) een analytische methode ontwikkeld voor de bepaling van een specifiek geneesmiddel, 
(ii) pre-klinische experimenten en klinische studies opgezet en (iii) door middel van 
wiskundige/statistische farmacokinetische/farmacodynamische (PKPD) modellen de 
veiligheid/werkzaamheid van deze geneesmiddelen geëvalueerd in deze specifieke 
patiëntenpopulaties. 
Hoofdstuk 1 beschrijft de interpretatie, mbv. wiskundige/statistische modellen, van data afkomstig 
van een eerder opgezette klinische studie naar de invloed van bariatrische chirurgie op de 
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biologische beschikbaarheid van moxifloxacine. Door een combinatie van het ontwikkelde 
farmacokinetisch model met eerdere, in de literatuur, gepubliceerde in-vitro farmacodynamische 
modellen, hebben we de waarschijnlijkheid van therapeutisch falen geëvalueerd in deze 
studiepopulatie. Zoals blijkt uit onze studieresultaten, is LBM een patiëntkarakteristiek met een 
sterke voorspellende waarde aangaande de waarschijnlijkheid voor therapeutisch falen. Hierdoor 
moet er naar onze mening in de toekomst aandacht besteed worden aan de ontwikkeling van een 
doseringsalgoritme gebaseerd op LBM voor de optimalisatie van moxifloxacine therapie in deze 
studiepopulatie.  
Gezien de grote hoeveelheden beta-lactam antibiotica die op jaarbasis gebruikt worden in België en 
gedreven door de resultaten uit hoofdstuk 1, beschrijven we in hoofdstuk 2 hoe een nieuwe 
analytisch meetmethode werd ontwikkeld voor de bepaling van beta-lactam 
antibioticaconcentraties in plasma. Om een zo breed mogelijke implementeerbaarheid van onze 
meetmethode te garanderen werden 13 verschillende antibiotica opgenomen in onze assay. Verder 
werd gedurende het ontwikkelingsproces aandacht besteed aan het reduceren van het benodigde 
staalvolume (dit is vaak een limiterende factor bij studies bij kinderen) alsook aan het zo kort 
mogelijk houden van de analysetijd. Door middel van een uitgebreide validatiestudie werd bewezen 
dat de performantie van onze meetmethode beantwoordt aan de huidig heersende specificaties. 
Naderhand werden dankzij de beschikbaarheid van deze methode in het laboratorium, in 
samenspraak met 2 Belgische ziekenhuizen, 2 nieuwe klinische studies opgezet ter evaluatie van de 
huidig gebruikte doseringsregimes voor beta-lactam antibiotica (zoals beschreven in de General 
conclusions & Future perspectives sectie). 
Hoofdstukken 3 t.e.m. 5 vormen het tweede luik van dit werk en kaderen in een project dat zich 
focust op de optimalisatie van IPEC-behandelingen bij patiënten met tumoren in het buikvlies. Het 
eerste deel van dit werk, hoofdstuk 3, beschrijft de ontwikkeling van een meetmethode voor de 
bepaling van paclitaxel, een geneesmiddel gebruikt bij IPEC, in tumorweefsel. Gezien, onder andere, 
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de technische uitdagingen geassocieerd met de bepaling van geneesmiddelen in weefsel, was er 
voordien niet veel gekend omtrent de mate waarin paclitaxel tumorweefsel binnen dringt na IPEC-
behandelingen. Tijdens de ontwikkeling van de meetmethode werd extra aandacht besteed aan 1) 
het limiteren van het benodigde staalvolume, aangezien dit rechtstreeks de resolutie van het 
bekomen penetratieprofiel beïnvloedt en 2) het gebruiksgemak van de methode, dit met het oog op 
het verwachtte aantal stalen uit verdere dierproeven. Aan de hand van een uitgebreide 
validatiestudie werd aangetoond dat de karakteristieken van de methodologie beantwoordde aan de 
huidig geldende normen. Op basis van verschillende tumorstalen, afkomstig van een IPEC 
behandeling van ratten, werd aangetoond dat paclitaxel een snelle en uitgesproken distributie naar 
het tumorweefsel kent, dit in tegenstelling tot wat eerder in de wetenschappelijke literatuur werd 
beschreven. 
In hoofdstuk 4 werden deze metingen gecombineerd met concentratiemetingen van paclitaxel in 
plasma van behandelde ratten, concentratiemetingen uit de vloeistof die gebruikt werd tijdens de 
IPEC-behandeling, metingen van de graad van apoptose (een effect geïnduceerd door paclitaxel in 
tumorweefsel), en metingen van het tumorvolume van behandelde ratten. Deze gegevens werden 
vervolgens aangewend om een farmacokinetisch-farmacodynamisch model te ontwikkelen dat deze 
verschillende aspecten, die het resultaat zijn van de IPEC behandeling, gelijktijdig kan beschrijven en 
dat gebruikt kan worden om na te gaan hoe deze IPEC behandeling geoptimaliseerd kan worden. 
Door middel van simulaties toonden we aan dat voor Taxol®, de farmaceutische formulatie 
goedgekeurd voor intraveneuze therapie maar vaak “off-label” gebruikt bij deze IPEC-behandeling, 
de gebruikte dosis sterk gereduceerd kon worden zonder verlies aan effect. Dit heeft als bijkomend 
voordeel dat de systemische blootstelling aan paclitaxel sterk teruggedrongen wordt en hierdoor ook 
de kans op schadelijke neveneffecten beperkt kan worden. 
Hoofdstuk 5, tot slot, beschrijft een in-vitro onderzoek naar de cellulaire kinetiek van paclitaxel. 
Hiertoe werden SK-OV-3 cellen, in cultuur, blootgesteld aan verschillende paclitaxel doseerregimes 
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en werd de intracellulaire opname vergeleken tussen de regimes. Naderhand werd aangetoond dat 
extracellulair ccCK18, een intracellulair proteïne dat vrijgesteld wordt dmv. paclitaxel geïnduceerde 
apoptose van de cel, een goede surrogaat is voor de bereikte intracellulaire paclitaxel concentraties.  
Verder onderzoek naar de vrijstelling van ccCK18 in de rat/de mens in combinatie met de integratie 
van de kennis uit hoofdstukken 4 en 5 ter ontwikkeling van een meer fundamenteel 
farmacokinetisch-farmacodynamisch model zou, ons inziens, in de toekomst moeten kunnen leiden 
tot het gebruik van ccCK18 metingen ter individualisatie en optimalisatie van IPEC-behandelingen 
bij patiënten met tumoren van het buikvlies. 
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Summary 
The main objective of this thesis was to evaluate currently used treatment regimens in two specific 
patient populations using an M&S-based approach. Although both therapeutic areas, i.e. anti-
infective therapy and oncology, differed somewhat in the specific issues associated with them, in 
both areas questions regarding treatment efficiency and optimization of therapeutic regimen exist. 
Furthermore, optimization of treatment regimens in these therapeutic areas is not straightforward 
since no easily obtainable measures of pharmacological effect are available to guide the optimization 
process.  
In addition to this challenge, the high frequency of off-label drug use, i.e. the use of drugs for 
unapproved indications, routes of administration, patient populations, etc. in specific patient 
populations further complicates the optimization of currently used treatment regimens. Off-label 
drug use in specific populations is in part related to the fact that these specific populations are 
usually not included in the clinical trials leading to a market authorization. Therefore the TRS is only 
sparsely characterized, hampering the optimization / individualization of treatment regimens for 
these patients. 
In order to increase our understanding of the processes that lead to therapeutic success, our generic 
approach has been to (i) develop a bioanalytical method for the quantification of the analyte of 
interest, (ii) set up a clinical trial/pre-clinical experiments and (iii) evaluate their outcome using PKPD 
modeling and simulation approaches. 
Based on a previously developed analytical method for the quantification of 4 different 
fluoroquinolone antibiotics in human plasma, we set up a clinical trial evaluating a 400 mg daily dose 
of moxifloxacin in post bariatric surgery patients. Chapter 1 deals with the population 
pharmacokinetic analysis and subsequent PKPD simulations, based on PKPD targets defined in the 
literature,  that were used to evaluate treatment efficiency in terms of bacterial eradication and 
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suppression of bacterial resistance formation. Throughout this study, we showed that treatment 
efficacy is compromised in this population and that LBM is a prognostic factor significantly related to 
the probability of achieving adequate bacterial eradication and suppression of bacterial resistance 
formation. Therefore, in our opinion, in order to increase treatment effect in this post bariatric 
surgery population, moxifloxacin dosing should be individualized according to a LBM derived dosing 
algorithm. 
In Chapter 2 we describe the development of a multi-compound analytical method for the most 
frequently used β-lactam antibiotics, based on mixed-mode SPE coupled to UPLC-Tandem MS 
detection. Throughout the process of developing the method, care was taken to minimize (i) the 
amount of sample needed and (ii) the overall analysis time. These assay characteristics were 
essential given that our goal was to develop a broadly applicable multi-drug platform. Extensive 
validation of the developed method showed that we succeeded in developing a reliable analytical 
method (i) lacking significant relative matrix effect and without significant bias/imprecision(ii) and 
capable of delivering accurate measurements on 13 different antibiotics in a timely fashion to the 
end-users. This analytical method will, to our opinion, leverage the clinical research into the 
optimization of currently used beta-lactam treatment regimens.  
Chapter 3 describes our efforts to develop a new analytical approach to quantify paclitaxel in tumor 
tissues of rats treated with IPEC. Thus far, paclitaxel had only been quantified in tumor tissue using (i) 
imaging techniques or (ii) mechanical, whole tumor, homogenization. In order to study PTX 
disposition as well as its tumor penetration post IPEC dosing, we developed an analytical method 
capable of handling small tissue sections whilst at the same time avoiding the use of laborious, time-
consuming mechanical tissue disruption techniques. By developing an enzymatic tumor tissue 
digestion protocol with subsequent SPE, to clean-up samples prior to UPLC-MS/MS analysis, we 
addressed all of these challenges. Extensive validation showed that the analytical performance 
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characteristics were well within current specifications and that our proposed methodology is suitable 
for studying the kinetics of PTX tumor uptake following IPEC dosing. 
Using the previously developed analytical method, tumor tissue from rats treated with paclitaxel 
trough IPEC was analysed. In Chapter 4 we described how these measurements were interpreted, 
using mathematical models, in order to elucidate the degree of tumor penetration following IPEC 
treatment. As shown throughout this chapter, IPEC treatment achieved a significantly higher degree 
of penetration compared to what had been previously described in literature for other routes of 
administration. Afterwards, by combining the information on the concentration-time course of PTX in 
plasma and tumor with measurements of induced tumor apoptosis and tumor growth inhibition we 
developed a quantitative modeling framework capable of adequately describing the complex 
cascade of events underlying this pharmacological intervention. Moreover, using our model, we 
prospectively evaluated through simulations, the effectiveness of new IPEC treatment regimens. 
Finally, in Chapter 5, by exposing cultured SK-OV-3 cells to different PTX treatment regimens and by 
quantitatively measuring the intra- and extracellular PTX concentrations, we studied the PK of PTX 
on a cellular level. Moreover, by simultaneously measuring the release of an endogenous 
intracellular protein, ccCK18, which is released from apoptotic cells and is non-tumor specific, we 
aimed to quantify the relationship between intracellularly bound PTX and the rate of ccCK18 release. 
Throughout this chapter we showed, albeit only preliminary, that ccCK18 released from apoptotic 
cells could be used as a biomarker for the intracellular achieved PTX concentrations and holds 
therefore the potential to be used  as a circulating biomarker for PTX pharmacodynamics, after 
thorough validation in the (pre-) clinical setting.
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The different phases of drug development 
The drug development process is typically divided into a number of representative phases, each 
focussed on answering certain questions before a decision is made to move the drug candidate to 
the next phase. After the “discovery” phase of drug development, during which basic research is 
directed towards gaining a fundamental, mechanistic understanding of biology, pharmacology, 
disease processes(3) and the identification of new molecular targets, a potential drug candidate is 
advanced to the (pre-)clinical arena.  
The pre-clinical evaluation of new compounds generally constitutes a number of tests designed to 
study the potential of a new compound to induce acute and/or chronic toxicity, prior to its first use in 
humans. Basically, during this phase, the focus is on safety. Using traditional animal toxicology 
screens, local (skin) as well as systemic (liver, heart, etc.) toxicity will be evaluated. Once an 
acceptable safety profile is established in a suitable preclinical animal model, typically mouse, rat, 
rabbit, dog, human (safety) testing is initiated. Figure 1 gives a schematic representation of the 
different stages in drug development. 
 
Figure 1. A schematic diagram of the different stages of (clinical) drug development, highlighting the potential for a more 
“learning” oriented approach to bridge between the different stages. Figure extracted from (4). 
The clinical development of a new compound, from first in humans to Regulatory (FDA/EMA/..) 
approval, is characterized by 4 distinct phases and is geared towards the establishment of drug 
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treatments with an acceptable benefit/risk profile. The first executed Phase 1 clinical trials, also 
called “first in human” trials, are mainly designed towards the identification of the safety profile 
within a cohort of male healthy volunteers. Using, amongst others, single and multiple ascending 
dose studies, the maximum tolerated dose (MTD) is established and the pharmacokinetics (PK) are 
evaluated for the drug under study.  
In addition to studying safety related issues in patients, phase 2 trials are directed towards evaluating 
efficacy in a small, selected, patient population (2A) or in a larger group of patients (2B), constituting 
the main beneficiaries for the treatment under development. Whereas phase 2A trials are merely 
evaluating efficacy for drug doses selected at the end of the phase 1 trials, phase 2B trials are 
generally designed as dose-finding studies and are used to evaluate efficacy/safety for a selection of 
dose regimens. Historically, data from phase 2B trials were analysed using an intention-to-treat 
analysis and dose selection was limited to selecting the lowest dose producing the best/similar 
outcome compared to the higher dose groups. 
Subsequent to dose selection in the target population in phase 2, phase 3 trials are confirmatory 
trials conducted to demonstrate, in a large and representative patient population, that acceptable 
benefit/risk is achieved with the selected drug dose regimen. During this phase of drug development, 
efforts are directed towards (i) the identification of “covariate effects”, i.e. patient-specific 
prognostic factors associated with treatment outcome, (ii) detection of adverse events (the relative 
scale of phase 3 versus phase 2 trials allows for the detection of less prevalent adverse events at this 
stage) and (iii) the comparison of the proposed treatment strategy against competing, well-
established treatment options. Once all of these issues are addressed properly, approval from 
Regulatory Authorities such as the FDA and/or EMA is granted and the new drug product, according 
to the approved dose regimen, is introduced into clinical practice. Simultaneously, the final clinical 
trial phase (phase 4), the so called post-marketing surveillance, is initiated to follow-up on safety, 
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efficacy and to provide, whenever necessary, updates with regards to drug use in the targeted 
patient population. 
This non-exhaustive overview of the different phases/challenges encountered during drug 
development is merely intended to serve as an introduction to some of the weaknesses that 
were/are associated with the process of getting a new drug to the patient. On the one hand, we will 
highlight some of the methodological innovations that were introduced in the pharmaceutical 
industry in the last decade in order to accelerate and make the process of drug development more 
efficient (i.e. the onset of the “model-based drug development” paradigm) and how these concepts 
are relevant to the work described in this manuscript. These concepts will be accompanied by a 
practical example we were faced with during the preparation of this manuscript, highlighting the 
potential increase in information yield when approaching complex problems with a model based 
approach. 
On the other hand, we will emphasize the problems associated with off-label drug use in “specific 
patient populations” and why the methodological advancements, described earlier, are useful to 
address this issue. These patient groups, e.g. the critically ill, young children, the elderly (>65-70 
years), etc., are frequently excluded from the conducted clinical trials and therefore thorough 
scientific knowledge on how to best treat these patients is generally lacking. 
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The transition towards a more “learning” oriented approach in clinical 
pharmacology 
The concepts of learning vs. confirming-oriented research were first introduced in the field of clinical 
pharmacology by Sheiner in 1997(1), in an attempt to create an awareness for the fact that the “old” 
way of organizing the clinical drug development path was inefficient. Historically, the clinical drug 
development path consisted of a series of successive phases, each accompanied by their end-of-
phase hypothesis test-type of analysis. For example, in dose finding studies, the question often was: 
does dose X of drug Y produce a statistically significant effect versus dose Z of drug Y or versus 
placebo.  
As argued by Sheiner(1), inspired by George Box, in order to be efficient, scientific progress requires 
alternating steps of induction (learning) and deduction (confirming). Therefore, according to Sheiner, 
the drug development process, till that time, was intrinsically inefficient and in order to accelerate 
and make the clinical drug development process more efficient, a more “learning” oriented approach 
had to be implemented.  
Nowadays, this concept has been further strengthened through the introduction of the “model-
based drug development (MBDD)” paradigm, which has been implemented in different phases of 
drug development and is actively encouraged by (some) regulatory agencies(3) (FDA/EMA). Although 
no significant improvements have been made in phase 2 attrition rates (5), in general, it appears that 
this transition from empirical drug development to MBDD has improved the quality of decision 
making, making it more objective, and formalized quantitative knowledge integration. This has 
improved the ability to discriminate between “good” and “bad” compounds prior to the conduct of 
costly late-stage trials(4), allows for a better prediction of clinical response based on pre-clinical 
data(5),facilitates the integration of information gathered throughout the different phases of the 
drug development process(6), etc.      
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We feel that these concepts are applicable in a more general setting, notably the academic research 
environment. Therefore, in this section, we will highlight some of the issues raised by Sheiner 
regarding the strategy of approaching complex problems through sequential, empirical experiments 
and how a more systematic, model-based approach, might circumvent some of these issues. The 
concept introduced by Sheiner is closely related to the optimization of experimental design through 
response surface methodologies, as encountered in numerous other quantitative sciences, and was 
comprehensively reviewed in 1966 by Hill and Hunter(7).      
In the process of clinical development of a drug, the additional benefit of a learning oriented 
approach is best exemplified by looking at the set up and subsequent analysis of phase 2B trials. As 
Sheiner(1) elegantly illustrated, dose finding, the major objective in phase 2B trials, is related to 
characterizing the therapeutic response surface (Figure 2). 
 
 
Figure 2. The therapeutic response surface for a given drug relates patient prognostic factors and dose regimen to benefit, 
the net utility of efficacy and toxicity. Figure extracted from (1). 
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The therapeutic response surface (TRS), although grossly simplified in Figure 2, describes the benefit, 
i.e. the net utility of efficacy and toxicity, in the population as a function of (patient-specific) 
prognostic factors (such as sex, age, weight, disease status, genetic make-up…) and dose regimen 
related factors (amount, administration route, timing, …). The TRS acknowledges that a patient’s 
response depends on his/her set of prognostic factors. Furthermore the TRS highlights that 
depending on the particular patient, the maximum achievable drug effect as well as the treatment 
regimen to obtain this maximum effect might differ from that of the typical patient within the 
population. A full characterization of the TRS allows answering different clinically relevant questions, 
such as: (i) what is an appropriate dose for the patient, (ii) what happens if a dose is missed, (iii) 
when will the therapeutic effect be discernible, etc.  
However, traditionally, phase 2B trials consisted of allocating different groups of homogeneous 
subjects (subjects within a narrow region on the prognostic factors axis) to a set of different drug 
doses. Given that an intention-to-treat analysis based on a (simple) statistical hypothesis test is used 
to detemine whether the different doses produce different effects, care is taken to minimize 
variation within the cohorts of test subjects (with respect to their prognostic factors) in order to 
maximize the power of the hypothesis test. Afterwards, the conclusion boils down to selecting the 
minimal effective dose.   
With respect to the TRS, this means that only a plane perpendicular to a narrow area on the 
prognostic axis at the value of the subject’s prognostic factors was studied, instead of the entire TRS. 
The consequence of this approach is that no fundamental knowledge is gained with regards to the 
variability in pharmacokinetics and pharmacodynamics within the target population and that the 
previously stated clinically relevant questions remain largely unanswered.  
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Pharmaco-statistical modeling as a tool to increase the signal-to-noise 
ratio 
As a way forward from the empirically-based hypothesis testing approach traditionally used in phase 
2B trials, a more learning oriented approach would allow to characterize the entire TRS answering all 
the dose-finding related questions as well as other clinically relevant questions with regard to 
treatment individualisation/optimization. However, since many different kinds of patients and 
dosages would have to be studied, information at each studied combination is less dense and data is 
only gathered for a finite number of points on the TRS, hence making an empirical interpretation 
impossible. 
In order to reliably interpret the complex quantitative relationships underlying the TRS (or any other 
response surface), mathematical models have to be used to separate out the noise from the actual 
drug effects. In order to increase this signal-to-noise ratio, usually a collection of specific (i.e. 
scientific) assumptions about how the data arise have to be made(1). These assumptions are usually 
explicitly stated within the model. Some of these assumptions are very intuitive and straightforward, 
such as assuming that the within-subject drug effect is bound between zero and the subject-specific 
maximum drug effect, i.e. it cannot be negative. Others are less intuitive but, nevertheless, generally 
accepted, e.g. the proportionality of the residual error variance to the measured concentration (i.e. 
the constant CV error model).  
Although these assumptions usually dramatically increase power, e.g. when previously gained 
knowledge on a drug’s pre-clinical PK behaviour is integrated into a model for phase 1 trial data, one 
must always be aware of the dependence of a model-based analysis on unproven (and often 
improvable) assumptions(1). This consideration led to the famous quote of George E.P. Box, who 
stated in his book titled: “Empirical model-building and Response Surfaces(8)” that “All models are 
wrong, but some are useful”. In general, in order to balance the influence of assumptions and actual 
observed data, a useful model should be as simple as possible, but not simpler (i.e. a parsimonious 
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model). In addition, sensitivity analyses on critical assumptions can be made in silico in order to 
evaluate how they influence the outcome. It is recommended that for highly influential assumptions, 
additional experimental data are generated to better inform on the potential outcome. 
Many famous examples exist regarding the successful use of mathematical models to explain 
complex phenomena in physics or chemistry. Some notable examples (taken from Bonate(2)) are:  
• Newton’s second law of motion, F = ma, which states that the force (F) acting on an object is 
equal to its mass (m) times its acceleration (a). 
• Boyle’s law, PV = constant, which states that for a given mass at a fixed temperature, the 
pressure (P) times the volume (V) of a gas is constant. 
In clinical pharmacology, nowadays, the science of developing and applying mathematical and 
statistical methods to characterize, understand and predict a drug’s pharmacokinetic and 
pharmacodynamic behaviour(9) is known as pharmacometrics (sometimes referred to as quantitative 
pharmacology). Pharmacometrics is regarded as a multidisciplinary profession combining knowledge 
of subject-specific matter (e.g. a particular disease area), mathematics, pharmacokinetics, 
pharmacodynamics, numerical analysis and programming in order to better understand and predict 
physiological and pharmacological phenomena using model-based approaches.  
In general we can distinguish various model components, each having a specific purpose in trying to 
differentiate the information (i.e. systematic component) in the system from the noise. (i.e. random 
components)(2). The structural model, which is usually defined as a set of ordinary differential 
equations (ODE), is typically represented by a series of connected compartments that describe our 
mechanistic understanding of the system (Figure 3) and its parameters are estimated based on the 
observed data. The statistical model on the other hand accounts for the random effects such as 
between- and within-subject variability, the error component, correlations between estimated model 
parameters, etc.  
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Figure 3. A two-compartment model (described by a set of 2 ordinary differential equations) with first-order input and first-
order (linear) elimination from the central compartment. Elimination clearance from the central compartment is denoted 
by CL and intercompartmental distribution is denoted by CLd. The volume of the central and the peripheral compartment 
are depicted with Vc and Vt, respectively. Typically, the volume and clearance terms are estimated based on the data. Figure 
extracted from (10).  
 
Depending on the complexity, models are categorized as linear or non-linear models and fixed or 
mixed effects models. Non-linear, mixed (random) effects models are most frequently encountered 
in the field of pharmacometrics. These models are used to describe continuous-type data as well as 
categorical- or survival-type data. For a complete overview on the different types of data/model 
structures we refer to Bonate(2) and Gabrielsson & Weiner(10). Once a model structure (set of ODEs 
and statistical model) is developed, model parameters are estimated using ODE solvers and 
maximum-likelihood minimization algorithms as implemented in NONMEM®(Icon Development 
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Solutions, Ellicott City, MD, USA), R®(R Foundation for Statistical Computing, Vienna, Austria), 
Berkeley Madonna® (University of California, Berkeley, CA, USA), etc. 
A substantial part of the process of model-building is devoted to the evaluation of the model’s 
goodness-of-fit and whether the assumptions that were made during model building (especially with 
regard to the structural model and the residual error) are valid for the data at hand. Afterwards, 
some sort of model evaluation is conducted. Depending on whether new data is used for the 
validation or not, we categorize model validation into external versus internal validation. (For more 
details, we refer to Bonate(2) or more specific literature dealing with model evaluation/validation 
(11;12)).  
Apart from the capacity to characterize the observed data, the strength of the model-based 
approach lies in the capacity to answer “what-if” questions using model simulations, thereby actively 
empowering the learning process and providing the basis for extrapolation towards new 
studies/experiments.            
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Model-based learning vs. empirical hypothesis testing: an example 
In analogy to the paper from Sheiner(1), in this section we will illustrate the value of taking a model-
based approach to address a typical learning problem. Both a basic confirmatory analysis and a 
learning analysis of the same problem will be presented to highlight the strengths and weaknesses 
associated with both approaches. 
The data, presented in Figure 4, are obtained from an extensive experiment evaluating the effect of 
exposing a cancer cell line to a cytotoxic drug. In this particular experiment, cell viability was assessed 
24 hours and 96 hours post exposure and the induced effect was compared between different drug 
products (represented by A, B and C in Figure 4) containing equimolar concentrations of the cytotoxic 
compound. The primary research question was to determine whether an additional add-on therapy 
(Type II versus Type I in Figure 4) had a relevant impact on the drug effect. For the sake of simplicity, 
we will focus on the viability measurements taken 96 hours post exposure.   
Upon inspection of the barplots presented in Figure 4, we notice that, for the viability measurements 
at 96 hours post exposure, the confidence intervals for the means, across all drug products 
evaluated, overlap for the 3 highest concentrations tested. However, the confidence intervals for the 
two lowest concentrations tested (0.01 and 0.1 µg/mL) appear to be non-overlapping, indicating a 
statistically significant difference between Type II and Type I treatments at these concentration 
levels. Since the add-on therapy did not produce an additional reduction in cell viability across the 
evaluated concentration range, the investigators concluded that there was insufficient evidence 
present to conclude that the Type II treatment was superior to the Type I treatment. 
When approaching this particular problem from a model-based perspective, a sensible first step 
would be to reflect on the nature of the data (even before looking at the observed measurements). 
Since the experiment concerns the measurement of a fractional viability, measured against a control 
group, the “true” fractional viability of treated cells will be bound between 0 and 1. However, due to 
e.g. measurement error, the observed fractional viability is not necessarily contained between 0 and 
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1. Here a clear distinction is made between the structural part of the model, which is constructed to 
make sure the expected viability is bound between 0 and 1 and the statistical part of the model, 
which allows random error to impact the experimental outcome and produce observations greater 
than 1.  
 
 
Figure 4. Cell viability as a function of exposure to the cytotoxic drug (x-axis) for 3 different formulations (A, B and C) 
containing equimolar concentrations of the cytotoxic compound. The main research question was to evaluate whether 
inclusion of an add-on therapy (Type II vs. Type I) had a substantial impact on the drug effect.  
 
A mathematical model well suited to describe a process that is bound between 0 and 1 is the logistic 
regression function. In this particular case, an extension to this basic function, known as the “Hill 
equation” or 4 parameter logistic regression model (Equation 1) is generally used to describe the 
expected impact of a cytotoxic drug on cell viability. 
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Equation 1 
 =  −	 × 

 + 
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Parameters:  B = Viability of the controls 
Emax = Maximum induced reduction in viability 
γ = Shape factor  
IC50 = The concentration producing half of the Emax 
Equation 1 describes the structural part of our model. Essentially, this model dictates that (i) in the 
absence of compound, the viability reduces to the viability of the controls, (ii) at a high (relative to 
the IC50) compound concentration the viability reaches a minimum, thereby incorporating what is 
generally known about the pharmacological effect of cytotoxic drugs. In between these extremes, 
the relationship between the concentration and the viability may take any shape (albeit 
monotonically increasing/decreasing) and is estimated using the γ and IC50 parameters. 
In addition to this structural part, the statistical part of the model accounts in this case for: (i) a 
normally distributed random error with mean 0 and variance proportional to the concentration used 
in the experiment (i.e. to account for expected heteroscedasticity), (ii) correlation among the 
estimated parameters (due to the fact that they are estimated using the same data). In order to 
address the research question whether the add-on therapy has a significant impact on the drug 
effect, we now have to consider 2 possibilities. 
The first potential effect (all of these hypotheses were generated prior to inspection of the data) of 
the add-on therapy could be to impact the Emax. This would mean that combining the treatment with 
the add-on therapy could result in a higher efficacy. The second plausible interaction between both 
could be that the add-on treatment impacts the IC50. This would mean that add-on therapy has a 
synergistic effect (i.e. less drug is needed for the same effect) but that once a certain limit is reached, 
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the combination of both no longer increases overall efficacy. Finally, a combination of the above is 
possible.  
Without going into too much detail, Figure 5 shows the results of the model-based analysis. Model 
building clearly showed that add-on therapy had a significant impact on the IC50, i.e. it significantly 
potentiates the drug effect of the cytotoxic drug (this is seen from the horizontal offset between the 
red and the black lines in Figure 5). In the absence of the add-on therapy, a 4-fold higher 
concentration of the cytotoxic compound was necessary to produce an effect similar to when the 
add-on therapy was present. 
 
Figure 5. Cell viability as a function of exposure to the cytotoxic drug (x-axis). The observed and predicted viabilities for the 
Type I and Type II treatments are shown in black and red circles, and related solid lines, respectively. Different line types 
were used to distinguish the different drug products tested.   
 
Furthermore, when we compare the power between the two approaches (i.e. compare the standard 
error on the effect estimate for a simple two-factor analysis of variance versus the model-based 
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estimate), the signal-to-noise raising capacity for the model-based approach is further highlighted. 
Using the traditional two-factor ANOVA (factors: drug product and add-on therapy or not), the effect 
and associated RSE of Type II versus Type I treatment is estimated to be -13.7 % and 43 %, whereas 
for the model-based analysis this is estimated to be -0.27 µg/mL (IC50 shift) and 17 %. In addition to 
the fact that the former estimated drug effect has no mechanistic basis for interpretation (i.e. it is 
the expected decrease in viability for Type II versus Type I, on average across the concentrations 
tested), the latter estimate (expressed as the absolute decrease in IC50 of Type II vs. Type I) is 
estimated with a 2.5 fold higher precision! One obvious consequence of this is that, in comparison to 
the empirical analysis, less replicates would have been needed for the model-based analysis to 
estimate the Type II effect with equal confidence.   
Finally, we would like to remark that, although it is generally known that wrong assumptions might 
impact the outcome of a model-based analysis, it is often overlooked that making no assumptions, 
e.g. in the empirical analysis the concentration levels are regarded as being independent and the 
effect of add-on therapy is evaluated for every concentration level independently, might equally bias 
the outcome of an experiment/study.    
Throughout this work, we will focus on applying the aforementioned concepts in two different 
specific clinical settings. In both settings off-label use of drugs and a general lack of clinical trial data 
precludes the optimal use of currently available pharmacological interventions. Using a modeling and 
simulation-based approach we will evaluate currently used treatments and provide insights in ways 
to further optimize / individualize treatment regimens in the future.     
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Off-label drug use in specific patient populations 
Off-label use is the use of pharmaceutical drugs for an unapproved indication, an unapproved age 
group, unapproved dosage or unapproved route of administration. Off-label use arises through many 
pathways but usually encompasses the use of drugs for unapproved clinical indications (e.g., 
gabapentin for painful diabetic neuropathy) or in unapproved subpopulations (e.g., bupropion for 
smoking cessation)(13). Off-label use is common and is thought to account for 21% of all 
prescriptions(13). Very high frequencies of off-label drug use are encountered in “special 
populations”. 
Although the physicians’ freedom to prescribe drugs off-label has some advantages, for instance to 
provide patients with rapid access to innovative medicines and to allow physicians to adopt 
treatments to new emerging scientific evidence(13), it also has huge disadvantages. By not going 
through the process of rigorously controlled clinical trials, usually neither safety nor efficacy is 
thoroughly evaluated. Furthermore, in general, only little knowledge is available with regards to 
optimal drug dosing regimens that optimize the benefit/risk in these particular patient populations. 
Two noteworthy examples of such populations, studied throughout this work, are post-bariatric 
surgery patients and patients treated with HIPEC for peritoneal carcinomatosis. In both populations 
off-label drug use is frequent.  For post-bariatric surgery patients, at the moment, no specifically 
approved drug products are available. In literature it is hypothesized that the 
restrictive/malabsorptive nature of the Roux-en-y bypass procedure, bypassing the majority of the 
stomach, the duodenum and the proximal 50 cm of the jejunum may affect the solubility and hence 
the absorption of oral drugs (14). The limited clinical data available on the effect of this procedure on 
the absorption of drugs on one hand and the hypothesis in literature , mainly based on theoretical 
considerations, that the effect is likely drug specific(15) on the other hand, make clinical trials 
addressing the safety/efficacy of drug products in this population an unmet need (14;16;17).  
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The second clinical setting addressed throughout this work is the treatment of peritoneal 
carcinomatosis via HIPEC. In this setting, drug products approved for the intravenous route of 
administration are frequently used (off-label) via the intraperitoneal route. It has been hypothesized 
in literature, by a.o. Dedrick et al.(20), that in the treatment of cancers confined to the peritoneal 
cavity, this local treatment (i.e. intraperitoneal administration) could increase treatment efficiency by 
exposing tumours within the peritoneal cavity to higher drug concentrations than what could be 
achieved through conventional i.v. chemotherapy.   
Nowadays, HIPEC is usually indicated for the treatment of locally advanced or recurrent intra-
abdominal cancer (18). It is most frequently used in the treatment of peritoneal carcinomatosis 
originating from ovarian, colorectal or gastric cancer and is generally used in combination with 
cytoreductive surgery, i.e. during surgery (HIPEC) or early post-operative (EPIC).  
During (H)IPEC, a solution containing a cytotoxic agent is instilled into the peritoneal cavity for 30-
120 minutes(19). During the treatment, an external heater circulator is used to maintain the 
temperature of the solution at mild hyperthermic (41-43 °C) or normothermic (37°C) conditions. 
Different compounds have been studied/used in this setting throughout the last decade. In general, 
taxane compounds (paclitaxel & docetaxel) and platinum-compounds (oxaliplatin, cisplatin, 
carboplatin) are used most frequently in HIPEC. Use of the former is limited to PC from ovarian 
origin, whereas the latter compounds are widely used to treat PC from ovarian, colorectal or gastric 
origin. Besides these compounds, 5-fluorouracil, mitomycine and doxorubicin are/were studied in 
the context of HIPEC administration.         
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The main objective of this thesis was to evaluate currently used treatment regimens in specific 
patient populations using an M&S-based approach. Two of these specific clinical settings where off-
label use of drugs is common and a general lack of clinical trial data precludes the optimal use of 
currently available pharmacological interventions are studied throughout this work. On the one 
hand, Chapters 1 and 2 will extend/explore in greater detail the laboratory’s previous efforts in the 
field of antimicrobial chemotherapy and on the other hand, throughout Chapters 3 - 5, we will focus 
on fundamental pharmacological research in oncology. 
Although both therapeutic fields are different in many ways and the specific issues associated with 
optimization of drug therapy in both fields are somewhat different, they share a common difficulty, 
i.e. in both cases no easily obtainable measure of pharmacological effect is available. Therefore, in 
(post-marketing) clinical trials, investigators are guided by measurements of “clinical cure” or 
“overall / event-free survival” to evaluate the efficacy of pharmacological interventions in these 
patient populations. However, these endpoints only rarely provide insights into the mechanistic basis 
for therapeutic success and are often not practical in making predictions on the efficacy of new 
therapeutic interventions or the efficacy of current interventions in different patient populations. 
In order to increase our understanding of the processes that lead to therapeutic success, we 
developed two new analytical methods to obtain accurate information on the time course of drug 
concentrations following initiation of therapy, in human plasma (Chapter 2) on the one hand and 
tumor xenografts (Chapter 3) on the other hand. The developed bio-analytical method in Chapter 2, 
focussing on β-lactam antibiotics in human plasma, was later used as a basis to set up new clinical 
trials (Details are given in “Future perspectives”). These trials were set up to evaluate drug dosing in 
two specific patient populations, i.e. the morbidly obese (LIMOP) and the general ICU patients 
(INCED). The analytical method developed in Chapter 3, i.e. the quantification of paclitaxel in tumor 
tissue, was used to evaluate IPEC administration of paclitaxel in a rat model for peritoneal 
carcinomatosis, as described in detail in Chapter 4. 
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Apart from focussing on the development of bio-analytical methods to provide quantitative 
knowledge on the concentration-time course of drugs in different biological matrices, we additionally 
developed PK(PD) models to integrate these quantitative measurements into a model-based 
framework where we could use them to explain/predict drug effects. In Chapter 1, based on 
previously collected data in human volunteers, we developed a PK model that we subsequently used 
to learn about the efficacy, and ways of improving this efficacy, of currently used moxifloxacin 
treatment regimens in post-bariatric surgery patients.  
In Chapter 4, an extensive PKPD model was developed to describe the PK of paclitaxel post IPEC 
administration as well as its induced pharmacological effects, in terms of tumor apoptosis and tumor 
shrinkage. This model was subsequently used in a simulation study to inform on how to – 
experimentally - best learn about ways to improve the currently used therapy so that, in the long run, 
patients treated with IPEC could benefit from our insights. Chapter 5 describes the first step towards 
the development of an integrated model-based framework that could ultimately be used to optimize 
IPEC treatment for patients with PC, extend our current knowledge on the degree of intracellular 
PTX accumulation, on the relationship with PTX pharmacodynamics and the possibility of using a 
soluble serum biomarker as a potential tool for monitoring PTX-induced tumor cell killing. 
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Chapter 1 
 
 
 
 
 
Moxifloxacin dosing in post-bariatric 
surgery patients. 
 
 
 
 
 
This chapter is based on:  
Pieter Colin, Douglas J. Eleveld, Michel M.R.F. Struys, Huybrecht T'jollyn, Luc M. Van Bortel, Johannes Ruige, Jan 
De Waele, Jan Van Bocxlaer & Koen Boussery. Moxifloxacin dosing in post-bariatric surgery patients.  
British Journal of Clinical Pharmacology 2013 (78:1) 84-93  
[Figure 8 and the conlusions drawn from Figure 8 were not included in the original publication.] 
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Introduction 
Recently, it was suggested that drug PK in post-bariatric surgery patients might differ significantly 
from PK in healthy volunteers due to, among other things, altered drug absorption.[1-3] In a previous 
study on the effect of roux-en-y gastric bypass surgery on moxifloxacin oral bioavailability, our group 
reported that non-compartmental analysis revealed no significant differences in absolute 
bioavailability compared to the absolute bioavailability in healthy volunteers[4]. Although our 
previous analysis showed that, on average, no differences exist between moxifloxacin exposure in 
post-bariatric surgery patients and healthy volunteers, this analysis did not address PK variability 
within the post-bariatric surgery cohort and its potential implications on antimicrobial therapy. 
 
One of the types of infections where moxifloxacin therapy is deemed necessary are lower respiratory 
tract infections (LRTI), e.g. community acquired pneumoniae (CAP). LRTI’s are the most common 
infectious cause of death in the world and the third most common cause of death globally[5]. The 
pathogens most frequently occurring in CAP[6,7] are Streptococcus pneumoniae and to a lesser 
extent Staphylococcus aureus, both Gram-positive bacteria.   
 
During antimicrobial chemotherapy there is no straightforward way to monitor the pharmacological 
effect of the treatment. Therefore, based on data from large clinical trials and/or in-vitro (kinetic) 
studies, a-priori specific treatment targets are defined in terms of pharmacokinetic-
pharmacodynamic (PK-PD) indices.  
 
For fluorquinolone antibiotics it is generally accepted that bacterial eradication and clinical cure are 
positively correlated with the AUIC (Eq. 1). 
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In the absence of data from large clinical trials on moxifloxacin PK-PD targets for treating LRTI’s, in-
vitro (kinetic) models[8-11] are used to define AUIC targets. For Streptococcus pneumoniae 
infections, Odenholt and Cars[9] advice on the use of an AUIC target of 100 h to guide moxifloxacin 
dosing. This recommendation is in line with earlier findings by Zhanel et al.[12] and Klepser et al.[13]. 
They recommended targeting a free AUIC between 35 h – 63 h[12] and total AUIC between 50 h – 
100 h[13]. 
 
Besides targets for optimal bacterial eradication, the in-vitro kinetic models provide targets for 
optimal suppression of bacterial resistance formation. In line with the mutant selection window 
hypothesis (MSW) of a.o. Zinner et al.[14] AUIC targets for suppression of bacterial resistance 
formation are usually higher than those for optimal bacterial eradication.  
 
In this study we will (i) use a population approach to describe pharmacokinetic variability in our post-
bariatric surgery cohort and (ii) use this model in a PK-PD simulation study to assess the target 
attainment rate in this vulnerable patient population against a hypothetical Streptococcus 
pneumoniae infection.   
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Patients and methods 
Model building was based on data from a randomized crossover (oral and intravenous 
administration) trial of moxifloxacin administration to a cohort of post-bariatric surgery patients [4] 
published previously. In short, 12 volunteers, who had undergone roux-en-y gastric bypass at least 6 
months prior to inclusion in the study, were administered moxifloxacin. Each volunteer received two 
single doses of 400 mg moxifloxacin, once as a tablet and once as a 1 hour intravenous infusion, 
separated by a 1 week washout period. The study protocol was approved by the local institutional 
review board of Ghent University Hospital. [4]  
 
For all patients venous blood samples were taken prior to administration and at serial time points up 
to 72h post-dose. Blood samples were collected in heparinized tubes. After centrifugation, plasma 
was collected and stored at -80°C until analysis. Samples were analysed by a validated HPLC-
Fluorescence assay published earlier.[15] Assay characteristics were evaluated and complied with the 
FDA’s guidance on bio-analytical method validation.[16]  
Pharmacokinetic analysis 
Model building 
The moxifloxacin concentration versus time data, for the oral as well as the intravenous moxifloxacin 
administration, were analysed simultaneously using the FOCE-I estimation algorithm in NONMEM® 
(Version 7.2; GloboMax LLC, Hanover, MD, USA). PLT-Tools (Version 4.6; PLTsoft, San Francisco, CA, 
USA) was used as a graphical user interface to NONMEM®. Furthermore, R®(R foundation for 
statistical computing, Vienna, Austria) was used to graphically assess the model’s goodness-of-fit 
(GOF) and to evaluate the model’s predictive capabilities.  
 
As a starting point for the development of the structural model we used a 2 compartmental model 
with a linear absorption into and a linear elimination from the central compartment, as published 
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earlier by Grosjean and Urien[17] and Simon et al[18]. Subsequently several other higher-order 
structural models were fitted to our data and their goodness-of-fit assessed (e.g. LAG-time and 
TRANSIT[19] absorption models). Throughout the course of this iterative procedure of fitting and 
evaluating different models, the Akaike information criterion (AICc) was used to compare the 
goodness-of-fit of different models. In addition, graphical evaluation was used to show the goodness-
of-fit according to the EMA Guideline on Reporting the Results of Population Pharmacokinetic 
Analyses (2007). Furthermore, the condition number was calculated on the covariance matrix of 
parameter estimates to detect possible ill-conditioning. 
 
Covariate screening was empirically approached by direct incorporation of different covariates in the 
pharmacokinetic model and comparison of the goodness-of-fit using the AICc and graphical 
techniques. Shrinkage (calculated by PLT-Tools) was considered prior to incorporating patient 
covariates in our final structural model. When shrinkage (calculated on the post-hoc parameter 
estimates) was high, inclusion of patient covariates on that particular model parameter was deemed 
unfeasible. Finally, model parsimony was assessed by selectively removing different parameters from 
the model and evaluating the goodness-of-fit of the reduced model. 
Internal Model Validation 
R®(R foundation for statistical computing, Vienna, Austria) and PLT-Tools (Version 4.6; PLTsoft, San 
Francisco, CA, USA) were used for model validation. The final pharmacokinetic model was validated 
using different methods: (i) visual predictive check (VPC) method[20] and (ii) the normalized 
prediction distribution error (NPDE) method[21]. Both methods address validation through the use of 
simulated data. Using the final pharmacokinetic population model, with all parameters fixed at final 
parameter estimates, 100 concentrations were simulated for all observed time-points. These 
simulations were performed using the $SIM statement in NONMEM®. Afterwards, for method (i), 
these simulated concentration-time profiles were analysed by non-compartmental pharmacokinetics 
using the PK package (version 1.2-5) for R®. The distribution of the calculated AUC’s for the simulated 
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concentration-time profiles were then compared to the observed AUC’s from our dataset (similarly 
calculated using the PK package in R®). The validity of the model is assessed by graphically comparing 
the degree of similarity in the distribution of both sets of calculated AUC’s. For specific details 
regarding method (ii), we refer to the work of Comets et al.[21] 
PK-PD simulations 
Using the calculated AUC24h’s of the simulated concentration-time profiles for the oral data, the AUIC 
was assessed for typical wild-type Streptococcus pneumoniae MIC-values[22]. Subsequently, these 
AUIC’s were plotted against typical AUIC thresholds to visualize the probability of target attainment 
(PTA) against Streptococcus pneumoniae MIC-values for the 400mg dosage regimen.  
 
Based on the findings by Odenholt and Cars[9] we decided to use an AUIC target for bacterial 
eradication of 100h in our simulation study. Furthermore, based on the results of the in-vitro 
dynamic model published by Zinner et al.[14], on the emergence of resistant Streptococcus 
pneumoniae, we used, as a target for optimal suppression of bacterial resistance formation, a free 
AUIC target of 100 h. When accounting for plasma protein binding (approximately 50% for 
moxifloxacin[23]), this latter free AUIC target is equivalent to an AUIC target of 200 h (to avoid 
confusion with the target for bacterial eradication defined as AUIC rather than free AUIC, in our 
simulation study we will define both targets as (total) AUIC targets). 
 
Finally, the effect of possible covariates identified in the final pharmacokinetic model, on PK-PD 
target attainment, was evaluated using graphical techniques.     
  
[34] 
 
Results 
Patients and Data 
The pharmacokinetic analysis was based on 432 observed total plasma concentrations from 12 
healthy volunteers who recently underwent bariatric surgery, obtained from a study performed by 
De Smet et al.[4] The following patient covariates were available: age, total body weight (TBM), lean 
body mass (LBM) calculated according to James[24], gender, height, serum albumin, creatinine 
clearance estimated using the Cockroft and Gault equation (CrCl) and estimated according to the 
Modification of Diet in Renal Disease equation (MDRD). A summary of the demographic information 
is given in Table 1. The observed concentration-time profiles for all patients are shown in Figure 1.  
Table 1  
Summary of patient demographics. 
Characteristic median [range] 
Age (years) 41 [25 – 57] 
TBM (kg) 78.1 [57.4 – 104.0] 
LBM (kg) 51.7 [41.9 – 77.6] 
Height (m) 1.68 [1.58 – 1.99] 
Sex (# males / # females) 4 / 8 
Serum albumin (g/dL) 3.96 [3.54 – 4.40] 
CrClCockroft-Gault (mL/min) 131.9 [100.4 – 221.5] 
CrClMDRD (mL/min) 101.5 [91.9 – 134.9] 
 
Pharmacokinetic Model Building 
According to Grosjean and Urien[17] and Simon et al[18], a two-compartmental model was found 
superior to a one-compartmental model in describing moxifloxacin pharmacokinetics for a standard 
400mg dose. In their final model Grosjean and Urien[17] incorporated an allometric scaling approach 
to predict volume and clearance terms as a function of LBM. On the other hand, Simon et al[18] 
incorporated no parameter-covariate relationship in their population model. Given the thorough 
study conducted by Grosjean and Urien[17] on the body size effects on moxifloxacin 
pharmacokinetics and the number of subjects included in their population analysis relative to Simon 
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et al.[18] (number of subjects included in the population analyses respectively 99 and 16) we decided 
to, as a starting point, fit the Grosjean and Urien[17] model with clearance and volume terms 
allometrically scaled to LBM. However, given the relatively small number of subjects in our data set, 
we initially simplified the Grosjean and Urien[17] model by excluding the TRANSIT absorption model 
and treating all model parameters as fixed effects.
 
 
Figure 1. Observed moxifloxacin plasma-concentration time profiles after oral dosing (A) and after a 1 hour i.v. infusion (B)  The LLOQ of 
the assay is depicted by the dashed line.
 
Subsequently, we investigated which of the model parameters were suitable to be included in the 
model as random effects, using the condition number as a measure of ill-conditioning. A 2-
compartmental model treating only the absorption constant (ka), the central volume of distribution 
(Vc) and clearance from the central compartment (CL) as random effects, whilst estimating the 
random effects variance-covariance matrix using a diagonal matrix, provided us with an initial model 
with an acceptable condition number (approximately 10³). The hierarchical model building procedure 
is depicted in Figure 2. 
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Figure 2. Overview of the structural model building: Vc: Volume of distribution for the central compartment; CL: Clearance 
from central compartment; Vp & Vp2: Volume of distribution for the first and second peripheral compartment; Qp & Qp2: 
Inter-compartmental clearance from the central compartment to the first and second peripheral compartment; θLag: 
Absorption lag time; θMTT: Mean transit time; θN: Number of transit compartments; σAdd: Residual error variance explained 
by the additive error term. 
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In their analysis, Grosjean and Urien[17] observe that including a LAG-time or TRANSIT compartment 
model significantly reduces the model’s objective function value. Therefore, after addition of an 
additive error term parameter to our model (which proved to be a requisite to fit an absorption 
model), we fitted both absorption models. Similar to Grosjean and Urien[17], we also observed a 
better fit for both models. However, when our structural model was fitted with an additional 
peripheral compartment we observed an even higher decrease in AICc. (As seen from Figure 2) 
Therefore, as a starting point to append more complex absorption submodels we choose the three-
compartmental model rather than the two-compartmental model as proposed by Grosjean and 
Urien [17]. 
 
Subsequently, the TRANSIT compartment and LAG-time absorption model were appended to our 3-
compartmental model. Both significantly reduced the model’s AICc. However, the condition number 
(approximately 1011 for the LAG-time model) indicated serious ill-conditioning in both cases. 
Although (some of) the estimated parameters for both models would suffer from poor precision, as 
indicated by the condition number, the estimated values (as noted in Figure 2) for the absorption 
model parameters point out that in our dataset little evidence is present to assume a delayed 
absorption of moxifloxacin (estimated LAG-time ≈ 0.19h; estimated mean transit time (MTT) ≈ 
0.19h). Based on the potential problem of poor precision of the estimated parameters and the lack of 
clinical significance of an estimated absorption delay of 0.20 hours , neither the TRANSIT 
compartment nor the LAG-time absorption model were found feasible for inclusion in our structural 
model. 
 
Finally, we (i) evaluated the feasibility of including covariates other than LBM in our model and (ii) 
studied whether we could simplify our model by removing, among other things, the allometric 
scaling component. After plotting of the post-hoc random effects estimates versus the patient 
covariates and calculation of the shrinkage, we decided to only evaluate CrCl and MDRD for 
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incorporation into our model. Hereto, CL was modelled as a linear function of CrCl or MDRD in two 
separate models. The first model, using CrCl as a predictor for CL resulted in a slightly lower AICc 
(∆AICc = -2.3), but goodness-of-fit plots (data not shown) revealed no observable difference in the 
fits of both models. Incorporation of MDRD into the model, as predictor for CL did not result in a 
decrease in AICc, and was therefore not incorporated in our final model.  
 
By removing or substituting some of the model parameters we studied whether our final model 
could be simplified further.  We started out by fitting a model using an allometric scaling of TBM 
rather than LBM as a way to predict clearance and volume terms. The resulting increase in AICc 
(∆AICc = 27.3) stresses the better model fit using an allometric scaling of LBM rather than TBM as a 
predictor of clearance and volume terms. Furthermore, leaving out the LBM covariate or the 
allometric exponent of 0.75 on the model’s clearance terms did not result in an improved goodness-
of-fit (∆AICc = +56.9 and -0.50 respectively).  
  
[39] 
 
Final PK model & Internal model validation 
The final parameter estimates and the estimated standard errors (SE) for our 3-compartmental 
model are shown in Table 2; final NONMEM® code is shown in the appendix.  
Table 2  
Population parameter estimates of the final pharmacokinetic model and the associated 95% bootstrap confidence intervals 
calculated on 100 bootstrap samples. All model parameters except ka (absorption rate) were centered for a typical subject 
with a LBM of 60 kg. 
Parameter Final pharmacokinetic 
model 
Fixed effects  
ka (h-1) 0.95 [0.72 – 1.21] /0 × (12345 )0 (L) 47.7 [31.6 – 78.6] 67 × (12345 )5.9: (L/h) 8.60 [7.80 – 9.70] /; × (12345 )0 (L) 61.5 [37.6 – 75.7] <; × (12345 )5.9: (L/h) 105.3 [55.2 – 140.0] /= × (12345 )0 (L) 48.4 [34.4 – 92.9] <= × (12345 )5.9: (L/h) 1.35 [1.23 – 1.56] 
 
Inter-individual 
variability 
 
ω2 (ka) 0.24 
ω2 (V1) 0.14 
ω2 (Cl) 0.04 
 
Residual error 
 
σ2 (Proportional) 0.03 
 
 
Figures 3 and 4 illustrate the model’s goodness-of-fit. In Figure 3 the observed plasma concentrations 
are contrasted with the plasma concentrations predicted by the final model, whilst in Figure 4 the 
observed plasma concentrations are plotted along with the median, 5% and 95% percentile of the 
simulated plasma concentrations for every observed time-point. As seen from Figure 4, the model 
gives a good prediction of the mean response at every time-point. Furthermore, it adequately 
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describes the variation around this mean response (this is seen by comparing the observed variation 
in plasma concentrations at every time-point versus the percentiles of the simulated distributions at 
these time-points). Alternatively, Figure 5 presents the results of the VPC method as described 
earlier. Again, it is noted that our model provides a good estimation of the mean observed AUC, as 
well as the observed variation around this mean AUC. The goodness-of-fit of our model was further 
confirmed by inspection of the distribution of the NPDE’s (Data not shown). Upon comparison 
against the standard normal distribution, no deviations were observed, hence demonstrating the 
goodness-of-fit of our model.  
 
 
Figure 3. Goodness-of-fit plots for our final PK model, insets show the first 3 hours post dosing. The black line represents a 
non-parametric smoother-line. 
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Figure 4. Observed moxifloxacin plasma concentrations after a standard 400 mg oral dose (open circles). The model 
simulated median moxifloxacin plasma concentration (solid line) along with the 5% and 95% percentile (dashed lines) from 
the simulations are shown to assess the model’s goodness-of-fit. 
 
 
 
Figure 5. Visual predictive check comparing the distribution of the 100 model simulated AUC72h values (histogram on top) 
against the observed AUC72h values (open circles) after a standard 400 mg oral dose of moxifloxacin. 
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PK-PD simulations 
The distribution of simulated AUIC’s for the standard 400 mg daily dose of moxifloxacin against 
typical Streptococcus pneumoniae MIC-values is depicted in Figure 6. To evaluate the expected 
efficacy of this treatment at every MIC-value, we simultaneously plotted the AUIC targets for 
bacterial eradication (AUIC > 100 h) and suppression of bacterial resistance formation (AUIC > 200 h).  
 
 
Figure 6. AUIC values calculated as the ratio of the model simulated moxifloxacin AUC24 values after a standard 400mg oral 
dose versus the theoretical Streptococcus pneumoniae MIC-values. Simultaneously the AUIC cut-off values for bacterial 
eradication as well as suppression of bacterial resistance formation, as proposed in literature, are shown. (long dashes: 
AUIC = 100; short dashed lines: AUIC = 200) 
 
For MIC-values up to 0.25 mg/L, the distribution of simulated AUIC’s remains well above the 
indicated targets for bacterial eradication. However, at MIC-values higher or equal to 0.5 mg/L, the 
median of the predicted AUIC’s is smaller than the proposed target of AUIC >100 h, leading to a PTA 
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(bacterial eradication) below 50%. Furthermore, when comparing the simulated AUIC’s versus the 
proposed target[14]  for the control of antimicrobial resistance formation, it stands out that even at 
MIC values as low as 0.25 mg/L the proposed target is attained for only a very small fraction of the 
simulated population (< 25%, given that the 75% percentile of the simulated distribution is below the 
AUIC threshold).     
 
To elucidate the effect of LBM on moxifloxacin PK-PD target attainment rate, we simulated two 
patient subpopulations. On one hand we simulated 100 plasma concentration-time profiles for a 
patient population with a LBM of 42 kg (for a person of average height, this would correspond to a 
TBM of around 60 kg, this is the lowest observed LBM in our cohort). On the other hand, simulations 
were performed for a population with a LBM of 78 kg (corresponding to a TBM of approximately 100 
kg, highest observed LBM in our cohort). Figure 7 provides the information on the simulated AUIC’s 
as a function of Streptococcus pneumoniae MIC-values. From this graph it is apparent that, for 
patients with a higher LBM, the PTA at every MIC-value is lower as compared to patients with a lower 
LBM (on average, the AUC24h in the high LBM group is  40.5 % lower than the AUC24h in the low LBM 
group).  
 
Furthermore, all simulated AUIC’s from the high LBM group drop below the recommended AUIC 
target of 100 h when targeting a microorganism with an MIC of 0.5mg/L, and hence the PTA for 
bacterial eradication for those patients approaches zero. Furthermore, when evaluating the PTA for 
suppression of bacterial resistance formation, for patients with a higher LBM, this PTA approaches 
zero at MIC values as low as 0.25 mg/L. 
 
[44] 
 
 
 
Figure 7. AUIC values calculated as the ratio of the model simulated moxifloxacin AUC24 values for subjects with a LBM of 42 
kg (open squares) and 78 kg (solid squares) after a standard 400mg oral dose versus the theoretical Streptococcus 
pneumoniae MIC-values. Simultaneously the AUIC cut-off values for bacterial eradication as well as suppression of bacterial 
resistance formation, as proposed in literature, are shown. (long dashes: AUIC = 100; short dashed lines: AUIC = 200) 
Overall, AUIC values for the high LBM group are 40.5 % lower than those for the low LBM group. 
Although Figure 6 and 7 elegantly show the relationship between AUICs and MIC values, they do not 
provide information on the average PTA in the population. Therefore, in order to put our results in a 
broader perspective, using the MIC distributions for Streptococcus pneumoniae[22], we calculated 
the average MIC (0.163 mg/L)  and evaluated, similar to our initial simulation study, the PTA for 
suppression of bacterial resistance formation for patients with different LBMs.  The distribution of 
LBM according to gender was calculated, according to the James’ equation, based on demographic 
information on weight and height for males/females in Belgium[25] and therefore represents the 
LBM distribution in the general population.  
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Figure 8. PTA for suppression of bacterial resistance formation as a function of lean body mass (LBM) for the average 
Streptococcus pneumoniae infection (MIC = 0.163 mg/L). The histogram on the bottom shows the distribution of LBM in the 
population. A solid line is used to denote the distribution of LBM for the females whereas a dashed line represents the 
distribution of LBM for males.  For the median, 75% and 90% percentile of the overall LBM distribution (not shown) the PTA 
was calculated. These PTAs are shown with a dashed, dotted and dashed/dotted line, respectively, in the top graph.      
As seen from Figure 8, for a patient with a LBM of 50.7 kg (i.e. the median of the Belgian population), 
suffering from an “average” Streptococcus pneumonia infection, the PTA for suppression of bacterial 
resistance formation is high (94%). However, for patients with a slightly higher LBM of 57.9 kg (i.e. 
the 75% percentile of the Belgian population), the PTA reduces to approximately 80%. This means 
that, under a once daily 400 mg dose of moxifloxacin, already 20% of patients do not achieve an AUIC 
in excess of 200h, which is necessary to suppress the formation of bacterial resistance formation. Of 
note here is that, according to our LBM distribution, 57.9 kg is the 75% percentile of the overall LBM 
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distribution, consequently, 25% of patients have a LBM in excess of 57.9 kg and hence a PTA less than 
80%. When looking at the PTA for patients with a LBM of 62.3 kg (the 90% percentile) we see that it 
has already reduced down to 64%, a PTA which, according to us, is unacceptably low.  
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Discussion 
Many authors reported in literature that moxifloxacin pharmacokinetics were best described using a 
1-compartmental [26] or a two-compartmental [17,18] model, with[17,26] or without[18] additional 
parameters to account for the observed absorption delay. In contrast to these observations, we 
found that a three-compartmental model produces a superior fit as compared to a two-
compartmental model. This discrepancy is explained by the difference in sampling times between our 
study (up until 72 hours post-dose) and the studies reported in literature earlier (restricted to 24 
hours post-dose). Given the relatively short sampling schemes of the foregoing studies, it would have 
been nearly impossible for these authors to reliably identify this third compartment. Although this 
third compartment might not have a significant impact on the single dose simulations performed in 
our study, it is expected to have an impact whenever trying to simulate moxifloxacin exposure after 
repeated doses. Moreover, not taking into account this 3rd compartment when simulating 
moxifloxacin PK will result in an underestimation of a subjects true (unobservable) AUC.     
 
As opposed to Florian et al. [26] and Grosjean and Urien [17] our study, as well as the study reported 
by Simon et al. [18], found no evidence in favour of a (clinically significant) delayed absorption and 
therefore no LAG-time nor TRANSIT-model was fitted. These differences are likely explained by the 
fact that Florian et al. [26] and Grosjean and Urien [17] used data originating from double-blinded 
trials in which moxifloxacin tablets were overencapsulated, thereby most likely prolonging the 
absorption phase. 
 
Based on our data, it seems that allometric scaling of LBM by an exponent of 0.75 is superior, 
compared to a simple linear regression model, for the prediction of moxifloxacin clearance terms. 
Furthermore, in concordance with the findings of Grosjean and Urien [17] we found that LBM rather 
than TBM should be used in the prediction of moxifloxacin pharmacokinetics. However, since it is 
well known[27] that the James[24] equation tends to overestimate the subjects’ percentage body fat, 
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thereby underestimating the true LBM, care has to be taken when using this model to estimate PK 
parameters in the morbidly obese (BMI > 30 kg/m²).    
 
Although the appropriate PK-PD targets to pursue when trying to optimise moxifloxacin treatment 
are still under debate , our PK-PD simulations show that, when taking into account currently 
propagated AUIC thresholds, in this population the PTA for bacterial eradication against a 
Streptococcus pneumoniae organism with a MIC-value of 0.5 mg/L is already below 50%. When we 
look at the PTA for the simulated population with LBM of 78 kg, this probability approaches zero at 
the MIC value of 0.5 mg/L. Furthermore, when evaluating the PTA of suppression of bacterial 
resistance formation it is apparent that at standard 400mg doses of moxifloxacin, even at MIC values 
of 0.25 mg/L this PTA is unacceptably low.  
 
Given the relatively low prevalence of MIC-values of 0.50 mg/L for the wild type Streptococcus 
pneumoniae species[22], at first glance, our results do not seem to have an important impact on the 
average PTA for bacterial eradication of moxifloxacin therapy in this population. However, as 
indicated in Figure 7, for subjects with a LBM of 78 kg, approximately 25 % will attain AUIC values 
below the recommended target of 100 h. (as seen by the near-overlap of the 25 % percentile of the 
simulated distribution and the dashed line for the AUIC target of 100 h) Moreover, although not 
included in our simulated population, from our model it is apparent that post-bariatric surgery 
patients with a LBM higher than 78 kg are likely to fail in achieving an AUIC of 100 h. 
 
When considering an AUIC target of 200 h, as proposed in literature[14] to optimally supress 
bacterial resistance formation, we see that the overall PTA is low (well below 50 %) even at MIC 
values of 0.25 mg/L for the entire simulated population. Furthermore, when considering the effect of 
LBM on this particular PTA, we observe that for subjects with a higher LBM (78 kg) the PTA for 
suppression of bacterial resistance formation approaches zero at this MIC value.  
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Using an extension of our initial simulation study, we showed that 25% of patients (with a LBM 
higher than 57.9 kg) have a probability of less than 80% of achieving an AUIC > 200h under a once 
daily moxifloxacin dose. Although a discussion on limits for the PTA are outside of the scope of this 
work, we do feel that 80% might already be unacceptably low. Furthermore, based on the 
quantitative relationship between LBM and the PTA for bacterial resistance suppression on one hand 
and the differential distribution of LBM for males and females on the other hand (as seen from Figure 
8), we hypothesise that it will be harder to achieve an AUIC24h > 200h in males than in females.    
 
This study has a number of limitations. At first, changes induced in the PK of moxifloxacin by the 
infection are not captured. Furthermore, given that the subjects in our study were included after 
having stabilised from their bariatric surgery, i.e. they were in a generally good condition, the 
observed PK variability might underestimate the variability seen in infected patient populations. The 
consequence of this limitation is that both PK and the probability of target attainment are likely to be 
even more variable in a patient population treated with moxifloxacin.  
Conclusions 
This analysis demonstrates that for antimicrobial dosing the “one dose fits all” paradigm is not 
correct. Throughout this simulation study, it was clear that optimization of moxifloxacin dosing 
should take into account the effect LBM on PK and, ultimately, the PK-PD endpoints. Our study 
results show that in order to optimize moxifloxacin chemotherapy, both in terms of bacterial 
eradication and optimal suppression of resistance development during therapy, individualized dosing 
strategies should be developed.  
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Appendix 
Final NONMEM® code 
$SUBROUTINES ADVAN6 TOL5 
$MODEL ;NCOMP=4 
COMP(DEPOT,DEFDOSE) 
COMP(CENTRAL,DEFOBS);Central compartment 
COMP(PERIPH) 
COMP(PERIPH2) 
 
$PK 
KA=THETA(1)*EXP(ETA(1)) 
V2=(THETA(2)*(78/60)**1)*EXP(ETA(2)) 
CL=(THETA(3)*(78/60)**0.75)*EXP(ETA(3)) 
V3=THETA(4)*(78/60)**1 
Q3=THETA(5)*(78/60)**0.75 
V4=THETA(6)*(78/60)**1 
Q4=THETA(7)*(78/60)**0.75 
K20=CL/V2 
K23=Q3/V2 
K32=Q3/V3 
K24=Q4/V2 
K42=Q4/V4 
S2 =V2 
 
$DES 
DADT(1)=-KA*A(1) 
DADT(2)=KA*A(1)-K20*A(2)-K23*A(2)+K32*A(3)-K24*A(2)+K42*A(4) 
DADT(3)=K23*A(2)-K32*A(3) 
DADT(4)=K24*A(2)-K42*A(4) 
 
$ERROR 
IPRED=F 
Y=F*(1+ERR(1)) 
 
$THETA ;Final estimates 
(0,0.949)     ;KA 
(0,47.75)     ;V1 
(0,8.605)     ;CL 
(0,61.53)     ;V2 
(0,105.3)     ;Q2 
(0,48.43)     ;V3 
(0,1.356)     ;Q3 
 
$OMEGA 
0.5     ;KA 
0.2     ;V1 
0.1     ;CL 
 
$SIGMA 
0.1 ;Proportional error term 
 
$ESTM SIG=3 MAX=0 METHOD=1 SORT INTERACTION POSTHOC PRINT=1 MSFO=MSFO.OUTPUTFILE 
$COV PRINT=E 
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Introduction 
Obesity is a worldwide problem, reaching epidemic proportions. According to the WHO in 2008, 1.5 
billion adults were overweight and 500 million were obese[1]. Accordingly, the frequency of bariatric 
surgery, one of the most effective treatment options in terms of long-term weight loss and co-
morbid medical conditions, is ever increasing. However, until today, the effect of these drastic 
surgical alterations of the gastrointestinal system on drug disposition remain unclear[2]. Changes in 
pharmacokinetic (PK) characteristics, for example in volume of distribution or in extent of absorption, 
may occur in this specific patient population [3,4].  
For most drugs, pharmacodynamic (PD) effects are easily measurable (e.g. blood pressure, glycaemia 
etc.). These measurements provide the clinician with a tool to individualize drug therapy or to adjust 
drug dosing in specific patient populations. However, for antibiotics (AB), no such easily measurable 
clinical endpoints are available. Nevertheless, for the majority of antibiotics, intermediate clinical 
endpoints, in terms of PK/PD indices, are defined to guide chemotherapeutic dosing. These PK/PD 
indices are not only correlated with therapeutic success, but show a negative correlation with the 
occurrence of antimicrobial resistance formation.            
For the beta-lactam AB, the most frequently prescribed class of antibiotics (based on data of the 
Belgian national institute for health and disability insurance for the period 05/2008 – 05/2009), 
clinical efficacy is correlated with the time that the AB plasma concentration remains above the 
MIC[5]. Optimization of treatment should therefore be based on knowledge of the antibiotic plasma 
concentration as well as the results of the microbial susceptibility testing of the pathogen. On the 
one hand, prediction of antibiotic plasma concentrations, based on a thorough understanding of 
underlying AB pharmacokinetics, could prove useful in optimizing AB treatment. However, a priori, 
studies measuring AB plasma concentrations in different subjects are needed to develop PK models 
capable of making these predictions. On the other hand, therapeutic drug monitoring (TDM) 
programs could be set up to help the clinician in adjusting patient dosing to achieve therapeutic 
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concentrations. In both cases, one relies heavily on accurate measurements of AB in human plasma 
samples to optimize clinical efficacy of AB treatment.         
Various analytical methods for simultaneous quantification of β-lactam AB are described in literature, 
some claiming applicability in a therapeutic drug monitoring setting [6-10]. Although MS/MS-
detection is regarded superior over other detection-techniques, in terms of specificity, sensitivity and 
speed, few authors report TDM-assays based on this technique. Of all consulted reports on TDM-
assays for β-lactam AB, only one is based on LC-MS/MS[8]. Others mainly rely on UV detection to 
quantify β-lactam AB in human plasma.  
Besides specificity, speed is of the essence when determining patient plasma concentrations in a 
therapeutic drug monitoring setting. In order to provide quantitative results in a timely manner, 
chromatographic runtime as well as sample preparation time should be minimized. To the author’s 
knowledge none of the previously published TDM-assays succeeded in reducing chromatographic 
run-time sufficiently. Apart from one author claiming chromatographic separation of eight β-lactam 
AB within 13 minutes[8], most published methods require up to 30 minutes of chromatographic run 
time. Generally, a minimum of 6 calibration standards and 6 quality control samples [11] are used to 
reliably quantify study samples. Although these recommendations were initially issued for the 
analysis of samples originating from clinical trials, given the lack of specific guidance on method 
validation in TDM assays, we adhere to these guidelines for the development of TDM capable assays. 
For the reported assays, given the FDA guidance, total chromatographic analysis would then add up 
to more than 6 hours. Moreover, most of the reported TDM-assays were based on time-consuming 
low-throughput sample preparation steps. Use of laborious procedures, e.g. multiple centrifugation 
steps[7], or evaporation-to-dryness procedures[6,8] significantly lengthen the total analysis time.  
To accommodate present and future needs for studies on β-lactam PK as well as therapeutic drug 
monitoring of β-lactam AB, we set out to develop a fast multi-drug assay. We focus on the 
development of a single analytical platform capable of addressing plasma samples containing a broad 
[59] 
 
selection of different AB. In addition to some important penicillin and cephalosporin AB (respective 
molecular structures are given in Figure 1 and 2), we choose to include the monobactam AB 
meropenem, the β-lactamase inhibitor tazobactam and one AB not from the β-lactam group, 
linezolid (molecular structures of the latter four are shown in Figure 3).  
 
 
Figure 1. Molecular structures of the penicillin antibiotics: amoxicillin (AMO), ampicillin (AMP), phenoxymethylpenicillin 
(FEN), flucloxacillin (FLU) and piperacillin (PIP) 
 
The development of one single method for many different AB was favoured. Although these drugs 
are virtually never co-administered, it provides us, however, with one single analytical platform that 
can be used at any time, irrespective of which of the individual AB is in a particular instance the 
subject of a certain study or therapeutic follow-up. Additionally, sample preparation time as well as 
chromatographic run-time will be minimized in order to significantly reduce total analysis time, thus 
making it possible e.g. to provide the clinic with quantitative measurements in a timely manner. 
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Figure 2. Molecular structures of the cephalosporin antibiotics: cefadroxil (CDX), cefuroxime (CEF), cefepime (CFP), 
ceftazidime (CFT) and cefazoline (CFZ) 
 
 
Figure 3. Molecular structures of monobactam antibiotics: meropenem (MER), β-lactamase inhibitor tazobactam (TAZ) and 
oxazolidinone antibiotic linezolid (LIN) 
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Material and methods 
Reagents 
Amoxicillin (AMO), Ampicillin (AMP), Phenoxymethylpenicillin (FEN), Piperacillin (PIP), Cefuroxime 
(CEF) and Cefadroxil (CDX) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Flucloxacillin 
(FLU), Meropenem (MER), Cefepime (CFP), and Ceftazidime (CFT) were purchased from the European 
directory for the quality of medicine (Strasbourg, France). Tazobactam (TAZ) was purchased from The 
United States Pharmacopeial Convention (Rockville, MD, USA). Linezolid (LIN), Cefazolin (CFZ), 2H4-
Amoxicillin, 2H4-Cefadroxil, 2H6-Meropenem and 2H5-Phenoxymethylpenicillin were purchased from 
Toronto Research Chemicals (Ontario, Canada). 13C,2H3-Cefepime was purchased from AlsaChim 
(Illkirch, France). HPLC-grade water was prepared using a commercial water purification system 
(Millipore Synergy 185, Millipore, Billerica, MA, USA).  All other reagents were of analytical grade. 
The Oasis® MCX 96-well µ-elution plate, as well as the Ostro® enhanced protein precipitation plate 
and the Oasis® 96-well sorbent selection plate (containing different mixed-mode solid phase 
sorbents: WCX, MAX, WAX and MCX) were from Waters (Milford, MA,USA). A vacuum manifold 
(Waters) was used to force liquids through the Oasis®- and Ostro®-plate.   
Instrumentation 
Chromatographic separation was achieved on an Acquity UPLC system (Waters, Milford, MA) 
equipped with an Acquity HSS T3 column (50 mm x 2.1 mm, 1.7 µm particle size) and an Acquity BEH 
C18 guard-column (5 mm x 2.1 mm, 1.7 µm particle size) all from Waters (Milford, MA). The column 
was kept at 40 °C. An aliquot of 1 µl was injected into the mobile phase stream using full loop 
injection. The mobile phases consisted of a 1 mM CH3COOH/CH3COONH4-buffer with 5% acetonitrile 
(MPA) and acetonitrile (MPB). Components were eluted using gradient-elution at a flow rate of 0.600 
ml/min. From 0 to 1 min the mobile phase contained 100% of MPA. From 1 to 2 min the amount of 
MPB in the mobile phase was increased linearly to 21%. At 3 min, the system was switched to 99% 
MPB. Finally, at 4 min, the analytical column was re-equilibrated to initial gradient settings.  Eluting 
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compounds were detected using a Waters Quattro Ultima triple quadrupole system (Micromass 
Waters, Manchester, UK) equipped with an electrospray source (orthogonal Z-spray®) operated in 
positive (ESI+) or negative ionization (ESI-) mode. The MS/MS instrument was operated with a 
capillary voltage of 3.5 kV, source block temperature of 150 °C and cone voltage of 10 V. Nitrogen 
was used as desolvation gas and was heated to 400 °C and delivered to the source at 750 L/h. The 
system uses argon gas to induce fragmentation in the collision cell. The dwell time for each MRM 
transition was 50 ms and the interchannel and interscan delays were set to 20 ms. Details of the 
MRM-transitions for each compound are described in Table 1. Peak areas were integrated using 
MassLynx 4.1 software (Micromass Waters, Manchester, UK). 
Table 1  
Detection parameters for the different antibiotics (AB) under study. Only one MRM transition (quantifier) was monitored 
for the stable isotope labelled internal standards, while for the analytes a quantifier and qualifier trace were monitored. 
Qualifier traces were used to calculate ion ratios for each studied AB (ratio of quantifier over qualifier). These ion-ratios 
were monitored during the analysis to confirm the identity of the measured AB. 
 Detection MRM-transitions  CE 
Compound Ionisation mode Quantifier Qualifier (eV) 
AMO ESI - 364.2 > 222.6 364.2 > 319.9 6 
AMP ESI - 348.3 > 206.6 348.3 > 303.8 6 
CDX ESI + 364.2 > 207.7 364.2 > 346.6 8 
CFZ ESI + 455.2 > 322.6 455.2 > 294.7 10 
CFP ESI + 481.1 > 323.7 481.1 > 395.8 14 
CFT ESI + 547.1 > 468.1 547.1 > 396.0 12 
CEF ESI - 423.3 > 317.8 423.3 > 206.7 7 
FLU ESI - 452.1 > 310.6 452.1 > 407.9 6 
LIN ESI + 338.3 > 295.8 338.3 > 194.8 20 
MER ESI + 384.4 > 253.7 384.4 > 297.6 14 
FEN ESI - 349.1 > 207.8 349.1 > 304.8 6 
PIP ESI - 516.0 > 329.9 516.0 > 232.6 8 
TAZ ESI + 300.8 > 167.7 300.8 > 206.8 14 
2H4-AMO ESI - 368.3 > 227.2 - 8 
2H4-CDX ESI + 368.4 > 212.1 - 8 
13H,2H3-CFP ESI + 485.5 > 327.6 - 14 
2H6-MER ESI + 390.4 > 259.8 - 14 
2H5-FEN ESI - 354.3 > 212.7 - 6 
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Stock solutions, standards and quality control samples 
A first set of stock solutions were prepared for all components except AMO, AMP, CFT and TAZ. All 
stock solutions were prepared in water, except for LIN which was dissolved in DMSO. Due to their 
lower solubility, AMO, AMP, CFT and TAZ were dissolved directly into, and mixed with aliquots of the 
stock solutions of the other components rather than first preparing a separate stock solution. Details 
regarding stock solution / mix solution concentrations are found in Table 2.  
Table 2  
Details on stock solution and mix working solution concentrations. All stock solutions were prepared in water, except for 
LIN, which was dissolved in DMSO. Mix working solutions were prepared in water. Internal standard working solution was 
prepared in water after appropriately diluting internal standard stock solutions. 
 Stock concentration Mix concentration IS working solution 
Compound (mg/ml) (mg/ml) (µg/ml) 
AMO - 1.07 - 
AMP - 1.47 - 
CDX 2.54 0.13 - 
CFZ 76.66 1.53 - 
CFP 21.53 0.45 - 
CFT - 1.91 - 
CEF 25.24 1.21 - 
FLU 10.63 0.19 - 
LIN 4.16 0.13 - 
MER 7.02 0.42 - 
FEN 1.27 0.15 - 
PIP 49.95 0.80 - 
TAZ - 0.59 - 
2H4-AMO 1.02 - 12.20 
2H4-CDX 0.59 - 2.40 
13C,2H3-CFP 0.96 - 5.80 
2H6-MER 1.13 - 4.50 
2H5-FEN 0.44 - 1.70 
 
The concentrations of the different antibiotics in this mixture, containing all 13 components, were 
chosen proportionally to their expected maximum plasma concentrations in patients on a standard 
treatment regimen[12]. This resulting mix was further diluted with water to obtain working solutions. 
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Blank human plasma (Red Cross, Ghent, Belgium) was spiked with the different working solutions to 
obtain calibrator samples containing all 13 components. In order to preserve the integrity of the 
plasma matrix, the plasma standards contained at most 5% (v/v) of working solution. A second 
independent set of stock solutions were prepared for all components. Apart from LIN, which was 
dissolved in DMSO, all stock solutions were prepared in water. These stock solutions were further 
diluted in water to obtain three working solutions. Again, concentrations were tuned to the 
appropriate measurement range for the particular AB. Plasma quality control samples (QC) were 
prepared by addition of working solution, containing a single component only, to appropriate 
amounts of blank human plasma. The final concentrations obtained in the calibrator and quality 
control samples as well as details regarding the construction of the calibration curves are 
summarized in Table 3. Internal standard stock solutions, prepared from the stable isotope labelled 
compounds, were prepared in water, except for 2H5-Phenoxymethylpenicillin which was dissolved in 
33% (v/v) acetonitrile. After mixing and further dilution of these stock solutions, an internal standard 
working solution was obtained. Details regarding IS stock and working solutions are given in Table 2. 
Stock solutions, internal standard stock solutions, plasma calibrator samples and quality control 
samples were stored in polypropylene tubes at -20 °C.      
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Table 3  
Details on calibration curves and concentrations of plasma calibrator and QC samples. Plasma calibrator samples were constituted of a mixture of the thirteen studied AB spiked to blank 
human plasma. QC samples contained a single AB in blank human plasma. Aliquots were stored in polypropylene vials at -20°C. 
 Weighting factor   Plasma concentration (µg/ml) 
Compound 
Axis 
transformation 
2nd order 
term 
Internal 
standard 
ST8 ST7 ST6 ST5 ST4 ST3 ST2 ST1 
QC 
Low 
QC 
Med 
QC 
High 
AMO 1 / X - 2H4-AMO 0.43 0.80 2.13 3.19 6.38 12.76 25.52 51.05 0.57 5.73 40.14 
AMP Log + 2H5-FEN 0.58 1.09 2.92 4.38 8.76 17.51 35.02 70.05 0.83 8.28 57.95 
CDX Square root + 2H4-CDX 0.05 0.09 0.25 0.38 0.75 1.51 3.02 6.04 0.07 0.69 4.83 
CFZ Log + 2H4-CDX 0.61 1.14 3.04 4.56 9.13 18.25 36.50 73.01 0.78 7.82 54.76 
CFP Square root + 13C,2H3-CFP 0.18 0.34 0.90 1.35 2.69 5.38 10.77 21.53 1.11 4.46 17.84 
CFT 1 / X + 13C,2H3-CFP 0.76 1.42 3.78 5.68 11.35 22.70 45.40 90.81 3.61 14.43 57.71 
CEF Log + 2H5-FEN 0.48 0.90 2.40 3.61 7.21 14.42 28.85 57.69 0.69 6.87 48.08 
FLU 1 / X + 2H5-FEN 0.08 0.14 0.38 0.57 1.14 2.28 4.56 9.11 0.11 1.08 7.59 
LIN Log + 2H4-CDX 0.05 0.09 0.25 0.37 0.74 1.48 2.97 5.94 0.07 0.71 4.95 
MER Square root + 2H6-MER 0.17 0.31 0.84 1.25 2.51 5.01 10.03 20.06 1.04 4.18 16.71 
FEN 1 / X + 2H5-FEN 0.06 0.11 0.30 0.45 0.91 1.82 3.64 7.28 0.09 0.87 6.07 
PIP 1 / X + 2H5-FEN 0.32 0.59 1.59 2.38 4.76 9.51 19.03 38.06 0.42 4.25 29.73 
TAZ 1 / X + 2H4-CDX 0.24 0.44 1.18 1.76 3.53 7.06 14.12 28.24 0.23 2.30 16.07 
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Solid Phase Extraction procedure 
Frozen samples were allowed to thaw at room temperature and a rotatory mixer was used to ensure 
complete homogenization of the samples prior to analysis. Oasis® MCX µ-elution 96-well plates were 
conditioned and equilibrated using respectively 200 µL of methanol and 200 µL of water. 50 µL 
aliquots of plasma samples were pipetted into empty wells of a 96-well plate. Subsequently 50 µL of 
internal standard working solution was added. Prior to homogenization by repeated aspiration with a 
multi-channel pipette, 400 µL of a 2.5 % (v/v) H3PO4 solution was added to the wells. Of this mixture 
200 µL was loaded onto the Oasis® µ-elution plate. 200 µL of a 2% (v/v) formic acid solution was used 
to wash the Oasis® plate prior to elution with 30 µL of a 5% (v/v) NH4OH solution in 
acetonitrile/methanol (60:40). Finally, eluates were diluted with 90 µL of a 1 M 
CH3COOH/CH3COONH4 buffer. After capping of the 96-well plate with a polypropylene cap mat, 
sample plates were placed in the autosampler at 5°C until injection.    
Relative matrix effect 
For the assessment of the relative matrix effect, the previously described calibrator working solutions 
were used to prepare calibrator samples in 8 different lots of human plasma at three different 
concentration levels. The concentrations of the calibrator samples were chosen to reflect the 
concentrations of the different antibiotics at the upper limit of quantification (ULOQ), at the center 
of the calibration curve and at 2 x the lower limit of quantification (LLOQ). All calibrator samples 
were analyzed in quadruplicate. To test for a statistically significant difference between analyte-to-
internal standard peak area ratios obtained for different plasma lots, Anova analysis was performed 
using R®(R foundation for statistical computing, Vienna, Austria). Additionally, absolute matrix effect 
was calculated according to Matuszewski et al. [13].       
Validation 
The validation experiments were based on the “Guidance for Industry-Bioanalytical Method 
Validation” recommended by the Food and Drug Administration (FDA) of the United States. [11] 
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Batches of quality control samples at three different concentration levels (Table 3) were prepared, 
aliquoted and stored at -20 °C. These samples were used throughout the validation experiments.  
1. Calibration model selection and linearity evaluation 
Calibrator working solutions were used to prepare calibrator samples at six different concentrations. 
All samples were analyzed in six-fold within the same run. Calibration model selection and linearity 
evaluation was performed according to Hartmann et al. [14].   
2. Trueness and (intermediate) imprecision 
Trueness was evaluated by analyzing QC samples in six-fold on the same day. It was calculated as the 
mean relative error of QC samples analyzed under repeatability conditions. Within-run imprecision 
was calculated as the coefficient of variation (CV%) of the concentration of the QC samples measured 
in six-fold on day 1. Between-run imprecision was evaluated by replicate measurements of QC 
samples on four different days. (Measurements in six-fold on day 1, triplicate measurements on days 
2, 3 and 4) Between-run imprecision was calculated as the CV% of the average QC concentrations 
measured on four different days. 
3. Lower Limit of quantification (LLOQ) 
The lower limit of quantification was defined as the concentration of the lowest calibrator sample 
which could be measured with an imprecision not exceeding 20% and a trueness between 80% and 
120%.      
4. Selectivity 
Selectivity was assessed by examining peak interference (signal-to-noise ratio < 9) from eight 
independent sources of blank human plasma. 
5. Stability 
Stability of the β-lactam antibiotics was studied in different experimental settings. At first, antibiotic 
stock and internal standard stock solution stability was evaluated at -20°C. Aliquots of internal 
standard stock solutions were kept at -20 °C and thawed at different time-points throughout an 86-
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day period. Stability data for the antibiotic stocks spanned a 35-day period. Samples were analyzed 
using UPLC-UV. Secondly, a short-term study was conducted to evaluate autosampler stability at 5°C. 
At different time points throughout a 24 hours study period, triplicate injections were made from a 
vial kept in the autosampler compartment at 5°C. Analyte-to-internal standard peak area ratios were 
measured by UPLC-MS/MS. Finally, a preliminary study was set-up to evaluate antibiotic stability in 
plasma calibrator samples kept at -20°C. In this study, calibrator samples were analyzed in triplicate 
before and after 4 days of storage at -20°C. Analyte-to-internal standard peak area ratios were 
measured by UPLC-MS/MS. For the stock stability studies, linear regression models of the peak areas 
versus time were constructed. From these models, regression coefficients were estimated and used 
to calculate the time point at which 15% of the initial concentration had degraded. In the 
autosampler stability and the calibrator stability experiment, statistical significance testing was 
performed at each time-point. A two-sided one-sample t-test at the 5 % level of significance was 
used to assess whether the obtained measurement was significantly different from the initial 
measurement.       
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Results and discussion 
 Method development 
1. Chromatography and mass spectrometric detection  
Prior to the optimization of the chromatographic separation, preliminary precursor and product-ion 
mass spectra were obtained for the different antibiotics in both negative and positive ionization 
mode. The choice of ionization mode was based on a comparison of the obtained sensitivity between 
either modes for each compound. Seven out of 13 components were detected in the negative 
ionization mode, while the other components proved more suitable for positive ionization 
electrospray. Details of ionization mode are presented in Table 1. Rather than focusing on 
accomplishing baseline separation for all adjacent peak pairs, we set out to maximize 
chromatographic resolution for most compounds, whilst minimizing overall run time. The limited 
retention of β-lactam antibiotics on conventional reversed-phase C18 columns was previously 
described by Ohmori et al. [8] Similar to the experiments described by these authors, we compared 
chromatographic separation and capacity factors between two different analytical columns. Both 
columns were chosen based on their compatibility with high aqueous content mobile phases. Initial 
experiments were carried out on a hybrid-particle column (Waters BEH C18 UPLC column; 50 mm x 
2.1 mm x 1.7 µm particles) but provided insufficient resolution. In contrast, better overall resolution 
was seen in experiments conducted with the second column (Waters HSS T3 UPLC column, 50 mm x 
2.1 mm x 1.7 µm particles). After optimization of mobile phase flow rate and gradient elution 
parameters, we achieved full chromatographic separation for all components detected in ESI- within 
4 min. On the other hand, of all components measured in ESI+, two pairs were not baseline 
separated. A chromatogram of a calibrator sample is presented in Figure 4. Finally, once all mobile 
phase constituents were selected, MS/MS detection parameters were optimized by post-column 
infusion of antibiotic stock solutions into the mobile phase stream. Optimized parameters as well as 
details on selected MRM transitions are given in Table 1.           
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Figure 4. Chromatogram of a calibrator sample. Concentrations of the different antibiotics in the calibrator sample 
according to Table 3. An asterisk denotes compounds for which a stabile isotope labelled internal standard was included. 
Analytical conditions as described under Instrumentation. 
 
2. Extraction procedure 
2.1. Protein precipitation 
Two different protein precipitation protocols were evaluated in terms of recovery and matrix effect. 
Procedure 1 consisted of precipitating plasma samples using cold acetonitrile. After centrifugation 
and transfer of the supernatant to a glass tube, the samples were evaporated to dryness under a 
stream of nitrogen gas at 30 °C. Prior to injection onto the chromatographic system, samples were 
reconstituted in a 5% (v/v) solution of acetonitrile in water. In procedure 2 we used a solution of 1% 
(v/v) formic acid in acetonitrile to precipitate plasma proteins. Subsequently, samples were filtered 
through an Ostro® plate to remove lipoproteins (Ostro® plates contain a reversed phase type sorbent 
embedded in the protein filter material) and precipitated proteins. Samples were then evaporated to 
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dryness under a stream of nitrogen gas at 30°C. Finally, the obtained dry residue was dissolved in a 
5% (v/v) solution of acetonitrile in water before being injected onto the analytical column. Recovery 
and matrix effect were calculated at 3 different concentration levels according to Matuszewski et al. 
[13]. All samples were analyzed in quadruplicate. Results of the analysis for the recovery experiment 
are summarized in Table 4.    
Table 4  
Recovery for protein precipitation protocol 1 and 2. Mean Recovery and standard error (SE) were calculated on 
quadruplicate analysis at 3 different concentration levels. (n=12 for both mean recovery and standard error) 
  Protocol 1 Protocol 2 
Compound Concentrations 
Mean 
Recovery 
SE 
Mean 
Recovery 
SE 
 
(µg/ml) (%) (%) (%) (%) 
AMO 0.25 - 5.90 - 46.48 56.7 3.1 49.4 1.5 
AMP 0.42 - 10.03 - 60.98 58.1 2.0 58.4 1.6 
CDX 0.03 - 0.82 - 6.54 65.7 6.3 49.2 1.8 
CFZ 0.39 - 9.36 - 74.91 81.7 6.2 59.1 1.1 
CFP 0.11 - 2.70 - 21.6 45.6 5.4 27.6 1.3 
CFT 0.41 - 9.85 - 73.35 28.6 3.8 22.4 2.0 
CEF 0.31 - 7.50 - 60.04 74.2 3.9 68.4 1.2 
FLU 0.05 - 1.16 - 9.27 57.5 2.6 56.9 1.6 
LIN 0.03 - 0.82 - 6.55 73.7 2.6 61.9 0.7 
MER 0.08 - 1.90 - 15.19 78.1 4.8 0.9 0.2 
FEN 0.04 - 0.85 - 6.8 49.9 3.8 57.0 2.5 
PIP 0.21 - 5.02 - 40.16 61.0 2.8 55.5 1.6 
TAZ 0.11 - 2.66 - 15.5 54.4 2.0 73.7 2.2 
 
No evidence is found for an overall difference in recovery between both procedures. Although 
recovery seems less variable for protocol 2 (illustrated by the lower standard error (SE)), the 
apparent lack of recovery for MER limits the suitability of this sample clean-up procedure for our set 
of compounds. Moreover, the results of the matrix effect experiment, as shown in Figure 5, reveal 
significant ion suppression for several compounds in both procedures. Based on these observations, 
we concluded that other sample preparation techniques, providing a reasonable recovery for all 
compounds as well as a less pronounced matrix effect, should be explored. 
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Figure 5. Matrix effect for protein precipitation protocol 1 and 2. The height of the bars represents the mean matrix effect 
for 4 replications at 3 different concentration levels. Error bars represent ± 1 standard error of the mean (n=12). 
 
2.2. Mixed-mode solid phase extraction 
The 13 β-lactam antibiotics studied greatly differ in their physical/chemical properties. Our selection 
contains acidic compounds (FLU, PIP, FEN, TAZ, CEF, CFZ), neutrals (LIN), as well as several 
zwitterionic compounds (AMO, AMP, CDX, CFP, CFT, MER) (Molecular structures are depicted in 
Figures 1-3). Therefore, ordinary solid phase extraction, solely relying on reversed phase retention, 
would be of little practical use in this case. However, providing an additional ion-exchange retention 
mechanism, mixed-mode solid phase extraction should provide sufficient retention for sample clean-
up. A screening experiment was set-up to evaluate suitability of this mixed-mode solid phase 
extraction for our set of compounds. Antibiotics from a spiked plasma sample were extracted on 4 
different kinds of solid phase material (MCX, MAX, WAX and WCX; all Waters Oasis® sorbents) using 
2 different protocols, as suggested by the solid phase extraction plates manufacturer. Afterwards, 
recovery-values were calculated and compared for the different types of mixed-mode SPE materials 
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(data not shown). The manufacturer’s standard protocol dictates differential elution using two 
different solvents, allowing separation of neutral molecules from (strong) acidic or (strong) basic 
compounds. Comparing the 4 SPE materials, it was clearly seen that overall recovery was highest for 
the MCX sorbent. However, none of both elution steps provided adequate recovery for all 
compounds. Consequently, the protocol was amended to accommodate elution of all compounds, at 
the same time aiming for a single elution step. A 5 % (v/v) NH4OH solution in a 60:40 mixture of 
acetonitrile and methanol was finally chosen. Ohmori et al. [8] evaluated the use of an Oasis® HLB 
sorbent (general SPE sorbent, lacking the ion-exchange capabilities) to extract eight β-lactam AB 
from plasma. They reported an absolute recovery of MER of approximately 70 % due to the highly 
hydrophilic nature of the compound. Our results clearly demonstrate that the additional ion-
exchange capabilities of the mixed-mode SPE sorbents significantly improves the recovery of 
hydrophilic compounds (average absolute recovery of MER ± SE: 91.5 ± 2.4). In parallel to the 
recovery assessment for this approach, also matrix effect was evaluated. Results are given in Table 5 
and Figure 6.  
Table 5  
Recovery for the final mixed-mode solid phase extraction protocol using the MCX sorbent with a single elution step (n = 3). 
Compound Concentration Mean Recovery (SE) 
 
(µg/ml) (%) 
AMO 44.30 69.4 (2.0) 
AMP 59.20 84.8 (2.6) 
CDX 6.25 96.1 (4.1) 
CFZ 75.40 82.1 (2.0) 
CFP 21.50 80.8 (2.0) 
CFT 73.20 74.8 (2.0) 
CEF 63.05 72.9 (2.3) 
FLU 6.65 73.9 (2.8) 
LIN 8.90 52.4 (0.6) 
MER 6.10 91.5 (2.4) 
FEN 15.15 52.2 (1.1) 
PIP 39.95 67.4 (3.5) 
TAZ 22.75 12.7 (1.0) 
 
[74] 
 
 
Figure 6. Matrix effect for MCX sorbent with single elution step (n=2). 
 
Despite the low recovery noted for TAZ, on average recovery was equally as good or better than 
using protein precipitation protocol 1 (average recovery SPE and protein precipitation are 
respectively 75 % and 64 %). Moreover, in contradiction to the ion suppression noted in the matrix 
effect experiment under 2.1., no significant ion suppression was observed after mixed-mode solid 
phase extraction. These observations are in agreement with those made by Ohmori et al.[8]. The 
authors demonstrated a lack of significant ion-suppression after SPE using a generic Oasis® HLB 
sorbent for sample clean-up. Similar to our protocol, the protocol of Ohmori et al. consisted of a 
single wash step (using an ammoniumformate solution) to rinse off interfering endogenous 
substrates. This observation, together with our results, suggest that a single wash step SPE protocol 
(as opposed to the general two-wash-step protocols reported in literature) might be sufficient to 
overcome significant matrix-effects. The elution step of our final MCX-sorbent SPE protocol thus 
comprises elution with a 5 % (v/v) NH4OH solution in acetonitrile / methanol 60:40 (v/v). This strong 
[75] 
 
alkaline solution does not allow direct injection of the eluate onto the analytical column. Therefore, 
an additional dilution-neutralization step is added. Compatibility with the mobile phase and 
autosampler stability was evaluated for three different solutions: a more concentrated mobile phase 
buffer (ammoniumacetate), a phosphate buffer and an acetic acid solution. The 1M 
ammoniumacetate buffer (pH 4.76) on the one hand was chosen because of mobile phase 
compatibility, the 1M  phosphate buffer (pH 7.20) and the 1.3 % (v/v) acetic acid solution on the 
other hand were chosen to evaluate whether β-lactam AB autosampler stability would improve if the 
pH of the eluate was adjusted to neutral (pH 7.20). Because of lack of evidence for improved stability 
for either the phosphate buffer- or the acetic acid solution-neutralized eluate (data not shown), we 
finally chose a 1 M CH3COOH/CH3COONH4 buffer (pH 4.76) for dilution of the eluate prior to injection 
onto the analytical column.  
3. Relative matrix effect 
Generally, absolute and relative matrix effect experiments are performed as part of the formal 
qualification/validation experiments. However, in our laboratory, we opt to perform these 
experiments prior to qualification/validation experiments. In our opinion, the extent of (relative) 
matrix effect is a very important performance characteristic of a LC-MS based analytical method. 
Furthermore, rather than focussing on developing an analytical methodology free of absolute matrix 
effect, we direct our efforts towards developing robust methods free of relative matrix effect. 
Therefore, a thorough study on the presence/absence of relative matrix effect is conducted prior to 
looking into other performance characteristics (e.g. precision, trueness). As a consequence, if a 
significant relative matrix effect is found, the sample preparation process is re-evaluated and the 
relative matrix effect experiment is repeated. 
For each compound, on every concentration level, an Anova-analysis was performed. Resulting p-
values for the different Anova-tests performed are given in Table 6. The relative matrix effect (in 
these experiments represented by the between-group variability) was calculated on the 
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quadruplicate measurements of compounds in eight different types of plasma. However, for LIN, at 
the high concentration level, only data from seven different types of plasma was used due to the 
presence of an outlier. To our opinion, the design of the experiment was not compromised by leaving 
out one of the plasma types for the LIN high concentration samples. Overall, we can state that at the 
5 % level of significance, no statistically significant evidence is found in the data to suspect the 
presence of a relative matrix effect.
Table 6  
Resulting p-values for the different anova-test performed on the analyte-to-internal standard peak area ratios for the different lots of 
plasma. Responses in eight different types of plasma were evaluated. All within-plasma type samples were analysed in quadruplicate. For 
the ULOQ level for LIN the results for 1 plasma type (n=4) were omitted prior to the Anova analysis. 
Level AMO FLU AMP CEF FEN PIP CDX CFZ CFT LIN MER CFP TAZ 
2 x LLOQ 0.907 0.977 0.743 0.743 0.948 0.756 0.917 0.326 0.529 0.821 0.864 0.891 0.988 
Mid-range 0.277 0.281 0.270 0.780 0.505 0.758 0.611 0.459 0.056 0.972 0.375 0.379 0.729 
ULOQ 0.975 0.614 0.402 0.819 0.868 0.938 0.102 0.753 0.232 0.223 0.543 0.512 0.882 
 
In terms of absolute matrix effect, no significant ion-suppression was observed. Absolute matrix 
effect ranged from 3 % to 24 %. As stated by De Bock et al. [15], the absence of an absolute matrix 
effect is not a prerequisite for a reliable bioanalytical method. However, the lack of variability in 
matrix effects between individual subjects (hence relative matrix effect) is indispensable in the 
development of reliable bioanalytical methods. Although relative matrix effects may influence the 
quantification of analytes using mass-spectrometry based techniques it is rarely formally tested[8] 
using plasma/serum from different subjects. Using different plasma lots, we extensively 
demonstrated our method to be free of a relative matrix effect, so no further adaptations were made 
to our final sample preparation protocol, despite of the documented absolute matrix effect for both 
AMO and CDX.          
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Validation 
1. Calibration model selection and linearity evaluation 
After a visual/statistical check for outliers different weighting factors/axis transformations were 
applied to the linear regression model and tests for homoscedasticity were performed. Subsequently, 
mean weighted residual plots were inspected to detect deviations from linearity. If necessary, a 
second order term was added to the linear regression model. Prior to starting the validation 
experiments, an experiment was set-up to evaluate the trueness and precision of the determination 
of single QC samples using the above mentioned calibration curves. It was noted that although 
trueness and precision were acceptable for the mid-range and low quality control levels, the high 
level quality control samples could not be measured accurately (data not shown). Upon investigation 
of these experiments, we found that the recovery for our calibration standards (mix of 13 β-lactam 
antibiotics) significantly differed from the recovery for the quality control standards (single antibiotic 
compound in plasma). Owing to the high concentration of the different compounds present in the 
plasma calibrator samples (concentrations up to 160 µg/ml), saturation of the binding sites of the 
mixed-mode SPE might have taken place. After reduction of the analytical range of our method and 
addition of an extra dilution step prior to loading of the samples onto the mixed-mode SPE plates, 
the statistically different recovery for the QC samples versus the calibrator samples disappeared. 
Final plasma calibrator sample concentrations, plasma quality control sample concentrations and 
details regarding the construction of the calibration curve are provided in Table 3. 
2. Trueness and (Intermediate) precision 
Between-day imprecision, within-day imprecision (both defined by CV% for replicate analyses) and 
trueness were evaluated (Table 7). For eight out of the thirteen β-lactam AB studied the performance 
characteristics of our analytical method fell well within the specifications dictated by the FDA-
guidance on bioanalytical method validation [11]. In contradiction to these results, our validation 
experiments revealed a significant bias for CFP. Calculated trueness for the low, medium and high QC 
samples were respectively 104 %, 125 % and 131 %. 
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Table 7  
Results for the analysis of validation samples for the different antibiotics under study ( * the results from the analysis of the medium QC samples of day 2 were excluded from the final 
trueness and imprecision calculations). 
  Within-day assay (n=6) Between-day assays (n=4) 
Compound Nominal concentration Trueness Imprecision Imprecision 
 (µg/ml) (%) (RSD%) (RSD%) 
Amoxicillin 0.57 - 5.74 - 40.14 103.1 - 98.4 - 102.2 8.2 - 8.1 - 9.2 2.5 - 9.7 - 5.4 
Ampicillin 0.83 - 8.28 - 57.95 92.5 - 110.3 - 108.6 18.2 - 12.4 - 15.1 10.7 - 5.9 - 6.9 
Cefadroxil 0.07 - 0.69 - 4.83 117.6 - 104.1 - 109.9 19.8 - 4.5 - 5.7 9.9 - 8.8 - 7.3 
Cefazolin 0.78 - 7.82 - 54.76 112.6 - 109.2 - 100.3 20.3 - 10 - 10.8 4.4 - 10.5 - 5.5 
Cefepime 1.12 - 4.49 - 17.94 103.8 - 125.1 - 131.2 14.9 - 7.3 - 12.5 1.6 - 5.7 - 10.3 
Ceftazidime 3.61 - 14.43 - 57.71 96 - 93.6 - 88.7 6.6 - 11.4 - 7.8 1.7 - 9.2 - 7.5 
Cefuroxime 0.69 - 6.87 - 48.08 93.1 - 102.9 - 98.7 18.8 - 17.6 - 15.9 12.5 - 7.9 - 11.2 
Flucloxacillin 0.11 - 1.09 - 7.59 122 - 116.5 - 92 18 - 10.2 - 8.2 12.8 - 7.7 - 20.8 
Linezolid 0.07 - 0.71 - 4.95 93.5 - 92.6 - 90.3 10.6 - 5.9 - 11.2 0.8 - 3.8 - 8.1 
Meropenem 1.05 - 4.18 - 16.71 100.7 - 106.1 - 105.6 6.6 - 8.2 - 5.8 7.5 - 2.1 - 4.6 
Phenoxymethylpenicillin 0.09 - 0.87 - 6.07 99.1 - 96.8 - 101.6 12.2 - 9.7 - 11.4 4.9 - 12.5 - 4 
Piperacillin 0.42 - 4.25 - 29.73 105.2 - 95.5 - 96 17.6 - 17.7 - 6.9 5.4 - 4.9 - 15.5 
Tazobactam 0.23 - 2.3 - 16.07 107.1 - 96 - 100.8 16 - 5.9 - 11.7 10.9* - 16.4* - 9.7* 
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Additional experiments (data not shown) revealed a difference in CFP extraction recovery between 
the calibrator samples and the QC samples. Similar to the experiments described under section 1, we 
hypothesised that the difference in total AB concentration between the calibrator samples (mix of all 
AB) and the QC samples (single AB in plasma) might be causing this differential recovery. Given that 
this difference in recovery was only observed for CFP, the addition of another dilution step prior to 
sample preparation was considered unfavourable. We acknowledge that a bias as severe as this 
observed for our CFP assay might compromise future study results. To overcome this differential 
extraction recovery, a potential solution might be the replacement of the currently used internal 
standard (13C,2H3-Cefepime) with an internal standard which might better correct for the different 
extraction behaviour of CFP in the calibrator versus quality control samples (e.g. pure 
>?@ -CFP 
analogue).  
Upon reviewing the results of the validation experiments, for some compounds, we found some 
measures of imprecision and trueness that did not fully comply with the specifications proposed by 
the FDA guidance on method validation [11]. For FLU the measures for trueness for the low and 
medium level are respectively 122 % and 117 %. For CEF, PIP and TAZ for the medium QC level and 
for FLU for the high QC level, we failed to demonstrate the imprecision to be smaller than 15%. 
Nevertheless, in all cases imprecision was limited to approximately 20 %, which equals the maximum 
amount of imprecision allowed at the low end of the analytical range.  
With respect to the observed variation in AB plasma concentrations in eg. the critically ill [16], a 
subpopulation for whom our assay might be used to guide drug dosing, the additional error 
introduced by our assay by not complying with the FDA specifications, is considered negligible. On 
the other hand, when performing PK studies e.g. to compare bioavailability between different 
formulations, this additional measurement error might (although to our opinion this is very unlikely) 
impact statistical power. Prior to conducting these studies, a formal assessment of the impact of the 
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method’s performance characteristics on the study outcome is deemed necessary, although this 
equally holds for every other assay used in a particular PK study.                  
3. Lower limit of quantification 
In accordance with the criteria described under material and methods, the lowest standard on the 
calibration curve for each compound in our selection was accepted as the limit of quantification.  
4. Selectivity 
No interferences were observed at the retention times of the analytes and the IS when analyzing 
blank human plasma from 8 independent sources. (Data not shown)  
5. Stability 
Table 8 summarizes the results of the different stability studies. For some compounds (AMO, AMP, 
CFT and TAZ) no stock stability study was performed. This is simply because in our routine practice no 
individual solutions of these compounds are made. Apart from limited stock stability for MER and 
CFT, overall stock stability at -20°C is acceptable (overall median = 35 days). Autosampler stability is 
limited for MER, LIN and CFZ, with time upon which significant degradation occurs respectively being 
6, 11 and 11 hours. All other compounds remained stable in the autosampler compartment at 5°C up 
until 20 hours. Of all compounds present within the plasma calibrator samples, only 5 showed no 
statistical evidence of degradation after storage at -20°C for 4 days. Highly significant differences are 
noted for AMO, AMP, CFP, CFT, LIN and MER. For the latter one, we estimated the degree of 
degradation as high as 30%. The main reason for setting-up this stability experiment was to assess 
whether plasma calibrator samples, once made, could be used for quantitation purposes during an 
entire week. From these results we concluded that calibrator samples should be made ex-tempore. 
Nevertheless, stock stability data clearly indicate that within a relatively short time-frame (1 month) 
plasma calibrator samples may be prepared from stored stock solutions.  
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Table 8  
Results for the different stability experiments performed according to experimental conditions as described in section 4. 
The minus sign indicates that stability was not assessed for a certain compound. 
Compound Stock stability Autosampler stability Calibrator stability 
 (days) (hours) (p-value t-test) 
AMO - 20 < 0.01 
AMP - 20 < 0.01 
CDX 35 20 0.77 
CFZ 35 11 < 0.05 
CFP 35 20 < 0.01 
CFT - 20 < 0.01 
CEF 35 20 0.31 
FEN 35 20 0.94 
FLU 35 20 0.17 
LIN 35 11 < 0.01 
MER 19 6 < 0.01 
PIP 35 20 0.80 
TAZ - 20 < 0.05 
2H4-AMO 54 - - 
2H4-CDX 82 - - 
13C,2H3-CFP 78 - - 
2H6-MER 12 - - 
2H5-FEN 86 - - 
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Conclusion 
This study presents the development and validation of a multi-drug assay to be used in 
pharmacokinetics studies as well as TDM-programs. Sufficient evidence is provided to gain insights in 
the performance of our multi-component method. Nevertheless, prior to the application of the 
analytical method some additional study-specific experiments have to be performed. On one hand, 
we did not include a formal selectivity study. On the other hand, additional information is to be 
gathered on the plasma stability of the different compounds. Selectivity studies as well as stability 
studies should be performed in a manner consistent with the future use of the method and are 
therefore study specific. For example, stability after storage of plasma samples is known to be 
dependent on type of sample tube used for storage or on the kind of anticoagulant added prior to 
blood collection. [17] Similarly, selectivity studies should account for, among other things, co-
medication which is expected to be present in patient samples. In the case of TDM-assays, drugs 
frequently prescribed in the institution where the TDM-program is run, should be included in the 
study.    
Through the use of an ultra-high performance liquid chromatography instrument, we minimized 
chromatographic runtime, resulting in a cycle-time (time between sequential injections) of 5 
minutes. Furthermore, the use of a 96-well SPE plate in combination with a multi-channel pipette 
allowed us to minimize time spent on sample preparation. If our method were to be applied in a 
therapeutic drug monitoring setting, time between sampling and reporting of plasma concentrations 
could be as little as 1.5 hours (analysis of calibrator samples and quality control samples included), 
demonstrating its suitability as, among other things, a potential multi-drug TDM assay. Moreover, 
the analytical method, as presented in this paper, can be used in the bio-analytical support of 
pharmacokinetic studies.  
As a concluding proof-of-concept, we used our multi-drug assay to analyse samples from a healthy 
volunteer given a standard 500 mg oral dose of Amoxicillin. The full pharmacokinetic results from this 
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study are beyond the scope of this publication. However, in Figure 7, the pharmacokinetic profile of 
amoxicillin after a standard 500 mg oral dose in one healthy volunteer is given, illustrating the 
practical applicability of our analytical methodology. 
 
Figure 7. Plasmaconcentration-time profile in a healthy volunteer after administration of a 500mg oral dose of amoxicillin. 
  
[84] 
 
Reference List 
 
 [1]  O'Brien PE. Bariatric surgery: mechanisms, indications and outcomes. J Gastroenterol Hepatol 
2010; 25(8): 1358-65. 
 [2]  Edwards A, Ensom MH. Pharmacokinetic effects of bariatric surgery. Ann Pharmacother 2012; 
46(1): 130-6. 
 [3]  Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric 
surgery and its theoretical implications. Obes Rev 2010; 11(1): 41-50. 
 [4]  De Smet J, Colin P, De Paepe P, Ruige J, Batens H, Van Nieuwenhove Y et al. Oral bioavailability 
of moxifloxacin after Roux-en-Y gastric bypass surgery. J Antimicrob Chemother 2012; 67(1): 
226-9. 
 [5]  Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J. 
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. 
International Journal of Antimicrobial Agents 2010; 36(4): 332-9. 
 [6]  Denooz R, Charlier C. Simultaneous determination of five beta-lactam antibiotics (cefepim, 
ceftazidim, cefuroxim, meropenem and piperacillin) in human plasma by high-performance 
liquid chromatography with ultraviolet detection. Journal of Chromatography B-Analytical 
Technologies in the Biomedical and Life Sciences 2008; 864(1-2): 161-7. 
 [7]  McWhinney BC, Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer JPJ. Analysis of 12 beta-
lactam antibiotics in human plasma by HPLC with ultraviolet detection. Journal of 
Chromatography B-Analytical Technologies in the Biomedical and Life Sciences 2010; 878(22): 
2039-43. 
 [8]  Ohmori T, Suzuki A, Niwa T, Ushikoshi H, Shirai K, Yoshida S et al. Simultaneous determination 
of eight beta-lactam antibiotics in human serum by liquid chromatography-tandem mass 
spectrometry. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life 
Sciences 2011; 879(15-16): 1038-42. 
 [9]  Verdier MC, Tribut O, Tattevin P, Le Tulzo Y, Michelet C, Bentue-Ferrer D. Simultaneous 
Determination of 12 beta-Lactam Antibiotics in Human Plasma by High-Performance Liquid 
Chromatography with UV Detection: Application to Therapeutic Drug Monitoring. Antimicrobial 
Agents and Chemotherapy 2011; 55(10): 4873-9. 
[10]  Pullen J, Stolk LML, Neef C, Zimmermann LJI. Microanalysis of amoxicillin, flucloxacillin, and 
rifampicin in neonatal plasma. Biomedical Chromatography 2007; 21(12): 1259-65. 
[11]  Guidance for industry-Bioanalytical method validation. FDA CDER 2002. 
[12]  Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's: The Pharmacological Basis of 
Therapeutics. 11 ed. Mc Graw Hill Medical. 2006. 
[13]  Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix 
effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 
75(13): 3019-30. 
[85] 
 
[14]  Hartmann C, Smeyers-Verbeke J, Massart DL, McDowall RD. Validation of bioanalytical 
chromatographic methods. Journal of Pharmaceutical and Biomedical Analysis 1998; 17(2): 
193-218. 
[15]  De Bock L, Boussery K, Colin P, De Smet J, T'jollyn H, Van Bocxlaer J. Development and 
validation of a fast and sensitive UPLC-MS/MS method for the quantification of six probe 
metabolites for the in vitro determination of cytochrome P450 activity. Talanta 2012; 89: 209-
16. 
[16]  Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The Effects of Hypoalbuminaemia on 
Optimizing Antibacterial Dosing in Critically Ill Patients. Clinical Pharmacokinetics 2011; 50(2): 
99-110. 
[17]  Nowatzke W, Woolf E. Best practices during bioanalytical method validation for the 
characterization of assay reagents and the evaluation of analyte stability in assay standards, 
quality controls, and study samples. Aaps Journal 2007; 9(2): E117-E122. 
 
[86] 
 
[87] 
 
Chapter 3 
 
 
 
 
 
Enzymatic tumor tissue digestion coupled 
to SPE- UPLC – Tandem Mass 
Spectrometry as a tool to explore 
paclitaxel tumor penetration.  
 
 
 
 
Pieter Colin, Lieselotte De Smet, Lies De Bock, Wim Goeteyn, Koen Boussery, Chris Vervaet and Jan Van 
Bocxlaer. Enzymatic tumor tissue digestion coupled to SPE- UPLC – Tandem Mass Spectrometry as a tool to 
explore paclitaxel tumor penetration.  
Talanta 2014 (129) 119-125  
[88] 
 
INTRODUCTION 89 
MATERIAL AND METHODS 91 
REAGENTS 91 
BUFFERS AND ENZYME SOLUTIONS 91 
STOCK SOLUTIONS, STANDARDS AND QUALITY CONTROL SAMPLES 91 
ENZYMATIC TISSUE DIGESTION PROTOCOL 92 
SOLID PHASE EXTRACTION PROCEDURE 93 
INSTRUMENTATION 93 
VALIDATION 94 
Accuracy and imprecision 94 
Selectivity 95 
Stability 95 
Robustness evaluation 95 
RESULTS AND DISCUSSION 96 
METHOD DEVELOPMENT 96 
Mechanical tissue homogenization 96 
Enzymatic tissue digestion 97 
VALIDATION 100 
Accuracy and (intermediate) imprecision 100 
Selectivity 101 
Stability 101 
Robustness evaluation 102 
INTRATUMORAL DISTRIBUTION OF PTX POST IPEC DOSING 104 
CONCLUSION 106 
REFERENCE LIST 107 
  
[89] 
 
Introduction 
Paclitaxel (PTX), which binds and stabilizes the microtubule, causing cell death, has been used as an 
anticancer agent since 1984. Paclitaxel shows anticancer activity for a variety of human cancers, 
including breast, ovarian and prostate. Its favourable pharmacokinetic properties, e.g. slow 
peritoneal clearance, makes it a good candidate compound for intraperitoneal perioperative 
chemotherapy (IPEC)[1] of peritoneal carcinomatosis (PC). During IPEC, a solution containing a 
cytotoxic agent, e.g. PTX, is instilled into the peritoneal cavity, thereby promoting close contact 
between the cytotoxic agent and the exposed (residual) tumor tissue.      
Although IPEC as a tool for regional drug delivery has a strong pharmacokinetic rationale in the 
treatment of PC, controversy remains regarding the optimal treatment strategies that will optimize 
efficacy whilst minimizing systemic exposure. Besides the ongoing debate on the duration of the 
perfusion or the optimal carrier solution, questions regarding the extent of tumor tissue penetration 
following IPEC treatment remain[2]. 
PTX penetration has been studied in-vitro as well as in-vivo, using, respectively, cell monolayers [3] or 
multicellular layer cultures [4,5] and human tumor xenografts [6-8]. Autoradiography [3,7,8], using 
3H-PTX, or fluorescence microscopy [5,6], using fluorescently labelled PTX, are used most often. Using 
these techniques, rather than an accurate determination of the PTX concentration in tumor tissue, a 
relative scale is used to describe penetration as a function of time and/or space. Because of the semi-
quantitative nature of these imaging techniques, they are sometimes combined with a conventional 
whole tumor homogenization and HPLC analysis [8,9] to be able to report accurate PTX 
concentrations in tissue. However, even in these instances questions remain with respect to the 
performance characteristics of the assay (imprecision/ bias).                
Besides the questions regarding the treatment modalities and the effective penetration of PTX in 
solid tumors, one of the reasons for its limited use is the toxicity (local and systemic) associated with 
IPEC administration of Taxol®. Although necessary for paclitaxel solubility, Cremophor EL, the main 
[90] 
 
constituent of Taxol®, has been shown to cause severe adverse effects after IPEC administration.[10] 
As such, despite its wide activity spectrum and its favourable pharmacokinetic properties, the use of 
PTX as a compound for IPEC remains limited. 
Therefore, in support of the development of a new Cremophor EL-free paclitaxel formulation, a 
bioanalytical method to quantify paclitaxel in human tumor xenograft tissue was developed. 
Furthermore, in order to study the effect of carrier solution and treatment modalities on PTX tumor 
penetration, using the tumor harvesting protocol shown in Figure 1, our sample pretreatment was 
optimized to handle low weight tumor tissue samples. 
 
  Figure 1. Tumor harvesting protocol. 
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Material and methods 
Reagents 
Trizma®-base, Sodium dodecyl sulphate (SDS), Proteinase K (from Tritirachium album, 500 units/mL, 
buffered aqueous glycerol solution) and lipase (from porcine pancreas powder) were all from Sigma-
Aldrich (Bornem, Belgium). EDTA, potassium dihydrogen phosphate and di-potassium hydrogen 
phosphate were from VWR® BDH Prolabo® (Leuven, Belgium). 13C6-Paclitaxel (IS) and PTX were from 
Acros Organics (Geel, Belgium) and Chromadex (California, USA), respectively. ULC-grade water and 
methanol were from Biosolve (Valkenswaard, The Netherlands).  
Buffers and enzyme solutions 
A phosphate buffer (70 mM) in H2O was made by accurately weighing and dissolving 2.0 g K2HPO4 
and 0.8 g KH2PO4 in 250.0 mL of H2O. Prior to dilution to 250.0 mL, the pH of the buffer was adjusted 
to pH 7.50 by titration with 1 M NaOH. Furthermore, a 50 mM Tris-HCl buffer was made by dissolving 
0.607 g Trizma®-base into a final volume of 100.0 mL of H2O after adjustment of the pH to 7.50 with 
a 1 M HCl solution.  
The final proteinase K solution was made by diluting the buffered aqueous glycerol solution (500 
units/mL) 100 fold in Tris-HCl buffer to a final concentration of 5 units/mL. Lipase solution (100 mg/L) 
was made by dissolving appropriate amounts of lipase in phosphate buffer.      
Stock solutions, standards and quality control samples 
A stock solution in acetonitrile was prepared for PTX at a concentration of 1.0 mg/mL. This stock 
solution was then further diluted with acetonitrile to obtain working solutions with PTX 
concentrations ranging from 0.016 µg/mL to 4.0 µg/mL. A separate stock solution as well as separate 
working solutions (PTX concentrations 0.04, 0.8 and 3.2 µg/mL, respectively) were prepared for the 
production of the quality control samples. The IS was dissolved in 1 mL acetonitrile and diluted to a 
concentration of 0.80 µg/mL using acetonitrile.    
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Blank bovine muscle tissue was spiked with the different working solutions to obtain calibrator- / 
quality control samples. Full details of the preparation of the calibrators and quality control samples 
are given in the next section.  
Enzymatic tissue digestion protocol 
Tumor samples and bovine muscle tissue were allowed to thaw at room temperature. Afterwards, 
excised tumor samples were rinsed using a physiological salt solution (9 g/L NaCl in H2O) to remove 
most blood and to rinse off any left-over Taxol® that might have adsorbed to the tumor’s outer 
surface. After further sectioning and exactly weighing of the tumor samples to produce tissue 
specimens weighing 25 mg, tissue specimens were placed in an Eppendorf® vial. 
To this Eppendorf® vial 500 µL lipase-solution, 250 µL proteinase-K solution, 30 µL SDS-solution (5 
mg/100 µL in H2O), 85 µL CaCl2-solution (30 mM in H2O), 50 µL EDTA-solution (100 mM in H2O) and 
85 µL of Tris-HCl buffer were added. 
For the calibrator samples and the quality control samples, 50 µL of the corresponding working 
solution in acetonitrile was added to the Eppendorf® vial. Concurrently, for the tumor tissue samples, 
50 µL of blank acetonitrile was added. Final concentrations of the calibrator samples ranged from 32 
to 8000 ng/g. Quality control samples were prepared at PTX concentrations of 80, 1600 and 6400 
ng/g, respectively.   
Afterwards, the Eppendorf® vials were left to incubate overnight at 55°C whilst continuously being 
shaken (IKA®-Werke GmbH & Co. KG, Staufen, Germany). After at least 16 h of incubation time, the 
Eppendorf® vials were vortex mixed and centrifuged for 10 min. at 3000 xg at 4°C. Following 
centrifugation, samples were stored at 4°C until further handling by solid phase extraction.         
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Solid Phase Extraction procedure 
After centrifugation 50 µL of IS solutions was added to 950 µL of the supernatant. This mixture was 
then loaded onto the SPE cartridges (Oasis® HLC cartridges, Waters, USA) prior to washing of the SPE 
tubes with a sodium hydroxide (pH 10.0) solution and a 70% (v/v) MeOH-solution in H2O. Following 
elution of PTX with MeOH, samples were concentrated by evaporation of the methanol under a mild 
nitrogen stream (30 min, 35°C).  
Finally, samples were reconstituted in 100 µL 50% (v/v) methanol in H2O, transferred to the 
autosampler compartment and kept at 5°C until injection onto the chromatographic system. 
In case of samples above the ULOQ, re-analysis was performed using the supernatant. To this end, 
the supernatant was diluted with a physiological saline solution (20 and/or 400 fold) prior to spiking 
of the IS solution. Afterwards, this mixture was again subjected to SPE prior to injection onto the 
chromatographic system. 
Instrumentation 
Chromatographic separation was achieved on an Acquity UPLC system (Waters, Milford, MA) 
equipped with an Acquity BEH C18 column (50 mm x 2.1 mm, 1.7 µm particle size) and an Acquity BEH 
C18 guard-column (5 mm x 2.1 mm, 1.7 µm particle size) all from Waters (Milford, MA). The column 
was kept at 50 °C. An aliquot of 1 µl was injected into the mobile phase stream using full loop 
injection. The mobile phases consisted of H2O (MPA) and methanol (MPB). Components were eluted 
using gradient elution at a flow rate of 0.450 ml/min. From 0 to 0.5 min the mobile phase contained 
55% of MPA. From 0.5 to 1.5 min the amount of MPB in the mobile phase was increased linearly to 
100%. Between 1.5 and 2.5 min, the system was maintained at 100% MPB. Finally, at 2.5 min, the 
analytical column was re-equilibrated to initial gradient settings. Eluting compounds were detected 
using a Waters Quattro Ultima triple quadrupole system (Micromass Waters, Manchester, UK) 
equipped with an electrospray source (orthogonal Z-spray®) operated in positive ionization (ESI+) 
mode. The MS/MS instrument was operated with a capillary voltage of 3.0 kV, source block 
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temperature of 150 °C and cone voltage of 20 V. Nitrogen was used as desolvation gas and was 
heated to 400 °C and delivered to the source at 750 L/h. The system uses argon gas to induce 
fragmentation in the collision cell at a collision energy of 20 eV. The dwell time for each MRM 
transition was 100 ms and the interchannel and interscan delays were set to 20 ms. Details of the 
MRM-transitions for each compound are described in Table 1. Peak areas were integrated using 
MassLynx 4.1 software (Micromass Waters, Manchester, UK). 
Table 1 
Detection parameters for the compounds under study. For the different compounds a quantifier and qualifier trace were 
monitored. Qualifier traces were used to calculate ion ratios. These ion-ratios were monitored during the analysis to 
confirm the identity of the measured compound. 
 Detection MRM-transitions  CE 
Compound Ionisation mode Quantifier Qualifier (eV) 
PTX ESI + 876.5 > 307.5 876.5 > 531.0 20 
13C-PTX ESI + 882.5 > 313.7 882.5 > 531.0 20 
 
Validation 
The validation experiments were based on the “Guidance for Industry-Bioanalytical Method 
Validation” recommended by the Food and Drug Administration (FDA) of the United States. Batches 
of quality control samples at three different concentration levels were prepared and analysed on 
separate occasions.  
Accuracy and imprecision 
Accuracy was evaluated by analysing results from QC samples measured under repeatability 
conditions on different days (QC samples were analysed in sextuplicate, triplicate or duplicate on 5 
different days). It was calculated as the mean relative error of QC samples analysed on five different 
days. Within-run imprecision was calculated as the average relative standard deviation (RSD) of the 
concentration of the QC samples. Between-run imprecision was evaluated by replicate 
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measurements of QC samples on five different days. Between-run imprecision was calculated as the 
RSD of the average QC concentrations measured on five different days. 
Selectivity 
Selectivity was assessed by examining peak interference (signal-to-noise ratio < 9) from four 
independent sources of blank bovine muscle tissue. 
Stability 
The stability of PTX in tissue, stored at -80°C was assessed using bovine muscle controls. On day 0, 
blank bovine muscle tissue was homogenized and PTX working solutions were spiked to achieve PTX 
concentrations at the respective concentrations of the QC samples. Using fresh calibrator samples 
PTX concentrations in bovine muscle tissue were quantified on day 0 and after 1 month of storage at 
-80°C. The measured concentrations (measured in sextuplicate on three different concentration 
levels) were then used in a two-way ANOVA analysis in R®(R foundation for statistical computing, 
Vienna, Austria) to test whether significant degradation had occurred during this 1 month period. 
Robustness evaluation 
To further explore the performance characteristics of the developed method with tumor tissue 
samples rather than bovine muscle tissue quality control samples, tumor tissue samples for which a 
duplicate sample was available (n=20) were analysed 1 month after the original analysis.  
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Results and discussion 
Method development 
Mechanical tissue homogenization 
Based on the work by Eckert et al.[11] we explored, as an initial sample preparation method, 
mechanical tissue homogenization using an Ultra-Turrax® (IKA®-Werke GmbH & Co. KG, Staufen, 
Germany) homogenizer in combination with a Potter-Elvehjem system (VWR Internation, Leuven, 
Belgium). The combination of both techniques, rather than only using an Ultra-Turrax®, is believed to 
produce a more complete cell disruption, making PTX bound to cell organelles freely available for 
extraction using SPE. Before homogenization a 6% phosphoric acid solution was added in a 1:1 (v/v) 
ratio to disrupt PTX protein binding. After centrifugation at 10,000 xg for 20 min the supernatant was 
subjected to SPE. 
Based on the method described by Matuszewski et al.[12], we assessed the performance of the 
sample preparation technique, in terms of recovery and matrix effect, using bovine muscle quality 
control samples at three different PTX concentration levels (0.2, 0.4 and 2.0 ng/mg). Measurements 
of pre- / post- and pure standards were made in triplicate. As shown in Table 2, the average recovery 
was low (69.1 %). Furthermore, significant ion suppression was observed (average matrix effect 30.8 
%). 
Table 2 
Recovery and Matrix effect for the different sample preparation protocols under study. Measurements were made in 
triplicate on 3 different paclitaxel (PTX) concentration levels. The reported recoveries and matrix effects are the average 
over the replicates and different concentration levels. * indicates an average recovery or matrix effect being statistically 
significant different from 100 % at the 5 % level of significance. 
 Recovery Matrix effect 
 Average (%) SE (%) Average (%) SE (%) 
Mechanical homog. 69.1* 12.3 30.8* 1.6 
Mechanical + PP 96.8 5.8 160.3* 9.1 
Enzymatic digestion 118.4 9.8 110.0 9.0 
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Based on the strong protein binding affinity of PTX[13] and in an attempt to improve recovery and 
reduce the ion suppression, we decided to introduce an additional protein precipitation step prior to 
SPE. To this end, the 6% phosphoric acid solution was replaced by a 1:1 (v/v) mixture of 0.06 N 
Ba(OH)2 and 0.06 N ZnSO4 (both Sigma-Aldrich, Bornem, Belgium). The average recovery and matrix 
effect of this improved sample preparation method were 96.8 % and 160.3 %, respectively. Although 
the average recovery was significantly better than the earlier method we were not satisfied with the 
results from this sample preparation method.  
On one hand the average matrix effect being significantly larger than 100 % (i.e. significant ion 
enhancement) and on the other hand the laborious procedure of mechanically processing the tissue 
with two separate techniques and the difficulties we faced, in terms of instrument 
maintenance/cleaning, when trying to mechanically homogenize low weight (± 25 mg tumor tissue) 
samples, in a high-throughput fashion, made us reconsider our approach. Although mechanical tissue 
homogenization has proven to be reliable in e.g. the accurate quantification of brain PTX 
concentrations[9], in our application, given the vast heterogeneity in tumor tissue composition and 
tumor tissue density it was regarded impracticable. For example, several of the tumors we 
encountered contained a high degree of dense fibrous-tissue, making it impossible, using mechanical 
techniques, to homogenize the tumor to a satisfactory degree (i.e. appearing like a homogeneous 
suspension).  
Therefore, based on a publication by Yu et al. [14], we explored enzymatic tissue digestion as an 
alternative sample preparation technique.  
Enzymatic tissue digestion 
The enzymatic digestion described by Yu et al. [14] was based on two different enzymes (collagenase 
or proteinase K) that are known to degrade connective tissue. Apart from these two enzymes, other 
enzymes, e.g. subtilisin A [15], capable of digesting tissue samples have been described in literature. 
However, proteinase K, which is known to break up the cell nucleus (hence its widespread use in DNA 
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extraction [16] protocols), in our opinion, since PTX resides, bound to the microtubules, inside the 
cell’s nucleus, would provide a more complete release of tissue bound PTX.  
Furthermore, in order to get rid of fatty residues from the tumor tissue which could disturb the SPE 
clean-up, we found it feasible to add lipase to the enzymatic digestion protocol. In literature, lipase 
has been used as an add-on enzyme in digestive protocols for the analysis of trace elements [17] as 
well as small-molecules [18] from a.o. human tissue samples.  
Based on these reports in literature, in a first step, we studied the effect of different concentrations 
of proteinase K (0.5, 1.0 and 5.0 units/mL) and lipase (100, 200 and 1000 mg/L) on the degree of 
digestion of tissue samples after an overnight incubation (approximately 16 hours) at 55°C. 
After centrifugation of the Eppendorf® vials, containing the incubated tissue samples, to precipitate 
any leftover solid particles, no residual solid pellet was observed for the highest proteinase K 
concentration (5.0 units/mL). Furthermore, by weighing of the residual pellet, obtained at the lower 
proteinase K concentrations, we found that the different lipase concentrations did not affect the 
degree of tissue digestion. Furthermore, using post column infusion of a PTX solution whilst injecting 
SPE extracts of bovine muscle tissue treated according to the different protocols, a qualitative 
assessment was made of the matrix effect. These results (data not shown) revealed that the most 
stable baseline following injection of the tissue sample extracts was obtained from the protocol with 
the highest proteinase K solution. However, no effect was observed for the different lipase 
concentrations tested. Therefore, it was decided to include lipase in the lowest concentration tested 
(i.e. 100 mg/L).  
In an attempt to compare this enzymatic tissue digestion protocol with the earlier evaluated 
mechanical tissue homogenization techniques, the Matuszewski [12] experiments were repeated 
using the final digestive protocol. From Table 2 it is observed that neither the average recovery, nor 
the average matrix effect differs significantly from the theoretical optimal 100 % value, making the 
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enzymatic tissue digestion the best sample preparation amongst the ones compared in our study. 
Moreover, albeit the fact that it takes overnight to perform the digestion, this protocol requires very 
limited operator involvement, whereas the mechanical disruption based approaches are, indeed, 
faster but highly labour intensive. 
As mentioned by Yu et al. [14], analyte instability should be considered and assessed when using an 
enzyme based digestive protocol. Therefore, we performed a stability study by comparing the PTX 
response in samples where PTX and IS were added prior to and after enzymatic tissue digestion (n=6 
in all groups). In short, PTX and IS were added to (i) blank bovine muscle tissue prior to digestion or 
(ii) digested blank bovine muscle tissue, at a final concentration of 2000 ng/g. As shown in Figure 2, 
PTX as well as the IS undergo mild degradation during enzymatic digestion. The half-life of 
degradation, calculated from the estimated slopes (as the reciprocal of log10(2) and the estimated 
slope, on a log10-scale) of the solid and dashed lines, are 57.4 h and 58.7 h, respectively. From these 
estimated half-lives we calculated that during our 16 h incubation period approximately 17.6 % and 
17.2 % of PTX and IS will be degraded. From a sensitivity perspective, this is definitely acceptable, 
moreover, given that PTX and the IS are degraded to the same extent, this degradation will have no 
influence on the quantification, since the latter is based on the ratio of peak areas from PTX and IS.  
Although, in general, in order to correct for variability during enzymatic digestion, one would choose 
to add the IS prior to the digestion, we choose to add it post digestion and prior to the SPE 
procedure. This way, samples above ULOQ could easily be diluted post digestion with a physiological 
saline solution, without having to use an IS supplemented dilution medium. 
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Figure 2. PTX and IS stability during enzymatic tissue digestion. The black symbols represent the measured peak areas for 
PTX, whereas the grey symbols denote the peak areas as a function of time for the IS. All 18 samples were analysed in a 
single run. The solid and dashed line are the predicted peak areas , according to a linear model treating time as a 
continuous covariate, for PTX and the IS, respectively. From the model estimated slopes it was estimated that the half-live 
for degradation for PTX and the IS were 57.4 h and 58.7 h, respectively. 
 
Validation 
Accuracy and (intermediate) imprecision 
As seen from Table 3, bias and imprecision were within specifications dictated by the EMA guidance 
on bioanalytical method validation[19]. Since bias and imprecision for the lowest QC level were < 
20%, this level was accepted as LLOQ. Based on these results, our method proved to be precise and 
accurate.    
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Table 3. 
Results for the validation experiments based on bovine muscle tissue quality control samples. QC’s were analyzed on 5 
different days. Analysis on day 1, day 2 and days 3,4 and 5 were carried out in sextuplicate, triplicate and duplicate, 
respectively. For QC low and QC medium 1 and 2 outliers were excluded, respectively. 
 Concentration Bias 
Within-run 
imprecision 
Between-run 
imprecision 
 (ng/g) (%) (%) (%) 
QC Low 80 10.7 17.2 7.9 
QC Medium 1600 7.3 5.0 13.6 
QC High 6400 7.9 6.3 11.8 
 
Selectivity 
No interferences were observed at the retention time of PTX and the IS when analysing blank bovine 
muscle tissue from 4 independent sources (data not shown). 
Stability 
Figure 3 depicts the measured QC concentrations (in sixfold) at day 0 and 1 month after the start of 
the stability experiment. From the graph it is seen that no significant degradation has occurred 
during storage at -80°C for 1 month. Moreover, a formal statistical significance test, using a two-
factor ANOVA analysis to test the null hypothesis of no degradation, revealed a p-value (0.507) well 
in excess of the 0.05 level of significance cut-off, indicating that in our data, no evidence is present in 
favour of significant degradation.     
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Figure 3. The measured PTX concentrations at day 0 and 1 month after the start of the stability experiment. Spiked bovine 
muscle QC samples were stored for 1 month at -80°C prior to analysis. The p-value indicates that using a two-factor ANOVA 
analysis, at the 5% level of significance, no evidence was present in the data in favour of significant degradation. 
 
Robustness evaluation 
The results from the original analysis and the reanalysis (1 month after the original analysis) of a 
subset of tumor tissue samples is shown in Figure 4. Results for samples that were below the lower 
limit of quantification (BLOQ) (n= 8 in original and reanalysis) are not depicted on this figure.  When 
comparing the results from both analyses, it stands out that for some samples the results were 
similar, whereas for other samples results differed significantly between both analyses. (This is 
observed from the high degree of variability in the slopes of the solid lines in Figure 4). We calculated 
that only in 6/12 cases (without taking into account the measurements that were BLOQ), results 
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were within -46.9% and 49.9% of their average value, indicating a high degree of variability between 
the results of both analyses.  
 
Figure 4. Results from the robustness evaluation. The individually measured concentrations from “duplicate” samples are 
depicted by open circles and are joined together by a solid line. The p-value indicates that, using a paired sample t-test, no 
evidence is found in favour of significant degradation when tumor tissue is stored at -80°C. 
  
Although our method proves to be accurate and precise, based on the validation data in bovine 
muscle quality control samples, the robustness experiment indicates that some aspect of the analysis 
is beyond our control. In our tumor tissue harvesting protocol (Figure 1) tumors roughly weighing a 
few hundred mg are partitioned in smaller subsections weighing approximately 50 mg. One part of 
this tumor tissue sample was used in the original analysis (25 mg), whilst the other part was used one 
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month later in the reanalysis. To our opinion, due to the heterogeneous distribution of PTX, 
characterized by an exponential decrease in PTX concentrations as a function of penetration depth 
(Figure 5) within the tumor tissue, we were unable to collect tumor tissue samples that were similar 
in PTX concentrations, hence explaining the high variability observed.      
Apart from considering these results as a way of quantifying measurement uncertainty, one could 
consider this experiment as an extension to our earlier conducted stability study. For the robustness 
experiment, tumor tissue samples which contained PTX were stored for 1 month at -80°C and 
therefore provide complementary information with regards to PTX stability. To test whether 
significant degradation had occurred in tumor tissue during storage, we used a paired sample t-test 
at the 5% level of significance. The resulting p-value of 0.679 indicates that no evidence is found in 
favour of significant degradation, which is in agreement with our earlier findings in bovine muscle 
tissue.    
Intratumoral distribution of PTX post IPEC dosing  
As a proof of concept for our developed methodology, Figure 5 provides details with regards to the 
analysis of tumor tissue samples harvested in an in-vivo experimental animal protocol described 
elsewhere[20]. In short, animals were treated with PTX by IPEC administration of Taxol®, and 
afterwards, tumors were harvested at different times post IPEC administration. PTX concentrations 
were determined for > 100 tumor tissue samples, using our developed method. The results from 
these analyses confirmed the suitability of our proposed methodology to address the question 
regarding the degree of and variability in tumor penetration of PTX post IPEC administration.  
The full pharmacokinetic results from this study are beyond the scope of this publication and are 
reported in detail elsewhere[20]. However, using the developed PKPD model, it was estimated that 
the half-width (similar to the half-live in plasma pharmacokinetics) of PTX tumor penetration was 
1.37mm. This means that, for every 1.37 mm increment from the tumor’s surface towards the 
tumor’s centre, the PTX concentration was reduced with 50%. In other words, coming back to our 
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hypothesis with regards to the high degree of variability observed in our robustness experiment, 
tumor tissue samples collected only 0.5 mm apart (with respect to the tumor’s centre) will, on 
average, show a 22.3 % difference in PTX concentration due to the exponential penetration profile.  
 
Figure 5. The PTX penetration profile in tumor tissue post IPEC administration of 30mg of Taxol®. The circles represent 
measured PTX concentrations as a function of penetration depth, whereas the solid and dashed lines represent the mean 
predicted PTX tumor tissue concentration, based on our published PKPD model[20], as well as the 95% confidence interval 
on this prediction. 
To our opinion, this explains why our robustness experiment showed such high variability between 
results from both analyses. Moreover, these results show that the pre-analytical phase, in this 
application, has a significant impact on the robustness of the analytical methodology and that the 
way forward, in this type of applications where the focus is on studying tissue penetration, is to 
further miniaturize the sample collection protocol.  
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Conclusion 
This study presents the development and validation of an assay to be used in the determination of 
PTX in tumor tissue samples. Sufficient evidence is provided to gain insights in the performance of 
the developed method. Nevertheless, future efforts should be directed to improve the robustness of 
the methodology with respect to PTX determinations in tumor tissue samples originating from in-vivo 
experiments. To our opinion, the pre-analytical phase, consisting of the harvesting and subsectioning 
of the tumors holds room for improvement. One way of addressing this problem, is to our opinion, 
the further minimization of the harvested tumor samples so that samples that are harvested in close 
proximity to each other show less variable tissue composition and PTX concentrations.    
Through the use of an enzymatic tissue digestion protocol, we minimized matrix effects whilst 
simultaneously maximizing recovery. Furthermore, sample handling was minimized as compared to 
the mechanical homogenization, providing the analyst with an easy, less labour intensive, sample 
preparation protocol. Finally, using automatic pipettes and/or robotic based instrumentation this 
sample preparation could easily be adapted to accommodate sample preparation in a high-
throughput fashion.    
 As a concluding proof-of-concept, we used our enzymatic tissue digestion protocol to analyse 
samples from an experimental animal trial with rats being administered PTX through IPEC.  
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Introduction 
Since its first description in 1980 by Spratt et al.[1], hyperthermic intraperitoneal perioperative 
chemotherapy (HIPEC) has gained interest as an alternative treatment option to systemically 
administered chemotherapy for the treatment of peritoneal carcinomatosis (PC). During hyper- / 
normothermic IPEC, a solution containing a cytotoxic agent is instilled into the peritoneal cavity for 
30-120 minutes[2]. During the treatment, an external heater circulator is used to maintain the 
temperature of the solution at mild hyperthermic (41-43 °C) or normothermic (37°C) conditions. 
During surgery, the abdominal muscle wall is expanded using traction sutures on the skin, thereby 
elevating the skin’s edge, creating a pouch to contain the cytotoxic solution. This technique, known 
as the “open” technique, which allows the surgeon to manipulate the abdominal contents during the 
procedure, thereby homogeneously distributing the cytotoxic solution throughout the patient’s 
abdomen, is usually preferred. After 30-120 minutes, the remaining solution is removed from the 
peritoneal cavity and the patient’s abdominal wall is sutured. 
In the treatment of cancers confined to the peritoneal cavity (e.g. PC), Dedrick et al.[3] hypothesized 
that this type of regional treatment could increase treatment efficiency by exposing tumors within 
the peritoneal cavity to higher drug concentrations. Furthermore, the peritoneal-plasma barrier is 
thought to limit/slow drug clearance from the peritoneal cavity to the systemic circulation, thereby 
minimizing systemic exposure and systemic adverse effects. 
Although IPEC as a tool for regional drug delivery has a strong pharmacokinetic rationale, controversy 
remains regarding the optimal treatment strategies that will optimize efficacy whilst minimizing 
systemic exposure[4]. Besides the ongoing debate on the additional benefit of hyperthermia in IPEC, 
questions regarding the dose to be administered, the duration of the perfusion or the optimal carrier 
solution to be used hamper the routine implementation of IPEC[5]. 
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Paclitaxel (PTX) is believed to be a good compound for IPEC treatment because of its favourable 
pharmacokinetic properties. Its high molecular weight is hypothesized to slow down clearance from 
the peritoneal cavity[4] into the bloodstream, thereby maximizing contact time with the peritoneal 
tumors. Furthermore, its high systemic clearance, as well as its pronounced first-pass effect are 
believed to limit systemic exposure after IPEC treatment. Although these pharmacokinetic 
advantages favour the use of PTX in IPEC, the limited knowledge on the degree of tumor penetration 
and accumulation along with the aforementioned issues regarding IPEC administration, currently 
limit its use in clinical centres. 
This study was set up to gain insight in PTX’s pharmacokinetics (PK) and pharmacodynamics (PD) 
after IPEC treatment using Taxol® in a rat model for PC. Concurrently, we investigated the influence 
of the treatment modalities (i.e. the effect of dose and duration of perfusion) on treatment outcome. 
In addition, the degree of PTX penetration in tumor tissue was quantitatively determined and linked 
to observed pharmacological effects after IPEC treatment in an in-vivo rat model for PC. 
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Materials and Methods 
Experimental procedures 
Materials 
Taxol® (6 mg/ml PTX in a 1:1 Cremophor®EL/ethanol mixture) from Bristol-Myers Squibb (Brussels, 
Belgium) was weighted and dissolved in 125 mL of a 0.9% NaCl solution to obtain the solutions (0.24 
mg/mL or 0.024 mg/mL) for IPEC treatment. These concentrations were chosen based on previous 
(unpublished) work that determined 0.24 mg/mL as the maximum tolerable dose following IPEC 
administration for 45 minutes. 
Rat tumor model 
A human ovarian carcinoma cell line (SKOV-3, obtained from the American Type Culture Collection) 
was cultured at 37 °C in a 5% CO2-containing humidified atmosphere. SKOV-3 cells were cultured in 
McCoys medium (Invitrogen, Merelbeke, Belgium), which was supplemented with 10% fetal bovine 
serum, penicillin, streptomycin (Invitrogen, Merelbeke, Belgium) and fungizone (Bristol Myers 
Squibb, Brussels, Belgium).  
Adult female athymic nude rats (Harlan, Horst, The Netherlands) were kept in standard housing 
conditions with water and food ad libitum and a 12 hours light/dark circle. All animal experiments 
were approved by the local ethics committee. 
Donor rats were injected with 30x106 SKOV-3 cells in a volume of 0.2 ml between the peritoneum 
and the abdominal muscle to induce tumor formation. The animals received a daily subcutaneous 
administration of 3 mg cyclosporine from 3 days prior until 10 days after injection of the SKOV-3 
cells. After 3 to 4 weeks, tumors had sufficiently grown to transplant tumor samples (5 x 5 mm, with 
a thickness of 3 mm) on the parietal peritoneum of another acceptor rat. The acceptor rat was dosed 
with cyclosporine in the same way as the donor rat. Approximately 3 weeks after transplantation, 
tumors had grown sufficiently to perform IPEC. 
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IPEC procedure 
After anesthetizing each rat with 3% isoflurane (Forene®, Abbott, Waver, Belgium), a vertical incision 
in the abdominal wall muscle was made along the midline. The abdominal wall muscle was attached 
to a metal ring which was placed a few centimeters above the incision. The inlet and outlet tubing 
(Pumpsil®, Watson-Marlow, Zwijnaarde, Belgium) was placed in the peritoneal cavity for perfusion 
with the cytostatic solution. A roller pump (Watson-Marlow, Zwijnaarde, Belgium) circulated the 
cytostatic solution through a heat exchanger set at 37 °C. During perfusion, the perfusate solution 
and body temperature of the rat were closely monitored. When the perfusion was finished, the 
peritoneal cavity was flushed with 0.9% NaCl solution and the abdominal wall was sutured. 
Tumor collection 
Tumors were excised at different time points (5, 15, 30, 45, 60, 90, 120, 240 and 480 min) after 
starting IPEC treatment. After excision of the tumor, rats were euthanized. A cross-section of the 
tumor was cut out, perpendicular to the peritoneal membrane, to obtain a cylinder-shaped tumor 
sample (± 10 mm of diameter) (Figure 1). This cylinder was split in half. After further sub-sectioning, 
one half was frozen at -20 °C for PTX concentration determinations whilst the other half was 
formalin-fixed and paraffin-embedded for caspase-9 staining. 
Collection of plasma & perfusate samples 
Blood was sampled in heparin-containing tubes via a catheter that was placed in the arteria carotis or 
arteria femoralis. Blood samples were taken between 5 min and 8 hours after starting the perfusion. 
Blood samples were immediately centrifuged at 2000 g at room temperature, and separated plasma 
was stored at -80 °C until analysis. 
During a pilot study, samples were collected from the perfusion solution used during the IPEC 
administration. Samples were collected at the start of the IPEC procedure and 15, 30 and 45 minutes 
thereafter.  
Plasma and perfusate samples were analysed as described previously[6].  
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Figure 1. Tumor harvesting protocol. 
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Tumor tissue concentration measurements 
After rinsing and weighing of the tumor section, a tumor tissue aliquot, weighing exactly 25 mg, was 
suspended in water and enzymatically digested using a proteinase-K and a lipase solution (both 
Sigma-Aldrich, Belgium). Tissue suspensions were left to incubate overnight at 55°C whilst 
continuously being shaken.  
After centrifugation of the digested tissue suspension at 10,000 g for 20 min, supernatant was 
collected and subjected to solid phase extraction after addition of internal standard (13C-paclitaxel). 
In short, after loading of the sample, the SPE cartridges (Oasis® HLC cartridges, Waters, USA) were 
washed with a sodium hydroxide (pH 10.0) solution and eluted using a 70% (v/v) methanol solution 
in water. Following elution, samples were concentrated by evaporation of methanol under a mild 
nitrogen stream (30 min, 35°C). Finally, after reconstitution, samples were injected onto the Waters 
Acquity UPLC system (BEH C18 column). Paclitaxel and 13C-paclitaxel were detected with a Quattro 
Ultima triple quadrupole system (Micromass Waters, Manchester, UK). The measurement range of 
the analytical method was 0.035 – 8.3 µg/g. Total imprecision and bias were calculated based on 
results of repeated analysis of quality controls (QC) and analysis values were reported only if 
quantification of the QC samples complied with the FDA guidance specifications on maximum 
tolerable bias and imprecision[7] (trueness < 15% and total imprecision < 15%).  
Apoptosis measurements 
After sample preparation, using xylene and ethanol, to remove a.o. the paraffin layer, tumor 
sections, 5 µm thick, were obtained through a rotary microtome (HM® 360, Microm, Walldorf, 
Germany). After washing in physiologically buffered saline (PBS), heat-induced antigen retrieval was 
performed for 30 min in a citrate buffer (pH 6.0), after which the tissue slices were cooled down for 
15 min at room temperature. The endogenous peroxidase activity was blocked for 15 min with a 
0.3% hydrogen peroxide solution (DAKO, Glostrup, Denmark). After the washing steps, each section 
was treated with a blocking solution (Tris-Buffered saline 0.1%) for 1 hour at room temperature. 
Primary antibody Cleaved caspase-9 (Cell signaling Technology, Leiden, The Netherlands, 1/400 in 
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PBST 5%) was incubated overnight at 4 °C. After washing, the tissue sections were incubated for 30 
min at room temperature with a labelled polymer horseradish peroxidase anti-rabbit secondary 
antibody (DAKO). A colour was developed using the chromogen 3,3-diaminobenzidine+ (DAB) for 10 
min. After washing, the tissue sections were counterstained with Mayer’s haematoxylin for 2 min.  
The number of apoptotic cell fragments present in each tissue section was expressed as a fraction of 
the total number of cells. The apoptotic index was determined with an Optronics Color digital camera 
(Olympus Corporation, Tokyo, Japan) and specialized software (Cell D Olympus Imaging Solutions, 
Münster, Germany). Ten regions of interest (ROI) were chosen at random at a magnification of 200x. 
The final apoptotic index used in the data-analysis was the geometric mean of these 10 ROI. Highly 
necrotic regions were excluded from the analysis. 
Tumor volume measurements 
Tumor growth was evaluated via a Siemens® Trio 3T clinical MRI scanner (Erlangen, Germany). Prior 
to the MRI scan, rats were anaesthetized with Rompun 2% (Bayer, Diegem, Belgium) and ketamine 
(Ceva, Amersham, UK) using a dose of 10 mg/kg and 90 mg/kg, respectively. The rats were placed 
prone in a (wrist) coil to measure the tumor volume. A T1-weighted 3D FLASH sequence was applied 
with a flip angle of 10°, a repetition time of 13 ms and an echo time of 4.9 ms to obtain a voxel size of 
0.19 x 0.19 x 0.4  mm3. Tumor volume was defined by creating a volume of interest (VOI) consisting 
of a stack of planar regions of interest (ROI) using PMOD software (PMOD Technologies, Adliswil, 
Switzerland). Rats were scanned 1 day prior to IPEC treatment to measure the initial volume of the 
tumor. Subsequently, tumor volume was evaluated 7 and 14 days after IPEC treatment. 
Available data 
The final dataset (Table 1) consists of data collected throughout different study periods (no 
previously published data were used). In one of the studies, 3 rats were used to evaluate the PK 
behaviour of PTX in absence of other Taxol® excipients. Therefore, in these rats, 105 µg of PTX was 
administered intravenously by fortifying 1 mL of blood, previously drawn from the animal, with 
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appropriate amounts of a 10 mg/mL solution of PTX in ethanol and re-instilling this blood 
intravenously to the animal as a bolus. This particular way of administering PTX (in rat blood) was 
used to overcome solubility issues in aqueous solutions. All other animals were treated with IPEC 
using Taxol®. In one study, the Taxol® excipients only (without PTX) were administered via IPEC to 2 
rats to control for any pharmacological effects induced by the excipients. Furthermore, 8 rats 
received a 0.024 mg/mL PTX IPEC treatment, whereas the majority of the rats (n=71) received a 0.24 
mg/mL IPEC treatment. The majority of the rats treated with IPEC were treated for 45 min (n=67). 
However, to study the effect of treatment duration, 4, 7 and 3 rats were treated for 5 min, 15 min 
and 30 min, respectively. 
Table 1  
In short: measurements were available for 84 rats. Perfusate concentrations were recorded in 5 rats, whereas 9 rats 
provided plasma concentration measurements, 15 rats provided apoptosis measurements and 18 rats provided 
measurements on tumor volume. In the remaining 37 rats, plasma and tumor concentrations as well as apoptosis 
measurements were recorded simultaneously. In total, 20 perfusate-, 90 plasma- and 145 tumor concentrations were 
recorded. Apoptosis measurements and tumor volume measurements amounted to 198 and 50 measurements, 
respectively. 
Study Description Dose # Rats Observations 
0 MTD study 0.24 mg/mL 5 Perfusate samples 
1 Rel. Bioavailability study 0.24 mg/mL 6 Plasma samples 
2 IPEC – High Dose 0.24 mg/mL 29 Plasma samples 
Tumor samples 
Apoptosis measurements 
3 Short perfusion (15 min) 0.24 mg/mL 3 Apoptosis measurements 
4 Placebo (only vehicle) 0 mg/mL 2 Apoptosis measurements 
5 i.v. study 105 µg 3 Plasma samples 
6 IPEC – Low Dose 0.024 mg/mL 8 Plasma samples 
Tumor samples 
Apoptosis measurements 
7 Pilot study 0.24 mg/mL 10 Apoptosis measurements 
8 TGD study 0.24 mg/mL 6 + 12 Tumor volume data 
 
  
[119] 
 
PKPD modeling 
During model building, a sequential approach was adopted where PD data were added after 
optimization of the structural PK model. Data fitting was performed using the FOCE algorithm with 
interaction in NONMEM® (Version 7.2; Icon Development Solutions, Ellicott City, MD, USA). Prior to 
inclusion into the dataset, concentration measurements were log-transformed, whereas apoptosis 
measurements and tumor volume measurements were handled on the non-transformed scale. Inter-
individual variabilities in PK parameters were modelled on the exponential scale whereas residual 
variability in the PK and PD data was modelled with, respectively, additive or proportional error 
structures. During model building PsN[8] and Pirana[9] were used as back- and/or front-end to 
NONMEM®. Graphical output from the model as well as goodness-of-fit (GOF) plots that were used 
to guide model building were generated using Xpose[10].       
Simulations 
Simulations based on the final parameter estimates obtained from the PKPD model were performed 
in R®(R Foundation for Statistical Computing, Vienna, Austria) using user-written scripts based on a.o. 
the R-library deSolve[11]. Throughout the simulation study, the effect of treatment was visualized for 
a tumor with a radius of 4 mm. Simulated endpoints include tumor PK and tumor apoptosis at 2 mm 
from the tumor surface and tumor growth curves after IPEC treatment. Furthermore, the R®-library 
PK[12] was used to calculate the area-under-the-curve (AUC) for the different simulated dosing 
schemes.  
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Results 
Exploratory data analysis of tumor tissue concentrations 
Prior to simultaneously modeling the PK of PTX  in plasma and tumor after IPEC administration, we 
explored the PTX tumor concentration profiles separately. When plotting the ln-transformed PTX 
tumor concentrations as a function of depth from the tumor’s dorsal surface, we noted a high degree 
of symmetry in the PTX concentrations on both sides of the tumor’s centre. Therefore, in an attempt 
to evaluate whether differences exist in PTX penetration between the ventral or dorsal side of the 
tumor, we separated measurements based on their orientation relative to the tumor’s centre prior to 
performing a simple linear regression analysis on both data sets.  
Linear regression analysis, treating PTX concentration as the dependent and depth from tumor 
surface as the independent variable was performed using PROC REG in SAS® (SAS Institute Inc., Cary, 
NC, USA). When considering the standard errors associated with the estimated parameters, we 
found that neither the intercepts, nor the estimated slopes differed significantly. A GOF plot for the 
regression analysis is depicted in Figure 2. This figure clearly shows that PTX penetrates the tumor 
equally efficient from both sides. Therefore, we decided, in the remainder of our PKPD analysis, to 
assume complete symmetry in PTX penetration in the tumor, irrespective of side.  
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Figure 2. Goodness-of-fit plot for the linear regression analysis of PTX tumor concentrations.  Open circles represent 
measured PTX tumor concentrations. The solid lines along with the dashed lines represent model predicted mean 
concentrations and the 95% confidence interval for the mean predicted tumor concentrations. 
 
Structural pharmacokinetic model 
The pharmacokinetic model for PTX after IPEC is shown in Figure 3; final parameter estimates are 
provided in Table 2. The system of differential equations that describe PTX disposition after IPEC is 
provided in the supplementary materials. 
PTX disposition after intravenous administration was best described by a 2-compartment model with 
first-order elimination from the central compartment (compartment 3 in Figure 3). After fitting the 2-
compartment model to the i.v. data alone , we decided, in order to increase model stability, to fix the 
parameters (Q, V4) describing the peripheral distribution of PTX to their estimated values. It is worth 
noting that parameter estimates derived from our model are significantly higher than those reported 
by Jiko et al.[13] and Choi et al.[14]. For example, we estimated plasma clearance to be 935 (± 196) 
mL/h as compared to 323 mL/h and 321 mL/h found by Jiko et al.[13] and Choit et al.[14]. 
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Figure 3. Overview of the structure of the final PK-PD model. The black arrow indicates the dosing compartment. 
Observations were recorded in compartments 1, 3, 5, 9 and 10. 
 
Similar differences are noted for the other parameters (V3, V4, Q). However, this discrepancy is most 
probably explained by the fact that the excipients in Taxol® influence the PK of PTX after i.v. 
administration[15] and that in this part of our study, as opposed to Jiko et al. and Choi et al., PTX was 
administered in its pure form (as described in the Materials and Methods section) rather than as 
Taxol® formulation. 
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Table 2  
Final model parameters as well as model predicted relative standard errors (RSE). The parameter estimates where the RSE 
is missing are parameters that were fixed, i.e. these were not estimated in the final PKPD model. 
PK model 
Parameter Estimate RSE (%) 
K12 0.393 h-1 33.0 
K23 0.032 h-1 35.0 
Zero13 180 µg x h-1 27.0 
V3 2040 mL 26.0 
CLPlasma 935 mL x h-1 21.0 
V4 2150 mL - 
Q 1250 mL x h-1 - 
Zero15 0.337 µg x h-1 21.0 
V5 0.025 g - 
CLTumor 0.0070 g x h-1 29.0 
Slope -0.505 µg x (g x mm)-1 14.0 
 
Apoptosis model 
Parameter Estimate RSE (%) 
BaseApoptosis 1.27 % 5.0 
Emax 19.8 h-1 14.0 
EC50 0.081 µg x g-1 49.0 
MTT 0.845 h 19.0 
keo 0.070 h-1 10.0 
 
Tumor growth delay model 
Parameter Estimate RSE (%) 
ke 0.00010 h-1 4.0 
kg 0.00230 h-1 5.0 
α 16.8 (h x % apoptosis)-1 8.0 
 
Inter individual variability 
Parameter Estimate (CV %) RSE (%) 
ωZero13 24.8 17.0 
ωZero15 10.2 23.0 
ωSlope 4.1 19.0 
 
Residual error model 
Parameter Estimate RSE (%) 
σComp1 (additive) 0.024 24.0 
σComp3 (additive) 0.148 13.0 
σComp5 (additive) 0.796 10.0 
σComp9 (proportional) 0.276 7.0 
σComp10 (proportional) 0.265 18.0 
  
[124] 
 
Additional modifications to the i.v. model were made to account for the PK behaviour of PTX post 
IPEC administration. The structure of the model, with a parallel absorption into the plasma-, the 
tumor- as well as the depot compartment provides an adequate fit of the complex absorption 
pattern that is observed (GOF plots for individual predictions  for both administered IPEC doses as 
well as the i.v. bolus dose are depicted in Figure 4).  
 
Figure 4. Observed versus model predicted (IPRED) plasma (top left panel) and tumor concentrations (top right panel) as 
well as observed and model predicted apoptosis (bottom left panel) and tumor volume (bottom right panel) 
measurements. 
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The absorption from the peritoneal cavity (depicted by the dose compartment in Fig. 3) into the 
plasma compartment (Zero13) is characterized by a zero-order process, inducing a rapid rise in plasma 
PTX concentrations after start of the IPEC administration. Simultaneously, a first-order, 
concentration-dependent absorption into plasma, through the depot compartment (characterized by 
rate constants k12 and k23), further increases the uptake of PTX into plasma during IPEC 
administration. At the end of the procedure, when the peritoneal cavity is flushed and the rat’s 
abdominal wall is sutured, this absorption route, from the depot compartment into plasma, 
adequately predicts the slow decrease or increase in plasma PTX concentrations post IPEC 
administration for the 0.024 and the 0.24 mg/mL perfusion concentrations respectively (Figure 5). 
This depot compartment is thought to represent the lymphatic system draining the abdominal cavity, 
where PTX has aspecifically accumulated, e.g. in fat. As postulated by Lu et al.[16], absorption into 
the lymphatic system is one of the major processes responsible for clearing highly lipophilic 
compounds from the peritoneal cavity. 
The absorption of PTX into the tumor was best characterized by a zero-order absorption process 
(Zero15). Attempts to model tumor absorption using first-order processes or more complex non-linear 
absorption models consistently resulted in higher objective function values and worse GOF plots. 
This result is in agreement with earlier reports of saturable drug uptake by monolayer cultures of 
human cancer cells[17]. A consequence of this saturable tumor absorption is that when 
administering PTX in high perfusate concentrations, several fold higher than the maximum uptake 
capacity of the tumor, changes in the perfusate concentrations will have little or no effect on the 
achieved tumor concentrations. This phenomenon is clearly illustrated in the GOF plot (Figure 4), 
where for both administered IPEC doses, similar tumor concentrations were observed. 
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Figure 5. Observed and model predicted mean plasma (top panel) and mean tumor concentrations (bottom panel) as a 
function of time.  In the top panel, plasma concentration measurements originating from IPEC administration of 240 µg/mL 
PTX are depicted with open circles whereas triangles are used for the 24.0 µg/mL administration. In the bottom panel, 
tumor concentrations measurements collected in tumor tissue slices no deeper than 3 mm from the tumor surface are 
depicted with open circles. Closed circles are used for measurements obtained between 4 mm and 6 mm from the tumor’s 
surface and triangles are used for measurements obtained between 7 mm and 12 mm. The solid line represents the model 
predicted mean tumor concentrations at a depth of 2 mm from the tumor’s surface. Similarly, the dashed and dotted lines 
represent the mean tumor concentrations at depths equal to 4 and 10 mm from the tumor’s surface as a function of time. 
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Despite the prolonged absorption from the peritoneal cavity into plasma, even after cessation of 
IPEC administration, during model building it became clear that absorption into the tumor continued 
only until IPEC administration was stopped. Furthermore, addition of an absorption process 
describing PTX absorption from plasma into tumor did not improve our model’s performance. This is 
in line with earlier work by Lu et al.[18] , who describes that following i.p. administration, plasma-to-
tumor absorption is only a minor route of drug delivery to the tumor due to the relatively low drug 
concentration in blood. 
During model building it was decided to fix tumor volume (V5) to 25 mg, the weight of the tumor 
sections that were used to quantify PTX tumor tissue concentrations. Fixing the tumor volume (V5) 
provided the additional benefit of reducing the observed correlation between different parameters 
associated with the tumor compartment (CLTumor, slope, V5), thereby providing stability to the model. 
Based on the model-estimated parameters, the half-life for PTX clearance from the tumor tissue was 
estimated to be approximately 2.5 hours. This finding is different from the tumor tissue half-life of 
PTX as estimated from data reported by Desai et al.[19] (approximately 9 hours). This difference is 
most likely explained by the fact that Desai et al.[19] determined PTX concentrations in tumor 
homogenates, whereas we took the spatial distribution of PTX within solid tumors into account. 
Finally, from our model based slope estimate (-0.505 ± 0.071), we calculated that the “half-width” for 
PTX penetration is approximately 1.37 mm, i.e. PTX tumor concentrations reduce by half every 1.37 
mm.  
PKPD model 
As a starting point to link tumor concentrations to the observed apoptosis measurements, we used 
an adaptation of the transduction model as described by Gabrielsson and Weiner[20]. Owing to the 
specific nature of the collected data, the typical system of differential equations used to describe the 
apoptosis as a function of time was modified to account for the depth at which the apoptosis 
measurements were performed. (Details are provided in the Supplementary material).  
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Using this transduction model, we estimated a.o. the time delay, expressed as mean transit time 
(MTT) between PTX binding to its intracellular receptor and the onset of the apoptosis to be 0.84 (± 
0.16) hours. Furthermore, our model estimates that the maximum apoptosis occurs approximately 
14 hours post IPEC treatment (Figure 6).  
By using this model, we assume that, within the tumors, a homeostasis exists between the onset (kin) 
and the disappearance (koe) of apoptotic signals. In the absence of PTX, our model estimates that this 
homeostasis leads to a baseline apoptotic signal of 1.27 (± 0.06) %. When PTX is present within 
tumors, it will stimulate the onset (kin) of apoptotic signals, giving rise to an increase in observed 
apoptosis. PTX-induced changes in kin were assumed to be additive and the concentration-effect 
relationship was modelled using an Emax model. From Table 2 it is noted that the EC50, i.e. the tumor 
concentration at which half of the maximum effect is achieved, is 0.081 (± 0.040 ) µg/g and that the 
maximum effect is 19.8 (± 2.8), the latter amounting to an approximate 20-fold increase in kin.  
Finally, in an attempt to integrate information on tumor growth with the potential tumor growth 
inhibition of PTX, we explored the PDPD link suggested by Ait-Oudhia et al.[21]. In their model 
describing a.o. PTX PKPD after i.v. administration of Taxol®, they assumed that the cytotoxicity 
induced by PTX is related to the kinetics and magnitude of the predicted apoptotic response. Based 
on this idea, we developed the final part of our model, assuming that tumor growth is governed by a 
balance between cell maturation/proliferation (kg) on the one hand and cell death (ke) on the other. 
In addition, it was assumed that by inducing apoptosis, cell death is stimulated. To produce 
predictions of tumor growth delay, we arbitrarily used predicted PTX-induced apoptosis at a depth 
half the size of the tumor radius as a predictor. Therefore, the estimate α, is interpreted as the 
percentage increase in cell death rate (ke) that is induced by achieving a 1 % increase in apoptosis 
from baseline at a depth from the surface of ¼ the size of the tumor. In contrast to Ait-Oudhia et al. 
[21], we did take the spatial distribution of apoptosis within a solid tumor into account. Therefore, in 
the future, our model might serve as a tool for the comparison of treatment efficiencies for tumors 
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of different sizes.
 
Figure 6. Observed versus model predicted mean apoptosis (top panel) and mean tumor volume (bottom panel) post IPEC 
dosing. Similar to the GOF plot for the tumor concentrations, different symbols were used to annotate apoptosis 
measurements as a function of the depth from the tumor’s surface. Open circles, closed circles and triangles were used to 
depict measurements obtained at approximately 2, 4 and 10 mm, respectively. The solid line represents the model 
predicted mean apoptosis at a depth of 2 mm from the tumor’s surface. Similarly, the dashed and dotted lines represent 
the mean apoptosis at depths equal to 4 and 10 mm from the tumor’s surface as a function of time. In the bottom plot, the 
model-predicted change in tumor volume after IPEC dosing with 240 µg/mL PTX for 45 min for a tumor with a starting 
volume of 85 mm³ (average tumor volume prior to IPEC dosing) is depicted by the solid line. 
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In the absence of PTX, our model adequately captures the growth of the tumors as observed from 
the control group (Figure 4). Moreover, when PTX is administered via IPEC, as seen in Figure 6, our 
predictions adequately capture the biphasic evolution of tumor volume post-dosing. It is predicted 
that prior to regrowth, tumor volume reaches a minimum approximately 50 hours post dose. 
PKPD simulations 
To evaluate the effect of changing perfusate concentrations or treatment duration on the outcome 
of the IPEC procedure, several treatment modalities were simulated. Using our final model 
parameter estimates, we simulated 15, 45, 90 and 120 min IPEC administrations at concentrations 
ranging between 0.01 µg/mL and 100 µg/mL. Typical tumor and plasma exposure (AUC obtained 
using non-compartmental analysis of simulated concentrations) for the different simulated IPEC 
treatments are depicted in Figure 7.  
From our simulations, it can be seen that AUCTumor reaches a maximum at a particular perfusate 
concentration. Increasing the perfusate concentration beyond this point does not increase AUCTumor 
any further. In addition, the perfusate concentration producing maximum tumor exposure depends 
on the treatment duration. For the 15, 45, 90 and 120 min treatment durations, our simulations 
show that perfusate concentrations attaining maximum tumor exposure are 0.40, 1.60, 4.00 and 6.35 
µg/mL respectively. The achieved maximum AUCTumor differs significantly between the simulated 
treatments. The maximum AUCTumor is 4.30, 13.09, 26.24 and 35.00 µg.h/g for the 15, 45, 90 and 120 
min treatments, respectively.   
When evaluating AUCPlasma, our simulations show that no such maximum exposure is achieved in 
plasma. For every simulated treatment, a clear positive correlation is observed between perfusate 
concentrations and AUCPlasma. A useful therapeutic index, weighing the desirable effect of the 
treatment (high AUCTumor) by the unwanted effects of the treatment (high AUCPlasma, hence high 
probability of systemic toxicities) is the AUCTumor over AUCPlasma ratio. When evaluating this index for 
the different simulated treatments, it can be seen that this index, depicted by the continuous line in 
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Figure 7, is high up to the perfusate concentration that achieves maximum tumor exposure. Beyond 
this point, this index declines steeply, indicating a less efficient delivery of PTX to its site of action. 
 
 
Figure 7. AUCTumor and AUCPlasma as a function of treatment duration (15, 45, 90 and 120 min treatments in the top-left, top-
right, bottom-left and bottom-right panels, respectively) and perfusate concentration. The shaded grey area depicts the 
AUCPlasma, whereas the solid line with embedded symbols depicts the AUCTumor. The solid line represents the AUCTumor over 
AUCPlasma ratio and its values are plotted against the left y-axis. The dashed lines represent the coordinates of the 
“saturation point”. 
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To compare the different simulated treatments at their optimal perfusate concentration (the lowest 
perfusate concentration achieving maximum AUCTumor), additional simulations were performed. 
Figure 8 shows the plasma-concentration-time profile as well as the evolution of the tumor volume 
following IPEC administration for the different optimal treatment duration / perfusate concentration 
combinations.  
 
Figure 8. Model predicted time-course of PTX plasma concentrations and tumor volume post IPEC dosing. 
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From Figure 8 it can be seen that peak plasma concentrations differ 4-fold between the shortest and 
the longest treatment duration. This difference in plasma concentrations is reflected in the overall 
plasma exposure (AUCPlasma for the different simulated treatments is 0.05, 0.18, 0.46 and 0.72 
µg.h/mL, respectively). Of note is that AUCTumor (cfr. supra) differs approximately 8-fold, whereas 
AUCPlasma differs approximately 14-fold between the shortest and the longest treatment duration. 
When comparing the different treatments in terms of the AUCTumor over AUCPlasma ratios, we found 
that the index decreases from approximately 85 for the 15 min treatment until 49 for the 120 min 
treatment. 
The lower panel of Figure 8 shows the evolution of tumor volume following the different treatments. 
Although none of the treatments achieves a complete reduction of the tumor, significant differences 
are observed between the simulated treatments. The achieved tumor shrinkage at approximately 50 
hours post treatment is 25, 35, 42 and 45 % for the 15, 45, 90 and 120 min treatment durations, 
respectively.  
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Discussion 
Based on our elaborate tumor tissue sectioning protocol we showed, in contrast to our expectations, 
that in our rat model, tumors attached to the peritoneal membrane are equally accessible for drug 
penetration from the ventral as well as the dorsal side. This finding is somewhat counterintuitive 
because of the perceived restricted access of the cytotoxic solution towards the ventral part of the 
tumor, which is attached to the peritoneal membrane. One plausible explanation might be that, the 
barrier between the cytotoxic solution in the peritoneal cavity and plasma, i.e. the peritoneum, does 
not correspond to the classic semipermeable membrane. Rather than being a physical transport 
barrier, its complex structure makes it highly permeable to water, small solutes and proteins[22], 
thereby potentially allowing peritoneal tumors to be homogeneously exposed to the cytotoxic 
solution. Another explanation for this peculiar finding might be that the tumors in our animal model, 
which are artificially grown on the peritoneum, might be somewhat more accessible to drugs than 
tumors that naturally occur in PC. However, given the lack of other studies that quantitatively 
evaluated tumor penetration post IPEC dosing, these hypotheses remain to be confirmed. 
When comparing the extent of PTX tumor penetration that was observed in our study (half-width 
approximately 1.37 mm) against earlier reports[23-27], it stands out that the extent and the kinetics 
of tumor penetration of PTX are significantly different in our study. Overall, in-vitro studies using a.o. 
multicellular layer cultures show that PTX penetrates only a few cell layers (approximately 100 µm). 
Even in in-vivo models of i.p. administration of PTX nano- / microparticles, used by Kamei et al.[24] 
and Lu et al.[28], penetration was limited to approximately 1 mm. Not only does the extent of tumor 
penetration in our study widely differ from these earlier reports (Figure 2 shows that post IPEC PTX 
was measured even at 12 mm from the tumor’s surface), the kinetics of penetration are different as 
well.  
Earlier studies[23-28] showed that PTX penetration is slow, whereas we found that even at 15 min 
post IPEC administration, significant PTX tumor concentrations (> 0.035 µg/g) are detected in the 
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tumor’s centre. Although these different kinetics might be attributed to the experimental design 
(most literature reports originate from in-vitro studies), the specific nature of the IPEC administration 
could be responsible for this phenomenon. On the one hand, the superior distribution of the 
perfusate within the abdominal cavity as opposed to the classical i.p. injection, bringing the cytotoxic 
solution in close contact with the tumor’s surface might be responsible for the faster tumor 
penetration. On the other hand, owing to the fact that drug penetration in solid tumors is governed 
by passive diffusion as well as convective processes[28], the hydrostatic pressure induced by the 
cytotoxic solution within the abdominal cavity might enhance convection towards the tumor’s 
interstitium, thereby increasing tumor penetration. Future work should be directed towards 
unravelling the physical/chemical phenomena that explain the higher degree of PTX tumor 
penetration following IPEC as compared to other routes of administration.         
The results from our simulation study show that, in our animal model, even  optimized combinations 
of treatment duration and perfusate concentration will not produce full tumor shrinkage after a 
single IPEC administration of PTX. Multiple dose strategies seem to be necessary to induce complete 
tumor shrinkage after IPEC treatment. On the other hand, our simulations also show that increasing 
treatment duration, whilst concurrently increasing the perfusate concentration, holds additional 
benefits in terms of achieving higher tumor exposure. This finding is in agreement with other reports 
on i.p. PTX dosing in the literature[27,28], that describe that in order to optimize pharmacological 
response, exposure to the cytotoxic agent should be prolonged. Our model, which simultaneously 
describes plasma- as well as tumor exposure after IPEC administration of PTX could be used to 
determine the characteristics of a modified release formulation producing maximal tumor exposure 
whilst simultaneously minimizing systemic exposure.    
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Conclusions 
Based on our animal studies, we clearly identified a non-linear dose-response relationship originating 
from saturable absorption into the tumor. Furthermore, we showed that IPEC treatment modalities 
differently affect tumor and plasma exposure, thereby allowing the optimisation of the therapeutic 
range, i.e. separating treatment efficiency from possible systemic toxicities. The complex processes 
underlying the absorption from PTX from the peritoneal cavity after IPEC and the interplay of these 
processes on efficacy and potential systemic toxicities make that for PTX dosing via IPEC less might 
truly result in more.  
We hypothesize that, based on the close resemblance between tumor exposure in our animal model 
and tumor exposure in patients treated under similar conditions, our study results are of great value 
for all stakeholders involved in the development of new treatment protocols for PC using IPEC. 
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Supplementary Materials 
System of differential equations 
PK model A-*? = −B?C ∗ A-*? − E?@ − E? 
A-*C = B?C ∗ A-*? −	BC@ ∗ A-*C 
A-*@ = E?@ +	BC@ ∗ A-*C − B@ ∗ A-*@ − B@F ∗ A-*@ + BF@ ∗ A-*F 
A-*F = B@F ∗ A-*@ −	BF@ ∗ A-*F 
A-* = E? −	B ∗ A-* 
PDApoptosis model 
A-*> = B%& ∗ G1 +  ∗
A-*I ∗ (JK-*.∗L.*+,)
 + A-*I ∗ (JK-*.∗L.*+,)M− BNO ∗ A-*> 
A-*P = (A-*> −	A-*P) ∗ BNO 
A-*Q = (A-*P −	A-*Q) ∗ BNO 
(RSTUVW(+ = (A-*Q −	A-*X) ∗ B-.  
PDTumor volume model A-*? = B) ∗ A-*? −	B. ∗ Y1 + Z ∗ [A-*X − R*-*+-\%\]^ ∗ A-*? 
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Final NONMEM® code 
$SUBROUTINE ADVAN13 TOL9 
$MODEL 
COMP(INPUT,DEFDOSE) 
COMP(DEPOT) 
COMP(CENTRAL,DEFOBS) 
COMP(PERIPH) 
COMP(TUMOUR) 
COMP(TRANS1) 
COMP(TRANS2) 
COMP(TRANS3) 
COMP(EFFECT) 
COMP(LIVE) 
 
$PK 
;------------- Depot ----------------------------- 
K12 = THETA(1) 
K23 = THETA(2) 
;------------- Absorption model ------------------ 
ZERO = THETA(3)*EXP(ETA(1)) 
;------------- Plasma PK ------------------------- 
V3=THETA(4) 
CL=THETA(5) 
V4=THETA(6) 
Q=THETA(7) 
K30=CL/V3 
K34=Q/V3 
K43=Q/V4 
S1=125 
S3=V3 
 
 
;------------------ Tumour PK --------------------- 
ZERO2=THETA(8)*EXP(ETA(3)) 
V5=THETA(9) 
CL2=THETA(10) 
K50=CL2/V5 
S5=V5 
;-------------------- Intratumoural distribution -------- 
TVSLOPE=THETA(11) 
SLOPE=TVSLOPE*EXP(ETA(2)) 
;-------------------- PD model -------------------------- 
BASE=THETA(12) 
EMAX=THETA(13) 
EC50=THETA(14) 
KEO=THETA(15) 
KIN = BASE*KEO 
;-------------------- TRANSIT Compartments --------------- 
MTT=THETA(16) 
KTR=3/MTT 
;-------------------- Initialization of Compartments ----- 
A_0(6)= KIN/KTR 
A_0(7)= KIN/KTR 
A_0(8)= KIN/KTR 
A_0(9)= BASE 
;-------------------- TGD data ---------------------------- 
;-------------------- Baseline model ---------------------- 
OBASE=10 
IF(TIME.EQ.0.AND.OBV.NE.0) THEN 
OBASE=OBV 
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ENDIF 
IBASE=OBASE*(1+(ETA(4)*THETA(20))) 
A_0(10)=IBASE 
;------------------- Apoptosis effect relation ----------- 
KE=THETA(17) 
KG=KE+THETA(18) ; First-order tumour growth constant 
ALPHA=THETA(19) 
 
$DES 
A1=A(1) 
IND=1 
IF(T.GT.0.76) IND=0 
ZER=0 
IF(A1.GT.0) ZER = ZERO 
ZER2=0 
IF(A1.GT.0) ZER2 = ZERO2 
;-------------------- PK --------------------------------- 
DADT(1)=-K12*A(1)*IND-ZER*IND-ZER2*IND 
DADT(2)=K12*A(1)*IND-K23*A(2) 
DADT(3)=ZER*IND+K23*A(2)-K30*A(3)-
K34*A(3)+K43*A(4) 
DADT(4)=K34*A(3)-K43*A(4) 
DADT(5)=ZER2*IND-K50*A(5) 
;-------------------- PD --------------------------------- 
DADT(6)=KIN*(1+EMAX*((A(5)/V5)*EXP(SLOPE*DEPTH))/
(EC50+((A(5)/V5)*EXP(SLOPE*DEPTH))))-KTR*A(6) 
DADT(7)=A(6)*KTR-A(7)*KTR 
DADT(8)=A(7)*KTR-A(8)*KTR 
DADT(9)=A(8)*KTR-A(9)*KEO ; Observation 
compartment 
;-------------------- TGD -------------------------------- 
DADT(10)=KG*A(10)-KE*(1+ALPHA*(A(9)-BASE))*A(10) 
$ERROR 
INT=-7 
IF(F.GT.0) INT = LOG(F) 
;------------------- Plasma observations ---------------------- 
IPRED=INT 
Y = IPRED+EPS(1) 
;------------------- Perfusate concentrations ----------------- 
IF(CMT.EQ.1) THEN 
IPRED = INT 
Y = IPRED+EPS(2) 
ENDIF 
;------------------- Error model Tumour concentrations ----- 
IF(CMT.EQ.5) THEN 
IPRED=INT+SLOPE*DEPTH 
Y = IPRED+EPS(3) 
ENDIF 
;--------------------- Error model PD measurements ----------- 
IF(CMT.EQ.9) THEN 
IPRED=F 
Y=IPRED*(1+EPS(4)) 
ENDIF 
;-------------------- Error model TGD measurements ---------- 
IF(CMT.EQ.10) THEN 
IPRED=F 
Y=IPRED*(1+(EPS(5)*THETA(20))) 
ENDIF 
IRES = DV - IPRED 
W = IPRED 
IF(W.EQ.0) W = 1 
IWRES = IRES/W 
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$THETA   
0.393 FIX ; K12 ; /h 
0.0318 FIX ; K23 ; /h 
180 FIX ; ZERO ; µg/h 
2040 FIX ; V3 ; mL 
935 FIX ; CL ; mL/h 
2150 FIX ; V4 ; mL 
1250 FIX ; Q  ; mL/h 
0.337 FIX ; ZERO2 ; /h 
0.025 FIX ; V5 ; g 
0.007 FIX ; CL2 ; g/h 
-0.505 FIX ; SLOPE; µg/g.mm 
1.26976 FIX ; BASE ; % 
19.8222 FIX ; EMAX; rel. 
0.0814429 FIX ; EC50 ; µg/mg 
0.0697099 FIX ; KEO ; /h 
0.844897 FIX ; MTT ; h 
(1E-9,0.000136843) ; KE ; /h 
(1E-9,0.00228513,1) ; KG ; /h 
(1E-9,16.8132) ; ALPHA ; /%APOP 
(1E-9,0.264815) ; RV_CMT10 ; rel. 
 
$OMEGA   
0.498  FIX  ;   IIV_ZERO 
0.203  FIX  ;  IIV_SLOPE 
0.320  FIX  ;  IIV_ZERO2 
1  FIX  ;      DUMMY 
 
 
 
$SIGMA   
0.148  FIX  ; Add. Plasma 
0.0238  FIX  ; Add. Perfusate 
0.796  FIX  ; Add. Tumour 
0.275816 FIX ; Prop. PD 
1  FIX  ;  Prop. TGD 
 
$ESTIMATION SIG=2 SIGL=6 MAX=9999 METHOD=1 
POSTHOC SORT PRINT=1 NOABORT INTERACTION 
MSFO=.msf 
$COVARIANCE PRINT=E SIGL=12 TOL=12 
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Introduction 
The use of Biomarkers (BM) and PKPD modeling in cancer research 
BM discovery is a fast-growing area of cancer research. Advances in the area of -omics research and 
an increased focus on systems biology approaches[1] have led to the discovery of a plethora of novel 
“predictive” and “prognostic” BMs. The first type of BM predicts the response to treatment at the 
cell-level, whereas the latter is related to clinical outcome[2]. These types of BMs are used to (i) 
optimize lead selection in drug discovery, and to (ii) stratify patients in terms of their probability to 
respond to therapy during the clinical drug development. 
For a drug to be effective, it needs to engage its target at a sufficiently high level, and result in 
downstream pharmacological effects, that can be measured through pharmacodynamic (PD) BMs[3]. 
The range of PD markers that can be determined preclinically is substantial, and in case translational 
PD markers can be identified, they can be used as a quantitative measure to inform clinicians about 
when to continue/stop treatment, or switch to an alternative option.  
Pharmacokinetic-pharmacodynamic (PKPD) modeling of BM data is recognized as a promising tool for 
quantitative-decision making[4]: it allows for adjusting the dose regimen using PD BM 
measurements. PKPD models that are constructed based on an in-depth understanding of the 
relationships between drug concentration at the site of action, PD BM response and treatment 
outcome, are a tool to quantitatively determine the level of PD BMs associated with effect and can 
help to optimize/individualize treatment[2]. 
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The utility of apoptosis BMs 
Apoptosis represents the final downstream event of many anticancer drugs [2]. Apoptosis-related 
markers can therefore be regarded as general or drug-independent markers of tumor cell killing. The 
biochemistry of apoptosis is complex, ultimately leading to dismantling of the cell [5]. Several (pro-
)enzymes and cleaved proteins involved in the apoptosis cascade have been identified as potential 
BMs[6].  
In vivo detection of apoptosis is challenging: it is generally asynchronous and the half-life of 
apoptotic cells in tissues is short[6]. Furthermore, several apoptosis BMs are constrained to the 
intracellular space (activated caspases) thus requiring biopsy, which precludes longitudinal sampling 
and limits their clinical utility. However, markers related to apoptosis have been identified in serum. 
Cytokeratin 18 (CK18), an intermediate filament protein making up the intracellular skeleton[7], is 
released from apoptotic/necrotic epithelial cells and can be detected in serum through the use of the 
M30 and M5 antibody[8], specific for the caspase-cleaved CK18 (ccCK18) fragment and the native 
CK18 protein, respectively.  
Towards a BM guided treatment individualization 
Several preclinical studies demonstrated/validated the correlation between drug-induced tumor cell 
apoptosis and an increase in circulating (cc)CK18[9] on a qualitative basis. However, until now, 
circulating (cc)CK18 levels are merely measured to predict patient prognosis[10-12] (responder/non-
responder) rather than to serve as a quantitative-decision tool for treatment individualization. 
Therefore, in this chapter, we will study the quantitative relationship between PTX exposure, 
intracellular PTX retention, the resulting reduction in cell viability and the quantitative relationship 
between cell viability and the release of ccCK18 from in-vitro cultured ovarian carcinoma cells (SK-
OV-3). Furthermore, a preliminary proof-of-hypothesis experiment will be set up to evaluate whether 
ccCK18 can be measured reliably in rats treated with IPEC.  
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We believe that these insights could provide the first building blocks in the development of an 
integrated modeling framework which, after thorough physiologically-based scaling from the animal 
to the human situation, could eventually be used as a biomarker-guided decision tool, aiding the 
clinician in rationalizing treatment for patients treated with paclitaxel. 
Materials and Methods 
Reagents 
13C6-Paclitaxel (IS) and PTX were from Acros Organics (Geel, Belgium) and Chromadex (California, 
USA), respectively. ULC-grade water and methanol were from Biosolve (Valkenswaard, The 
Netherlands). All other solvents and chemicals were of analytical grade. Drug-free heparinized rat 
plasma of female athymic nude rats was obtained from Harlan laboratories (Indianapolis, USA). 
Sirocco plates and 96-well collection plates were purchased from Waters (Massachusetts, USA). 
SK-OV-3 cell culture 
SK-OV-3 cells (obtained from the American Type Culture Collection) were cultured at 37°C in a 5% 
CO2-containing humidified atmosphere. The culture medium consisted of McCoy’s 5A medium 
(Invitrogen, Merelbeke, Belgium) supplemented with penicillin, streptomycin (Invitrogen, Merelbeke, 
Belgium) and fungizone (Bristol Myers Squibb, Brussels, Belgium). 
Drug treatments 
For the static incubation experiments, i.e. no simulation of an extracellular clearance, 5 x 104 cells/mL 
were seeded in 96-well plates and were allowed to attach to the plate surface by growing in drug-
free medium for 72 hours prior to the start of the experiments. For the dynamic experiments 7.5 x 
104 and 3.0 x 104 cells/mL were seeded for protocol 1 and protocols 2 & 3, respectively. Cells were 
then treated with different PTX concentrations by replacing 20 µL of the 200 µL culture medium by 
20 µL of the respective PTX solutions. PTX was dissolved in ethanol and diluted with a 1% ethanol 
solution in McCoy’s medium to final concentrations ranging between 0.01 and 1000 µg/mL. By up 
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front diluting the PTX stock solutions with a 1% ethanol solution in McCoy’s medium prior to spiking 
into the cell culture, we made sure that the final concentration of ethanol did not exceed 0.1% in the 
cell culture.  
Incubations were performed in six-fold and blank controls were included in every experiment. To 
avoid problems caused by evaporation of medium in wells located at the edge of the plate [13], only 
the inner wells (rows 1-7 and columns 2-11) were used to measure viability, PTX concentrations, etc. 
During the dynamic incubations, changes in the extracellular PTX concentrations were induced by 
removing 100 µL of culture medium at pre-specified time points and replacing it with 100 µL of fresh 
culture medium.     
MTT assay 
Cell viability was assessed 96 hours after the start of the treatment by replacing 100 µL of culture 
medium with 100 µL of MTT reagent, consisting of MTT (1mg/mL; Sigma, Bornem, Belgium) dissolved 
in Dulbecco’s phosphate buffered saline (Sigma, Bornem, Belgium). After a 2 hour incubation period, 
the medium was entirely removed and replaced with DMSO. Finally, using a plate reader (Paradigm 
Detection Platform, Beckman Coulter, Suarlée, Belgium), the extinction was measured at 570 nm 
relative to a reference wavelength at 650 nm. On average, throughout our experiments, 18 wells 
were used per concentration level. Viability was then calculated as the ratio of the extinction 
measured for the different treated cells against the average extinction for the controls.  
ccCK-18 ELISA 
ccCK-18 was determined in calibrators and (QC) samples according to the commercially available 
M30 Apoptosense® ELISA kit (Peviva, Stockholm, Sweden). In short, the M5 antibody, immobilised to 
a 96-well plate, was used to capture human (cc)CK-18 present in the sample. Afterwards, the M30 
antibody, conjugated with horseradish peroxidase (HRP), was bound to the exposed CK-18-Asp396-
neo epitope. Finally, after addition of tetramethylbenzidine and a 1.0 M sulphuric acid solution, the 
extinction of the solution was measured at 450 nm. A four-parameter logistic regression curve was 
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fitted to the measured extinctions of the calibrator samples, using R® (R foundation for statistical 
computing, Vienna, Austria), and was subsequently used to calculate the ccCK-18 concentrations in 
the samples. Concentrations of ccCK18 were expressed as fmol/L, using the correction factor 
supplied by the manufacturer (1 U/L corresponds to 1.24 x 103 fmol/L).     
Intra- / extracellular PTX concentration measurements 
Extracellular and intracellular PTX concentrations were measured using an adaptation of a previously 
developed method for the quantification of PTX in plasma samples[14]. The adaptation consisted of 
diluting the extracellular/intracellular fractions with plasma (1/10 dilution; in case of plasma 
calibrator samples) or McCoy’s medium (1/1 dilution; samples and calibrators prepared in 50:50 
McCoy’s medium:acetonitril) in order to match the composition of the calibrator samples. 
Intracellular fractions were obtained, based on Mateus et al.[15]. After removal of the culture 
medium, the cells were rinsed with 2 x 100 µL fresh culture medium. Afterwards, 100 µL of 
acetonitril was added and cells were left to lyse for 15 minutes.  
Subsequently, a volume of 50 µl was transferred to an empty well of a 96-well filtration plate and 
200 µl of acetonitrile containing internal standard (IS; 13C6-paclitaxel) was added. After vacuum 
filtration, the filtrate was diluted with 150 µl of water and 5µL was injected onto a Waters Acquity 
UPLC BEH C18 column (50 mm x 2.1 mm, 1.7 µm particle size). PTX and its IS were detected using a 
Waters Quattro Ultima triple quadrupole system (Micromass Waters, Manchester, UK). 
The amount of PTX (ng) recovered after cell lysis was calculated by multiplying the measured PTX 
concentration with the volume of acetonitril used to lyse the cells (100 µL).    
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Results and Discussion 
PTX uptake kinetics 
In order to study PTX uptake kinetics different dynamic PTX incubation experiments were set up. The 
first explored protocol consisted of spiking PTX to the culture medium at a concentration of 10 
µg/mL. Afterwards, at 1 hour intervals, 100 µL of culture supernatant was removed and replaced 
with fresh culture medium for a total of 6 cycles.  
Based on the measured intra- / extracellular PTX concentrations, a preliminary compartmental PK 
model (structure not given but similar to the final PK model), was developed and subsequently used 
to simulate new experimental protocols. One of the objectives in our study was to evaluate the 
relationship between intracellular PTX kinetics and pharmacodynamics of PTX. Therefore, these 
simulations were used to identify new experimental protocols that would result in significantly 
different intracellular concentration-time profiles. 
 
Figure 1. Simulations based on the preliminary PK model to identify subsequent experimental protocols. The open circles 
are the measured intracellular PTX concentrations from Protocol 1, with the model predictions depicted by a solid line. 
Predicted intracellular PTX concentrations for Protocol 2 and 3 (cfr. supra) are shown with dashed and dotted lines, 
respectively. The LLOQ for the quantification of intracellular PTX is shown in red.   
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Two additional protocols (the predicted intracellular concentration-time profiles are shown in Figure 
1) were selected. Protocols 2 and 3 differed from protocol 1 in the applied initial PTX concentration 
(Protocol 3; 1 µg/mL instead of 10 µg/mL) and the induced extracellular half-life (Protocol 2 and 3, 
half-lives of 0.5 and 2 hours, respectively). The measured intra- / extracellular PTX amounts and 
concentrations from these experimental protocols are depicted in Figure 2. 
 
 
Figure 2. Measured PTX concentrations for the different dynamic protocols. Open circles represent the extracellular 
concentrations (left y-axis; ng/µL) whereas solid triangles are used for the measured intracellular PTX amounts (right y-axis; 
ng). The solid lines are non-parametric smoothers. 
 
Using the data from the different dynamic experiments, we developed a compartmental PK model 
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on the FO algorithm as implemented in NONMEM® (Version 7.2; Icon Development Solutions, Ellicott 
City, MD, USA) and observations were ln-transformed prior to inclusion into the dataset. The 
structure of the final model is shown in Figure 3 and the final parameter estimates are given in Table 
1; final NONMEM® code is shown in the appendix. 
 
 
Figure 3. The final PK model describing PTX uptake kinetics during the incubation experiments. The model consists of an 
extracellular PTX compartment (PTX and NSB compartment) and an intracellular compartment (PTX and PTXbound). In the 
extracellular compartment unbound PTX is bound to / released from non-specific binding sites (NSB) according the rate 
constants kon and koff. Furthermore, the unbound PTX is able to distribute to the intracellular compartment (PTXintra), with 
an estimated volume of Vintra, at a rate of Q2. Within the intracellular compartment PTX is irreversibly bound at a rate of Kon. 
Due to the specific nature of the experimental protocols, no clearance parameter was estimated for 
the extracellular compartment. Instead, the manipulations to the culture medium were hard coded 
into the dataset. Hereto, CLexp, which was fixed to 6900 µL/h and was activated for 0.02 h at the 
different moments when culture supernatant was removed. In this way, at each specific time point 
during the incubations when culture supernatant was removed, in-silico half of the available 
extracellular PTX was removed as well. Once the final model was in place, we challenged this 
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assumption by allowing CLexp to be estimated from the data. The non-significant improvement (∆OFV: 
- 0.5) in OFV showed that our assumption is valid and that fixing CLexp will not significantly bias the 
parameter estimates.      
During model building it became clear that in order to adequately describe the intracellular PTX 
concentration-time course for the different protocols a separate Vintra should be estimated. At first 
we estimated an additional Vintra for protocols 2 & 3 (∆OFV for additional Vintra: - 52.8). The estimated 
intracellular volumes were 1.87 µL for protocol 1 and 0.848 µL for protocols 2 & 3, respectively. The 
difference between these estimates is in agreement with the different number of cells that were 
seeded at the start of the experiments (for protocol 1 and protocols 2 & 3, respectively 7.5 x 104 and 
3.0 x 104 cells/mL were seeded).  
Table 1  
Final estimated model parameters as well as model predicted relative standard errors (RSE).  
Parameter Estimate RSE (%) 
Vcell 1.90 x 10-5µL 9.9 
Q2 3.40 µL x h-1 35.6 
kon,NSB 0.203 h-1 9.4 
koff,NSB 0.00204 h-1 74.0 
kon 0.0425 h-1 19.8 
   
σExtracellular (additive) 0.287 15.6 
σIntracellular (additive) 0.210 29.3 
 
In the end, we choose to model the intracellular volume on a per cell basis and use the number of 
seeded cells per protocol to account for the variability in Vintra between protocols, instead of using 
two estimates for Vintra. This approach proved to perform equally well in terms of GOF (∆OFV: 1.0; 1 
estimated parameter less) and had the additional benefit of being able to predict Vintra for 
subsequent experiments based on the number of seeded cells. 
Furthermore, instead of a single homogenous extracellular compartment, an additional 
compartment had to be added to the model to account for the extracellularly bound PTX (∆OFV for 
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inclusion of NSB compartment: -153.1). We believe that this compartment represents extracellular 
non-specific binding sites binding PTX (at a rate of kon,NSB), thereby making it unavailable for 
distribution to the intracellular compartment or clearance from the extracellular compartment. 
Although proteins are added to the culture medium to prevent NSB, we believe that, based on earlier 
experience with NSB of PTX in a.o. ultrafiltration devices (unpublished data), NSB of PTX is very likely 
in this experimental set-up. This hypothesis is supported by the estimated equilibrium between the 
bound and unbound PTX fraction in the extracellular medium (kon,NSB/koff,NSB) of 100.        
Inclusion of an additional irreversible intracellular binding compartment significantly improved the 
model’s GOF (∆OFV for inclusion of irr. binding compartment: -12.8). Based on the data we were not 
able to estimate the koff-rate, i.e. the speed of dissociation of PTX from its intracellular binding places. 
Although intracellular PTX binding might truly be irreversible, the most likely explanation for this is 
that the time-frame of the experiment was too short to detect significant dissociation. Our 
observations are in line with work from Kuh et al. [16] who elegantly showed, by placing cells 
containing PTX in drug-free medium, that 50% - 75% of intracellularly bound PTX is retained within 
the cells even after 24 hours.   
Finally, by modeling kon as a 2nd order rate-constant, i.e. making the binding rate-constant (kon) 
dependent on the number of cells in the culture medium (as a surrogate for the number of 
intracellular binding places), we were able to further improve the GOF (∆OFV: -5.7).  
Figure 4 shows the GOF of the final model. Overall, the developed model describes the observed 
data well. Nevertheless, when looking at the intracellular PTX concentrations, we can see that the 
model does not fully capture the absorption phase from protocol 2, leaving some room for future 
improvements. 
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Figure 4. Goodness-of-fit plot for the final PK model. The top and bottom-left graphs show the observed PTX concentrations 
(black and red open circles for extracellular concentrations and intracellular amounts, respectively) with model predictions 
overlaid on top (solid / dashed lines). The bottom-right graph depicts the measured PTX concentrations/amounts versus the 
model predicted concentrations/amounts (x-axis).   
Based on our model, the half-life for PTX uptake and excretion is estimated to be 40.8 and 0.39 
hours, respectively. These findings are in contrast with earlier work from Au et al.[13] on the uptake 
of PTX in prostate cancer cells (PC3). In their work, the authors reported half-lives for the uptake and 
excretion of PTX of 1.8 and 1.5 hours respectively. Despite differences in the experimental protocols 
(the tested PTX concentrations were 10-fold lower in the work from Au et al.) used to study the 
intracellular kinetics, cell specific properties, such as the (lack of) expression of uptake/efflux 
transporters are most likely causing these divergent findings between SK-OV-3 and PC3 cells. For 
example, it is well known that breast cancer cells express the mdr1 P-glycoprotein (pgp), for which 
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PTX is a proven substrate ( Jang et al.[17] and Zuo et al.[18]), whereas, it is known that SK-OV-3 cells 
are pgp-negative[19]. 
Cell viability following PTX treatment 
In a first experiment we wanted to study the effect of PTX exposure on cell viability using a static 
experimental design. In these experiments cells are incubated in culture medium spiked with 
different PTX concentrations for a specific duration, without simulation of an extracellular clearance. 
Afterwards, all culture medium is removed, cells are rinsed with fresh culture medium and are left to 
grow in drug free medium until cell viability is measured (typically 96 hours post dose), using the MTT 
assay. Then, the parameter(s) of interest, e.g. IC50 & Emax, are estimated by fitting a four-parameter 
logistic function, generally known as the Hill equation (eq. 1) to the data. 
Equation 1 
 =  −	 × 

 + 
  
Parameters:  B = Viability of the controls 
Emax = Maximum induced reduction in viability 
γ = Shape factor  
IC50 = The spiked concentration producing half of the Emax 
 
 
Using this four-parameter logistic regression model, implemented using the “nlme” package in R®(R 
foundation for statistical computing, Vienna, Austria), IC50 and Emax were estimated to be 0.21 ± 0.04 
ng/µL and 0.51 ± 0.02, respectively. Although a similar experimental design was used, our estimates 
are in contrast to documented findings from Au et al.[13], who estimated, from a 3 hour PTX 
exposure to SK-OV-3 cells that IC50 and Emax were 0.064 ± 0.020 ng/µL and 0.87 ± 0.05, respectively. In 
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order to discriminate whether these differences were due to the different PTX exposure duration (3 
hours in their experiments versus 1 hour in our experiment), we set up a new experiment, exposing 
cells to a variety of PTX concentrations for 48 hours.  
From this experiment we estimated a significantly lower IC50 (0.0044 ± 0.0012 ng/µL), providing a 
potential explanation for the discrepancy between our estimated IC50 and the reported IC50 from Au 
et al.  Nevertheless, even after a 48 hour exposure of SK-OV-3 cells to PTX, based on our data, Emax 
was estimated to be around 0.61 and not 0.87 as documented by Au et al.[13].  
The underlying cause(s) for this discrepancy in estimated Emax are not entirely clear. Moreover, Au et 
al. used a maximum PTX concentration of 8.54 ng/µL (10.000 nM), more than tenfold lower than our 
maximum concentration (100 ng/µL) and still they reported a significantly higher Emax. We believe 
that the amount of time, prior to conducting the drug treatment (72 hours in our case versus 24 
hours in Au et al.) is crucial and might have caused this higher Emax. Since free-floating cells, not yet 
attached to the bottom of the well, might be more accessible for PTX uptake, the true reduction in 
viability against structurally embedded cells might be overestimated using the experimental design 
proposed by Au et al.  
Figure 5 shows the results from the different incubation experiments and the model predictions as a 
function of the extracellular PTX concentration (at the start of the experiment). From this figure we 
can clearly see that by increasing the treatment duration the IC50 reduces significantly. In their 
publication [13], Au et al. hypothesised that the amount of PTX that is retained intracellularly is 
responsible for the increased drug effect for long versus short treatments. Therefore, in an attempt 
to confirm/negate this hypothesis we explored whether the time-course of intracellular PTX 
exposure (AUCIntra) rather than the PTX concentration at the start of the experiment would be a 
better predictor for drug effect.       
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Figure 5. The median of the measured (n = 18 per concentration level) viability as a function of the applied extracellular PTX 
concentration at the start of the experiment. The results from the 1 hour experiment are shown with open circles and the 
model predicted viability is shown with a a solid line. The 48 hour experiment and associated model prediction is shown 
with solid triangles and a dashed line, respectively. The grey triangles represent the measured viability for dynamic 
protocols 1-3.   
 
In a first step, we used our previously developed PK model to estimate the intracellular AUC96hs 
(bound and total) associated with all of the performed experiments (static and dynamic incubations). 
Afterwards (using NONMEM®), we fitted the measured viability as a function of the estimated 
intracellular AUCs using the “Hill equation”. Table 2 shows a comparison between the different 
tested models. 
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Table 2  
Different evaluated models, the predictor used in the “Hill model” and their respective objective function value (OFV).  
 Comment OFV 
Reference [PTX]Extracellular,Start - 844.6 
Model 1 AUCIntra, bound - 957.6   
Model 2 AUCIntra, unbound - 959.8 
Model 3 AUCIntra, total - 958.0 
 
From Table 2 we can clearly see that all evaluated models based on the AUC96h significantly 
outperform the reference model. Furthermore we can see that no significant difference in GOF is 
obtained between the different AUC96h-based models. Given that from a physiological point-of-view 
model 1 is the most plausible model and despite the marginally higher OFV, compared to the other 
AUC-models, we choose to proceed with the AUC96h of the intracellularly bound PTX as a predictor 
for drug effect. Figure 6 shows the estimated AUCIntra,bound for the different experiments performed 
versus the measured viability. The solid line represents the model predicted viability.   
This approach has some benefits over the earlier explored approach. Earlier, due to the large 
differences in the viability as a function of PTX start concentration between the 1 hour and 48 hour 
experiments, it was unfeasible to model the data using a single model. As a result, the separate 
developed models could only be used to predict viability for new 1 hour or 48 hour experiments. The 
AUC-based model however allows the data to be modelled simultaneously. As a consequence, it is 
possible to use this model to predict the viability for new experiments with different treatment 
durations and simulated extracellular clearances.  
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Figure 6. Median measured viability versus model predicted intracellular AUC96h for the 1 hour (open circles) and 48 hour 
static experiment (solid black triangles) and the dynamic experiments (solid grey triangles). According to the fitted model, 
AUC50 was estimated as 0.28 ± 0.05 ng/µL*h.  
 
Furthermore, in comparison to the earlier estimated IC50 which depended on the initial spiked PTX 
concentration only and did not take into account PTX distribution, nor the time-course of PTX 
concentrations within cells or the induced experimental clearance, the model based AUC50 estimate 
does take these processes into account. Therefore, once the processes governing the intracellular PK 
in in-vivo conditions are known (or are estimable) this parameter could be used as a target for future 
treatment optimization.   
Overall, using a dynamic predictor (AUC96h) to predict the drug effect significantly reduced the 
variability around the model predictions (the median absolute prediction error decreased from 23.2 
to 20.1 %) and helped in explaining why different experiments with the same start PTX concentration 
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but different treatment durations resulted in significantly different viabilities. Although, our 
proposed approach is a step up from the approach presented initially, significant improvements 
could be made.  
As seen from Figure 6, significant bias remains in the predictions. On one hand, the viability 
measurements for the 1 hour experiment are underestimated (i.e. the drug effect is overestimated) 
whereas on the other hand, the opposite holds for the 48 hour experiments. One approach that 
could potentially be useful to further improve our model is the use of so-called cell-cycle models 
[20,21]. These models take into account the specificity of PTX for cells in a particular phase of the cell 
cycle (Mitosis phase). These models might explain why prolonging treatment exposure, i.e. allowing 
more cells to reach the PTX sensitive mitosis-phase, increases drug effect. 
Moreover, more general delay PKPD models, e.g. TRANSIT compartment models [22], taking into 
account the time-delay between PTX binding to its intracellular receptor and the onset of effect 
might be equally useful. However, in our specific case, implementation of a cell-cycle specific model 
or a delay PKPD model, in the future, will require more data on the time-course of viability or will 
require borrowing information from related literature to fix parameters which are not estimable 
from our data.       
In the next section we will assess whether ccCK18 could be used as a biomarker for PTX 
pharmacodynamics by trying to correlate these MTT measurements against ccCK18 measurements 
obtained from the culture supernatant during the dynamic experiments. 
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ccCK18 release from treated SK-OV-3 cells 
During the dynamic incubations, at 24, 48, 72 and 96 hours post the start of the experiments, culture 
supernatant was removed and replaced with fresh culture medium. Using the commercially available 
ELISA M30 Apoptosense® kit, we measured ccCK18 concentrations in the collected supernatant. 
After calculation of the amount of ccCK18 (fmol), rather than the concentration, present in the 
different fractions, cumulative amounts of ccCK18 were calculated by summing over the collection-
intervals. We assume that the amount of ccCK18 that is potentially released post treatment is 
depending on the number of cells present at the start of the experiment. Therefore, cumulative 
release was expressed per 100,000 cells. Figure 7 shows the calculated ccCK18 fractions as a function 
of time for the different experimental protocols.  
Figure 7 shows that, once corrected for the different number of cells, there were no differences in 
biomarker release between protocols 1 and 2. However, biomarker release in protocol 3 seems to be 
different from protocols 1-2. Furthermore, an apparent lag-time is observed prior to onset of ccCK18 
release into the extracellular medium. In order to get a rough estimate of this lag-time and to 
compare the release rate of ccCK18 between the 3 protocols, an empirical compartmental model 
was developed in NONMEM®. For this model, we used the FO algorithm and modelled the ln-
transformed relative cumulative amounts of ccCK18. More details with regards to the model are 
found in the appendix.  
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Figure 7. Scatter plot showing the relative cumulative amount of ccCK18 released into the culture supernatant during 
protocols 1-3 (grey circles, grey triangles and black triangles, respectively). Model predictions, cfr. supra, for the different 
protocols are shown with a solid, a dotted and a dashed line for protocols 1-3, respectively. The model estimated a lag-time 
of approximatly 35 hours before significant amounts of ccCK18 are detected. 
From the model fit, it was estimated that the time lag between PTX administration into the in-vitro 
culture and the detection of ccCK18 was 34.8 ± 2.1 hours for all three experimental protocols. 
Furthermore, from the model we successfully estimated that the rate of release of ccCK18 for 
protocol 2 and 3 were 1.01 ± 0.03 and 0.87 ± 0.03 times the release rate for protocol 1. In other 
words, although no significant difference is observed between protocols 1 and 2, ccCK18 is released 
significantly slower from cells treated according to protocol 3. 
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The significantly different release rate between protocol 3 and the other protocols could be 
explained (qualitatively) by looking at the model predicted intracellular bound AUC96h (66.2, 15.7 and 
4.41 ng/µL x h for protocols 1-3). Protocol 3, for which a > 10-fold lower intracellular AUC96h was 
predicted, as compared to protocol 1, had a significantly slower release of ccCK18 into the 
extracellular medium, potentially indicating that AUC96h might serve as a predictor for ccCK18 release 
(and hence tumor cell killing). Furthermore, it appears that at a particular point a maximum release 
rate is achieved for ccCK18 above which further increasing the AUC96h is no longer effective (i.e. 
protocols 1 and 2, with different AUC96h result in the same ccCK18 release rate).  
Concurrently with the in-vitro ccCK18 evaluations using the dynamic incubation protocols, we set up 
a small animal study to assess whether ccCK18 is reliably detected in rats treated with PTX through 
IPEC. To this end, we compared ccCK18 concentrations, measured at several occasions post dose, 
between a group of tumor bearing rats treated with 240 µg/mL PTX for 45 minutes and a treated 
non-tumor bearing group. Based on our previous work[23], which showed that maximum apoptosis, 
as measured by a caspase-cleaved caspase-9 antibody, occurred 14 hours post IPEC dosing, and 
based on a report of Olofsson et al.[12], describing a significant difference in ccCK18 levels in 
responding and non-responding breast cancer patients 24 hours post therapy, it was decided to 
sample rat plasma up to 24 hours post IPEC administration.  
ccCK18 concentrations measured in plasma from treated tumor bearing and non-tumor bearing rats 
were all significantly higher than the LLOQ of the ELISA assay. However, no differences could be 
detected between both treated groups, nor could we observe an increase in circulating ccCK18 levels 
up until 24 hours post dose (data not shown). This is in line with another paper in literature dealing 
with the release of ccCK18 into the bloodstream of treated gastrointestinal adenocarcinoma 
patients. Scott et al.[10] demonstrated that ccCK18 was increased in the patient’s serum only several 
days post treatment.  
[165] 
 
Although our feasibility study showed that it is technically possible to use the ELISA Apoptosense® kit 
to detect circulating ccCK18 in our rat model for peritoneal carcinomatosis, in the future, we should 
collect plasma samples a few days post therapy instead of up to 24 hours post dose only.          
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Conclusions 
Based on the performed dynamic incubations, which allow the simulation of in-vivo achievable PTX 
exposures to incubated cells rather than using the static approach, we were able to quantify the 
uptake and release of PTX from cultured cells. Although the estimated parameters are in contrast to 
previous findings reported in literature, we showed that the developed model was able to predict 
PTX pharmacodynamics under static incubation conditions as well as under our evaluated dynamic 
protocols.  
By comparing the model-predicted intracellularly bound AUC96h with the measured ccCK18 release 
profiles in-vitro, we were able to show that ccCK18 release, in-vitro, is (to some extend) correlated to 
the AUC96h. Nevertheless, we were not able to validate whether ccCK18 is a good surrogate for the 
measured viability in-vitro.  
However, based on our developed model and using model simulations to inform us, prior to 
conducting the experiments, we will be able to design better experiments. On one hand, dynamic 
protocols resulting in viability measurements spanning the entire viability spectrum should be 
selected. On the other hand, the time-frame of the in-vitro ccCK18 detection should be extended. 
This should allow us to detect the maximum amount ccCK18 released per protocol and might 
therefore provide us with an additional predictor, besides the estimated release-rate, to correlate to 
the viability measurements.           
Furthermore, based on our in-vitro findings, we now know that, in order to demonstrate the 
feasibility of using ccCK18 in animals to evaluate the effects of PTX treatment, sampling should be 
extended significantly, potentially up to a few days post treatment.    
Although at the moment, we cannot quantitatively relate ccCK18 release to intracellular PTX kinetics, 
we believe that our results, on a qualitative basis, show that ccCK18 measurements are related to 
PTX exposure. Therefore, we feel that our results will be valuable to (our) future research for the 
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following reasons. Firstly, the ability to design more informative in-vitro studies will help us to 
validate the use of ccCK18 in monitoring PTX PKPD. Secondly, in-vitro multiple dose studies, based on 
our developed PK model, will help in deepening our understanding of intracellular PTX PKPD and 
might play a role in furthering our understanding of resistance development in tumor cells.  
Overall, we feel that a new step has been taken towards the development of an integrated model-
based framework that could eventually, in the future, be used as a biomarker-guided decision tool, 
aiding the clinician in rationalizing treatment options for patients receiving paclitaxel. 
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Appendix 
Empirical model to describe ccCK18 release in-vitro 
In order to be able to estimate the lag-time and obtain a relative comparison between the release 
rates of ccCK18 for the different protocols, we set up a pseudo - 1 compartmental model (Figure 8). 
For this model it was assumed that from a pool of PTX-affected cells in the depot compartment 
ccCK18 was released into the extracellular matrix (represented by compartment number 1). This 
process of release was characterized by a first-order release rate (Ka,i) which was off-set with a Lag-
time (T). Due to the arbitrariness of the number of cells in the depot compartment, the absolute 
value of Ka,i has no meaningful interpretation. However, by modeling the release rates of protocols 2 
and 3 relative to protocol 1, these relative differences do have an interpretable meaning.    
 
 
Figure 8. Pseudo- 1 compartmental model used to estimate the Tlag associated with the release of ccCK18 into the 
extracellular medium. The dose that was administered into the depot compartment was arbitrarily chosen. 
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Final NONMEM® code 
$SUBROUTINE ADVAN13 TOL9 
$MODEL       
COMP(CENTRAL,DEFDOSE) 
COMP(PERIPH,DEFOBS) 
COMP(COLLECT,INITIALOFF) 
COMP(NSB) 
COMP(INTRA) 
COMP(LIVE) 
 
$PK 
CALLFL=-2 
;------------------- Initialize compartments --------------- 
CELLS=110423 
IF(STUDY.EQ.2.OR.STUDY.EQ.3) CELLS=44537 
A_0(6)=CELLS 
;------------------- Extracellular compartment ------------- 
VE = 200 ;µL 
CL_EXP=6900 ;µL/h 
;------------------- Intracellular compartment ------------- 
V_cell = THETA(1) 
VI = V_cell*(A(6)/100000) 
Q2 = THETA(2) 
K14 = THETA(3) 
K41 = THETA(4) 
Kon = THETA(5)*(A(6)/100000) 
K12 = Q2/VE 
K21 = Q2/VI 
K13 = CL_EXP/VE 
S1=VE 
 
S3=100 
STOP_TIME=0 
IF(CLEAR.EQ.1) STOP_TIME=TIME+0.02 
 
$DES 
OUT=1 
IF(T.GE.STOP_TIME)OUT=0 
DADT(1)= -K12*A(1)+K21*A(2)-K14*A(1)+K41*A(4)-
K13*A(1)*OUT 
DADT(2)= K12*A(1)-K21*A(2)-Kon*A(2);+Koff*A(5) 
DADT(3)= K13*A(1)*OUT 
DADT(4)= K14*A(1)-K41*A(4) 
DADT(5)= Kon*A(2);-Koff*A(5) 
DADT(6)= 0 
 
$ERROR 
A1 = A(1) 
C1 = A1/VE 
A2 = A(2) 
C2 = A2/VI 
A3 = A(3) 
C3 = A3/100 
A4 = A(4) 
A5 = A(5) 
IPRED=-10 
IF(F.GT.0) IPRED=LOG(F) 
Y = IPRED+ETA(1) 
;------------- Intracellular compartment ------------------ 
IF(CMT.EQ.2.AND.A2.GT.0) THEN 
IPRED = LOG(A2+A5) 
[170] 
 
Y = IPRED+ETA(2) 
ENDIF 
IRES = DV - IPRED 
W = 1 
IWRES = IRES/W 
 
$THETA 
(1E-9,1.83905) ; V_cell ; µL 
(1E-9,3.90501) ; Q2 ; µL/h 
(1E-9,0.200275) ; K14 ; /h 
(1E-9,0.00196532) ; K41 ; /h 
(1E-9,0.0444913) ; Kon ; /h 
 
$OMEGA 
0.287133 ; SIGMA1 
0.22671 ; SIGMA2 
 
$ESTIMATION SIG=3 SIGL=9 MAX=9999 METHOD=0 
SORT PRINT=1 NOABORT 
$COVARIANCE PRINT=E 
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In the last decade, since the publication of the FDA’s critical path initiative[1], model-based drug 
development has received a lot of attention. It is believed that MBDD, by taking a pivotal role in the 
drug development process, will lower the attrition rate and increase productivity, leading to more 
innovative drugs reaching the patients [2-5] faster. Multidisciplinary collaboration, quantitative 
knowledge integration and the application of pharmaco-statistical modeling and simulation are 
considered essential components in this model-based approach. A consequence of this new 
approach, focussing on knowledge integration, is that for new drugs reaching the clinic the 
therapeutic response surface is well studied and based on patient characteristics (genetic make-up, 
race, etc.) an informed decision can be made with respect to the optimal treatment regimen.  
However, for drugs already on the market the TRS is only sparsely characterized, hampering the 
optimization / individualization of treatment regimens based on patient characteristics. A direct 
consequence of this is that the (off-label) use of marketed drugs in specific patient populations often 
poses a great challenge for the treating clinicians. To address this knowledge gap, several studies 
addressing the efficacy of currently used treatment regimens in specific patient populations have 
been reported in literature the last few years. Specific patient populations frequently studied and 
suspected to be vulnerable to over- / under-dosing, are (very) young children [6], the critically ill [7-
9], the morbidly obese [10,11], etc.           
The main objective of this thesis was to evaluate currently used treatment regimens in two specific 
patient populations using an M&S-based approach. Although both therapeutic areas, i.e. anti-
infective therapy and oncology, differed somewhat in the specific issues associated with them, in 
both areas questions regarding treatment efficiency and optimisation of therapeutic regimen exist. In 
an attempt to address these challenges, a multi-disciplinary strategy was followed. In a first step, we 
developed bioanalytical methods to inform us on the time-course of the plasma / tissue 
concentration of the analyte of interest. In a second step, experimental work was conducted either 
through a clinical trial or through pre-clinical (in-vitro / animal) tests and finally, in a third step, the 
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experimental results were interpreted and integrated across experiments using various pharmaco-
statistical modeling and simulation approaches.     
Rationalized dosing in antimicrobial therapy 
The first part of this work focussed on anti-microbial therapy and the potential impact of 
pharmacokinetic variability within a patient cohort on the expected outcome of the treatment. Based 
on a previously developed bioanalytical method for the quantification of moxifloxacin in human 
plasma[12], we set up a clinical trial evaluating a single dose of 400 mg moxifloxacin in a cohort of 
post-bariatric surgery patients. Subsequent to evaluating whether differences existed in terms of oral 
bioavailability between our specific patient population and healthy volunteers[13], we investigated, 
in chapter 1, whether the currently approved dosing regimen was sufficient to achieve therapeutic 
success in this specific population. 
From our simulations, based on an integrated model combining our developed PK model and 
exposure-response models published in the literature, it became apparent that the probability of 
achieving suppression of bacterial resistance formation is low under the currently used treatment 
regimen. Furthermore, we showed that lean body mass is a significant prognostic factor for the 
expected exposure (PK) and hence the probability of therapeutic success. Furthermore, we found 
that achieving a high PTA (> 80%) is likely to be problematic in 25% of the population (patients with a 
LBM in excess of 57.9 kg). This led to the hypothesis that the development of a LBM derived dosing 
algorithm for this patient population would significantly increase treatment efficiency.  
At this stage we would like to acknowledge that the optimization of a therapeutic regimen comprises 
more than solely increasing efficacy by increasing the exposure to the drug. In the case of 
moxifloxacin, a compound well-known for its QT-prolonging capabilities, increasing exposure could 
simultaneously lead to an (unacceptable) increase in the probability of inducing life-threatening side 
effects in the patients (in casu, Torsades de Pointes). Therefore, in order to reliably 
optimize/individualize the treatment regimen for moxifloxacin, quantitative PKPD models, 
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simultaneously optimizing the antibacterial effect size while minimizing a potential QT-prolonging 
effect, should be developed. 
Finally, to put our work into perspective, we would like to point out that, nowadays, the PKPD 
endpoints, used to optimize antimicrobial therapy (AUIC, T[unbound]> MIC, etc.) are scrutinized for their 
lack of mechanistic interpretation and the poor correlation often observed between PKPD endpoints 
derived from in-vitro/animal experiments and those derived from clinical trial data. Recently, a 
review[14] highlighted some of the problems associated with the currently used PKPD thresholds. In 
general, quantitative information on antibiotic PKPD is lost by summarizing data into variables (like 
AUC) with limited possibilities for extrapolation to different dosing regimens and study populations. 
Furthermore, the authors stressed that integrative PKPD models, built using in-vitro, animal and 
clinical data, will resolve some of these issues and will speed up the development of new antibiotics 
and promising antibiotic drug combinations. We strongly agree with the authors of this review and 
feel that these model-based approaches are the way forward to optimize/ individualize antimicrobial 
treatment therapy.               
Together with the work described in chapter 1, we started the development of a multi-compound 
analytical assay for the simultaneous quantification of several β-lactam antibiotics, as described in 
chapter 2. β-lactam antibiotics, at the time, were considered a class of antibiotics for which 
individualized dosing was crucial in the battle against the ever expanding problems associated with 
bacterial resistance formation. Therefore, as a first step towards the improvement of currently used 
β-lactam treatment regimens, we developed a multi-drug assay capable of being implemented in PK 
studies as well as TDM programs.  
Through the use of an ultra-high performance liquid chromatography instrument, we succeeded in 
the development of a reliable analytical method with a cycle-time (time between sequential 
injections) of 5 minutes. Furthermore, the use of a 96-well mixed-mode SPE plate in combination 
with a multi-channel pipette allowed us to minimize time spent on sample preparation, thereby 
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safeguarding its suitability as, among other things, a potential multi-drug TDM assay. A thorough 
validation study demonstrated that this method was reliable and could be used to provide 
quantitative measurements on 13 of the most frequently used β-lactam antibiotics, in a timely 
manner.     
Supported by the ability to quantify the time-course of these antibiotics and with the intent to 
further expand our efforts to support individualized dosing in specific patient populations, we 
designed two clinical trials. On the one hand, in collaboration with the department of internal 
medicine (Ghent University Hospital) an international clinical trial was set up to evaluate the 
pharmacokinetics and pharmacodynamics of linezolid administered intravenously to morbidly obese 
patients with MRSA pneumonia. Unfortunately, although patient inclusion was expected to be 
completed the first year of the study, up until today only 4 patients were enrolled, making a 
preliminary evaluation unfeasible. Due to the specific inclusion criteria dictated by the study 
protocol, patient inclusion has been prolonged and is now expected to be complete by the end of 
2014.  
On the other hand, a single-centre clinical trial was set up in collaboration with the department of 
microbiology (OLV hospital Aalst, Belgium), aimed towards evaluating the feasibility of implementing 
a model based individualized cefepime dosing in the intensive care unit. Since the start of the trial 
(patient recruitment started early 2014) over 15 patients were enrolled and cefepime concentrations 
were determined for 9 of them. Based on the favourable inclusion rate in this trial, patient 
recruitment is expected to be complete (as soon as 20 patients are recruited) by mid-2014 and 
subsequent cefepime concentration measurements and PK(PD) modeling will be undertaken shortly 
thereafter. 
Based on the results of our moxifloxacin evaluation in post-bariatric surgery patients and the 
continuously increasing scientific interest to optimize/personalize the use of marketed antibiotics in 
specific patient populations, we feel that, as demonstrated throughout the first part of this thesis, 
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the reliable quantification of anti-microbial agents and the subsequent quantitative interpretation 
using an integrated PK(PD) modeling and simulation approach are the way forward. Furthermore, 
through the development of our multi-compound analytical assay we have supplied the necessary 
tools for clinicians and scientists involved in anti-microbial therapy to further explore the possibility 
of individualizing anti-microbial therapy in the future.            
Towards rationalized dosing in patients with peritoneal carcinomatosis 
The second part of this thesis focused on the treatment of peritoneal carcinomatosis with (H)IPEC. 
Although IPEC is nowadays widely used, albeit generally using platinum compounds, several critical 
questions remain with regards to drug disposition within the tumor, strategies to optimize currently 
used treatment regimens, e.g. by increasing local uptake in the tumor whilst minimizing systemic 
disposition and thus side effects etc. Therefore, in close collaboration with the Laboratory of 
Pharmaceutical Technology (Faculty of Pharmaceutical Sciences, Ghent University) and the 
Laboratory for Experimental Surgery (Faculty of Medicine, Ghent University), an IPEC descending 
dose study with paclitaxel (Taxol®), which is believed to be a good compound for IPEC treatment 
because of its favourable pharmacokinetic properties (slow i.p. clearance, high first-pass effect), was 
set up in rats bearing tumor xenografts (SK-OV-3 cells were used to grow the xenografts).  
Since one of the key questions related to optimization of treatment efficiency, was to what extent 
PTX penetrates a solid tumor, prior to the animal experiments, we developed an analytical method 
capable of quantifying PTX in tumor tissue. In chapter 3 we described the development and 
validation of our analytical method based on an enzymatic tumor tissue digestion protocol coupled 
with SPE- UPLC-MS/MS. The ease of use of the enzymatic method to disrupt the tumor tissue and 
release PTX from the tissue/cells coupled with the reliability of the SPE-UPLC-MS/MS system allowed 
us to accurately quantify PTX in harvested tumor tissue samples in a timely fashion.        
Based on these quantitative measurements, combined with PTX measurements in plasma and the 
abdominal cavity post IPEC dosing, we were able to determine the kinetics as well as the extent of 
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PTX tumor penetration post IPEC administration. As described in chapter 4, our results show that PTX 
tumor penetration post IPEC is much more pronounced than what was observed from imaging 
studies using regular i.p. administration of PTX formulations. Furthermore, we found that the kinetics 
of PTX tumor uptake are saturable and that the saturation of the underlying (unknown) mechanism is 
responsible for the marked non-linearity in tumor and systemic exposure upon escalating Taxol® 
doses.  
By combining this knowledge with apoptosis measurements within the tumors and the effect of 
treatment on tumor size, we were able to develop a PKPD model capable of adequately describing 
the cascade of events underlying this complex therapy. These events include the time-course of PTX 
in tumor and plasma post IPEC administration, the interaction between this dynamically changing 
PTX concentration and the apoptosis induction and the degree of apoptosis necessary to induce 
significant tumor shrinkage. Subsequently, we used this PKPD model to simulate different new 
treatment strategies and evaluate their relative effect sizes. From these simulations, we concluded 
that the way forward is to lower the currently used dose, whilst, at the same time, lengthen the 
treatment duration, potentially using a controlled-release PTX formulation.  
Another approach, which we hope will lead to a better understanding of the different phenomena 
underlying successful PTX-based therapy, was described in Chapter 5 and concerns an in-vitro 
investigation into the kinetics of PTX uptake in cell cultures. In this chapter, we studied the time-
course of PTX uptake in cells and its relationship to the reduction in cell viability and subsequent 
release of a potentially interesting biomarker (ccCK18). In contrast to the apoptosis measurements 
we used in chapter 4 (i.e. based on the intra-tumor presence of cleaved-caspase 9), ccCK18 is 
released into the bloodstream and might serve as a circulating, and therefore, easily measurable 
marker for PTX induced tumor cell killing.  
The results described in chapter 5 indicate that the release of ccCK18 into the extracellular 
environment might serve as a good surrogate (i.e. biomarker) for the achieved intracellular PTX 
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concentrations in our in-vitro system. Although our experiments provide a first step towards the use 
of ccCK18 as a marker for PTX exposure in the future, we acknowledge that several hurdles are to be 
taken before ccCK18 will be able to be used as a quantitative decision tool to inform clinicians on 
how to optimize treatment in patients. For example, the biomarker disposition, the potential 
background release of ccCK18 from treated non-tumor tissue and the relationship between tumor 
growth inhibition and ccCK18 release will have to be studied extensively in the future. All of these 
processes have to be accounted for prior to making a decision with regards to the feasibility of using 
ccCK18 as a BM for PTX PD.        
At this moment, several strategies are set up to continue this line of investigation and follow up on 
these conclusions. On the one hand, in close collaboration with the Laboratory of Pharmaceutical 
Technology, work has started on the development of an extended release PTX formulation. In 
support of this new formulation additional rat/mice experiments are being set up to further deepen 
our understanding of the processes underlying PTX tumor uptake and to validate the findings from 
our simulation study. Furthermore, additional modeling approaches are explored to further 
disentangle the complex processes giving rise to the observed non-linear tumor uptake. One of the 
approaches we are currently working on is the exploration of additional model structures to check 
whether the process of encapsulation of paclitaxel in the cremophor micelles (i.e. the excipient in the 
Taxol® formulation) might be responsible for the markedly non-linear absorption phenomenon we 
described in chapter 4.   
On the other hand, as a way to bridge between our current knowledge of the pharmacology of PTX in 
rats and the questions with regards of the potential use of PTX in the clinic, efforts are directed 
towards the development of more mechanism-based PKPD models, which should provide the 
necessary leverage to extrapolate our findings towards the human situation. We believe that these 
strategies, in the future, will lead to a more rational individualized/optimized model-based treatment 
of patients with peritoneal carcinomatosis.        
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To conclude, we feel that, throughout this thesis, we demonstrated a general approach that allows 
the optimization of treatment regimens in specific patient populations. Essential elements in this 
approach are the application of reliable bio-analytical methods to quantify (marketed) drugs in the 
biophase of interest and the subsequent use of an integrated M&S approach to quantitatively 
interpret study results. We believe that this approach will deepen our understanding of the complex 
therapeutic response surface underlying currently used treatment regimens in specific patient 
populations and will, ultimately, lead to an optimized/individualized treatment regimen for patients.     
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